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Introduction: Black African populations present with low insulin sensitivity (SI) and 
hyperinsulinemia, the latter due to high insulin secretion and reduced clearance. In 
addition, they exhibit lower levels of central and ectopic fat, compared to their white 
counterparts, contradicting the known correlates of SI typically reported in white 
populations. Moreover, in black African women hyperinsulinemia is in excess of the 
level needed to compensate for low SI, with a corresponding high disposition index (DI), 
a marker of insulin response that accounts for the level of SI. Further, obese, black 
African women have a high risk for type 2 diabetes (T2D), but the correlates of 
hyperinsulinemia have not been fully elucidated, especially the role of ectopic fat and 
body fat distribution. Exercise training is beneficial to improve SI and DI, however, 
whether these effects are mediated by changes in ectopic fat in skeletal muscle, liver 
and pancreatic depots is unknown. Accordingly, exercise training can be used as a 
model to assess the correlates of hyperinsulinemia and SI in cohorts at high risk for 
developing T2D, such as obese black African women. This thesis therefore aims to 
describe the correlates of hyperinsulinemia and SI and to evaluate the effect of exercise 
training on these components with emphasis on the role of body fat distribution and 
ectopic fat in mediating these changes. 
Methods: Firstly, a cross-sectional analysis of 45 obese (BMI 30-40 kg/m2) black South 
African women (age 20-35 years) without T2D was conducted. Thereafter the women 
were block randomized into an exercise training (n=23) or no exercise (control, n=22) 
group. The exercise training group participated in a 12-week combined aerobic and 
resistance training programme (40-60 min session, 4 days/week) supervised by a 
20 
 
biokineticist. Pre and post-intervention testing included assessment of acute insulin 
response to glucose (AIRg), SI, DI (AIRg x SI), insulin secretion rate (ISR), hepatic 
insulin extraction (HIE) and peripheral insulin clearance (CLp) (frequently sampled 
intravenous glucose tolerance test); body fat mass and regional adiposity (dual-energy 
X-ray absorptiometry); hepatic, pancreatic and skeletal muscle fat and abdominal 
subcutaneous (aSAT) and visceral adipose tissue (VAT) (magnetic resonance imaging); 
intramyocellular (IMCL) and extramyocellular fat content (EMCL) (magnetic resonance 
spectroscopy). 
Results: The baseline results showed that a high DI was associated with low VAT (r-
0.565, p<0.001), pancreatic fat, soleus IMCL and EMCL with VAT explaining most of 
the variance in DI (32%). SI was inversely associated with VAT (rho -0.417, p=0.007) 
and AIRg was inversely and HIE was positively associated with VAT-aSAT ratio (rho -
0.345, p=0.029 and rho 0.510, p=0.011, respectively). DI was positively associated with 
CLp (rho 0.528, p=0.006), while its components (SI and AIRg) were not. Results from 
the intervention showed that exercise training increased DI (median (interquartile 





, p=0.005) and VO2peak (mean ± standard deviation: 24.9±2.42 
to 27.6±3.39 ml/kg/min, p<0.001), with no changes in control group. Exercise training 
decreased body weight (84.1±8.7 to 83.3±.9.7 kg, p=0.038) and gynoid fat mass 
(18.5±1.7 to 18.2±1.6%, p<0.001). AIRg, ISR, HIE, CLp, aSAT, VAT and ectopic fat 
were unchanged after exercise training. However, the control group increased body 
weight and aSAT. The increase in SI and DI were not associated with changes in body 
composition, body fat distribution or ectopic fat. 
Conclusion: Novel results from our cross-sectional analysis showed that, in obese 
black South African women, DI was positively associated with peripheral insulin 
21 
 
clearance, probably due to higher SI of peripheral tissue. Moreover, the most important 
correlate of a high DI was low VAT independent of ectopic fat accumulation in other 
sites. Further, we showed that low AIRg and high HIE correlated with a high VAT-aSAT 
ratio, while low SI was associated with high VAT. These associations require further 
exploration to determine direction of causality. Findings from our exercise intervention 
study extend on previous research by showing that moderate-to-high intensity 
combined aerobic and resistance exercise training increased SI and improved 
cardiovascular fitness, but insulin secretion, hepatic insulin clearance, ectopic and 
central fat depots did not change. Our results suggest that hyperinsulinemia may not 
occur solely as a compensatory mechanism for low SI and that ectopic and central fat 
might not be the primary correlates of insulin resistance in this cohort. Rather, intrinsic 
factors within muscle and adipose tissue may be putative mediators for observed 
improvements in the metabolic outcomes but will require further elucidation. Further 
research is required to confirm the causal role of VAT on low DI and to determine 
whether a long-term exercise training program and/or a low carbohydrate/glycemic 





CHAPTER 1: LITERATURE REVIEW 
 
1.1 EPIDEMIOLOGY OF TYPE 2 DIABETES AND OBESITY – THE SOUTH 
AFRICAN CONTEXT 
 
The prevalence of type 2 diabetes (T2D) is increasing worldwide with trends in Africa 
surpassing other world regions (1). The global prevalence of T2D in adults has 
increased from 4.7% in 1980 to 8.5% in 2014 (2). Furthermore, the International 
Diabetes Federation (IDF) predicts that the number of people living with diabetes aged 
20-79 years will increase from 463 million in 2019 to 700 million in 2045 (1). Globally, 
sub-Saharan Africa has the highest projected rate of increase in T2D over the next 26 
years, increasing by 143% from 19 million in 2019 to 47 million by 2045 (1). In 
addition, T2D is a significant contributor to morbidity and mortality worldwide with T2D 
associated morbidity and mortality rates more prevalent in populations of African 
descent compared to white populations (3,4). The increased prevalence of T2D 
coincided with an increase in the global prevalence of overweight and obesity of 
27.5% for adults between 1980 and 2013 (5). In Africa, mean BMI increased in both 
men and women between 1980 and 2014, however the increase was greater in 
women (6). Regional differences were also noted with Northern and Southern African 
women having a mean BMI higher than the global average (6). The link between BMI 
and prevalence of T2D is evident with a strong positive association found in both 
sexes in 1980 and 2014 (correlation coefficient ~0.9) (6). 
The IDF estimated that in 2019 approximately 4.6 million people were living with 
diabetes in South Africa (SA), with a further 2.4 million people undiagnosed (1). 
Furthermore, black African urban populations seemed to be more affected as the 
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diabetes prevalence increased from 8% in 1990 to 12.2% in 2009 (7). Concomitantly, 
the obesity epidemic has been increasing in SA (8) and excess weight was shown to 
contribute to 86.9% of T2D cases (9). Moreover, BMI and hyperglycemia are the 
second and third most important contributors to mortality and morbidity in SA, after 
unsafe sex (6). Notably, women are disproportionately affected, with an overweight 
and obesity prevalence of 68% compared to 31% in men in 2016 (10), with SA women 
having the highest prevalence of obesity in Sub-Saharan Africa (5). Furthermore, 
within SA, black SA women (40.9%) have a higher prevalence of obesity, compared to 
white (30.6%) SA women (10). Clearly, black SA women are disproportionately 
affected by the obesity epidemic, and the increase in T2D prevalence in this 
population is concerning. Understanding the correlates of insulin sensitivity (SI), insulin 
secretion and clearance, the key components in the pathogenesis of T2D, in obese, 
black SA women are therefore of interest. 
 
1.2 PHYSIOLOGY OF INSULIN FUNCTION, SECRETION AND CLEARANCE 
 
Glucose is an essential energy source to human cells, but is toxic to tissue that is 
exposed to prolonged elevated plasma levels. Insulin, plays a key role in the regulation 
of plasma glucose levels within a narrow range by ensuring the uptake and safe storage 
of glucose within muscle (11). Processes involved in the regulation of plasma insulin 
levels such as the secretion, action and clearance of insulin are therefore integral in the 





1.2.1 INSULIN FUNCTION 
 
Although insulin exerts its effect on many body tissues (12), this review will focus on the 
effects on muscle, liver and adipose tissue. Essentially, within the muscle, insulin 
promotes the uptake of plasma glucose and the net synthesis of glycogen. In the liver, 
insulin suppresses endogenous glucose production (EGP) and stimulates glycogen 
synthesis, while increasing lipogenesis. In the adipose tissue, insulin inhibits lipolysis 
and favours the uptake of plasma free fatty acids and the synthesis of triglycerides (TGs) 
(13). The cellular pathways that culminate in these insulin effects are initiated when 
insulin binds to its receptor. Although the downstream insulin effects may differ 
depending on the tissue, the initial insulin signalling pathway are similar between 
tissues. Firstly, autophosporylation of the insulin receptor β-subunit leads to tyrosine 
phosphorylation of the insulin receptor substrate molecule (IRS-1 or IRS-2). This sets 
off a cascade of phosphorylation events that involves activation of key cellular 
molecules such as phospatidyl-inositol-3-kinase (PI3K), protein kinase 1 (PDK1), Akt1/2 
and protein kinase C (PKC), amongst others. Akt activates AS160 and promotes the 
translocation of glucose transporter containing vesicles to the cell membrane. Akt also 
stimulates glycogen synthase which induces glycogenesis (14). Suppression of EGP in 
the liver is mediated by Akt, which inactivates the forkhead transcription factor (FOXO1), 
an important regulator of gluconeogenic genes. Moreover, insulin activates the sterol-
regulatory-element-binding protein-1c (SREBP1c), which promotes transcription of 
lipogenic genes and promotes de novo lipogenesis (DNL) (13). Further, the uptake of 
free fatty acids into the tissue is initiated by insulin stimulating the expression of 
lipoprotein lipase (LPL), an important enzyme involved in the the hydrolysis of plasma 
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TGs (15). Further, insulin inhibits hormone sensitive lipase (HSL), the rate-limiting 
enzyme involved in lipolysis (13) and thus promotes storage of TGs. 
1.2.2 INSULIN SECRETION 
 
The pancreas is a retroperitoneal organ that has both exocrine and endocrine functions. 
The islets of Langerhans, dispersed amongst the exocrine cells, contribute ~4.5% to the 
overall pancreatic volume (16). Insulin is synthesized, processed, packaged and 
secreted from the β-cells, which is the most abundant cell within the islets (16). This 
thesis will now provide a summary of the processes involved in insulin secretion, which 
has been published before in a detailed review by Tokarz et al. (17).  
The synthesis of insulin involves transcription and then translation into pre-proinsulin 
peptide by the ribosomes on the endoplasmic reticulum. The endoplasmic reticulum is 
also where the peptide is cleaved into pro-insulin and folded. After pro-insulin has been 
stabilized into a 3D-form it is transported to the Golgi-apparatus where it is packaged 
into secretory vesicles. Inside the vesicles, pro-insulin is cleaved into insulin and C-
peptide. Insulin secretion occurs from two different pools. The first phase insulin 
secretion reflects readily available insulin already present in storage vesicles within the 
β-cells, whereas the second phase insulin secretion reflects newly synthesized insulin. 
Insulin secretion is triggered by various stimuli of which glucose is the main stimulus. 
The cascade of events starts with glucose entering the β-cells through glucose 
transporter (GLUT1) where it is immediately phosphorylated to glucose-6-phosphate by 
glucose kinase. This reaction produces ATP which gives rise to an increase in the 
ATP:ADP ratio within the cell and results in the closure of the K+-ATP dependent 
channel. Depolarization follows and the Ca2+ gated channels open. An influx of Ca2+ 
into the cell triggers the release of insulin and C-peptide in equimolar quantities via 
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exocytosis. This K+-ATP dependent pathway is not the sole pathway responsible for β-
cell insulin secretion. Other factors that influence β-cell insulin secretion are free fatty 
acids, amino acids, neuronal factors (cholinergic stimulation increases insulin secretion 
and adrenergic stimulation via catecholamines reduces insulin secretion), hormonal 
factors (somatostatin inhibits insulin secretion, while incretins derived from the gut 
stimulate insulin secretion), and adipokines (leptin can increase insulin secretion) (17).  
1.2.3 INSULIN CLEARANCE 
 
The liver is the main organ involved in insulin clearance and clears approximately 50-
70% of insulin during first pass through the liver (18). Insulin is also cleared by peripheral 
tissue such as the kidneys, muscle and adipose tissue, amongst others. However, the 
kidneys are the most important site, clearing over 80% of extrasplanchnic insulin (19), 
followed by the muscle (20). After binding of insulin to its receptor, CEACAM1, a 
transmembrane protein, is activated by phosphorylation and subsequently initiates the 
internalization of the insulin-receptor complex by endocytosis (17). Inside the endosome 
the insulin degrading enzyme (IDE) degrades insulin bound to its receptor into smaller 
particles. Next, these smaller particles are delivered to lysosomes where further 
degradation occurs via proteolysis, after which the insulin receptor is recycled back to 
the cell membrane (17).  
 
1.3 OVERVIEW OF THE PATHOGENESIS OF TYPE 2 DIABETES 
 
Our understanding of the pathophysiology of T2D has certainly improved since the 19th 
century when Claude Bernhard identified the role of the liver in gluconeogenesis and 
Joseph von Mering and Oscar Minkowski first discovered the central role of the 
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pancreas in the development of diabetes (21). Further, the advancement of molecular 
science and the conduct of longitudinal studies in populations at risk aided our 
understanding of the causal factors involved in the development of T2D, which are 
multifactorial. T2D is characterized by high fasting glucose or impaired glucose 
tolerance (IGT) and involves two key factors, a reduced sensitivity of tissue to insulin 
(insulin resistance) and pancreatic β-cell dysfunction (22).  
Insulin resistance occurs when a normal amount of insulin produces a subnormal 
biological response (23). However, the effects can differ by organ. Insulin resistance in 
the muscle is characterized by the reduced uptake of glucose and glycogenesis (24). 
Hepatic insulin resistance involves reduced suppression of EGP, however the effect of 
insulin on DNL remains intact (25). Adipose tissue insulin resistance is defined by 
reduced suppression of lipolysis by insulin, resulting in elevated levels of plasma free 
fatty acids, which may be redistributed to ectopic sites (26). Considerable strides have 
been made to unravel the molecular mechanisms involved in reduced insulin action with 
defects both at the receptor level and in the insulin signalling pathway being implicated 
(13). An increase in BMI parallels the presence of insulin resistance and different 
theories (lipotoxicicity, inflammation, adipokines) have emerged to explain excess 
accumulation of fat as a cause of insulin resistance (27–29). However, these 
mechanisms may not act in isolation. Therefore a paradigm that considers the 
interconnectedness of these various theories, together with intrinsic cellular 
mechanisms such as mitochondrial dysfunction, endoplasmic reticulum and oxidative 
stress (30) may all contribute towards the underlying pathogenesis of insulin resistance. 
That being said, such a paradigm is complex and to investigate all these components 
at once is not always feasible. Nevertheless, the adipose tissue expandibility hypothesis 
suggests a finite ability of adipocytes to store fat (31). This may explain insulin 
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resistance in the midst of obesity by taking the differential association between regional 
fat depots and SI into account while providing a reason for ectopic fat accumulation and 
its role in hepatic and peripheral insulin resistance (32).  
The ability of the pancreatic islet β-cells to secrete insulin is critical in delaying the onset 
of T2D. Even when insulin resistance is present, the pancreatic β-cells and the liver 
regulate insulin secretion and clearance, respectively, to ensure higher plasma levels 
of insulin to maintain normoglycemia (33). Notably, a failure to ensure an adequate 
insulin response for the level of SI, will result in deterioration of glucose tolerance and 
progression towards T2D (22). Indeed, longitudinal studies in Pima Indians, whom have 
a high risk for T2D (34), have illuminated the key role of insulin secretory dysfunction, 
together with low SI in the progression to T2D (35,36). Subsequently, another study in 
Pima Indians evaluated whether the contribution of insulin response and SI to the 
progression of T2D differed depending on the severity of IGT (36). They demonstrated 
that during the progression from normal glucose tolerance to IGT and from IGT to T2D, 
both a low insulin response and low SI were additive predictors in the progression of 
worsening glucose tolerance. Further, the role of insulin response in the progression of 
T2D was found to be similar across different ethnicities (African Americans, Hispanics 
and non-Hispanic Whites) (37). This longitudinal study reported that while a reduction 
was found in SI, regardless of the glucose tolerant status at follow-up, the direction and 
magnitude of change in the insulin response determined the glucose tolerance status 
after a follow-up of 5.2 years (37). Further, the insulin response is dependent on both 
insulin secretion and clearance. Based on a longitudinal study in healthy African 
American offsprings of T2D patients, it appears that the deterioration in insulin secretion 
contributes more to the reduced insulin response and subsequently increased risk for 
T2D compared to the reduction in hepatic insulin clearance (38). While the course of 
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T2D may be similar across ethnicities, the underlying mechanisms of low SI and the 
ability to increase the acute insulin response may still differ amongst ethnic groups.  
 
1.4 ETHNIC DIFFERENCES IN INSULIN SENSITIVITY  
 
Lower SI is frequently found in black Africans compared to white populations. Indeed, 
South African ethnic-comparison studies (Table 1.1) showed that obese pre-
menopausal black women had lower SI compared to white women without T2D, 
measured using a frequently sampled intravenous glucose tolerance test (FSIGT) (39), 
and a hyperinsulinemic-euglycemic clamp (HIEG) (40). This finding was also apparent 
in normal-weight women (39,41). Nevertheless, two South African studies using the 
HIEG (42) and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) 
index (43) found no differences in SI between white and black women that were also 
obese, pre-menopausal and without T2D. Whether differences in quantifying SI (fasting 
vs stimulated or steady state vs dynamic conditions) or whether adjusting for the fat 
mass index (42,43) or not (39,40) may account for these discrepant findings are not 
clear.  
Further afield, ethnic-comparison studies conducted in the United States of America 
(USA) and the United Kingdom (UK) included participants over a wider age range 
(children to post-menopausal women), and level of glucose tolerance (Table 1.2). 
Amongst those without T2D, a lower SI was found in African American adults compared 
to their age and BMI matched white counterparts. This finding was apparent regardless 
of BMI (44–47) or age (45,48–50). However, amongst those with T2D, no significant 
ethnic differences in SI have been reported (51–53). In children, the influence of 
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lifestyle/environmental factors on SI are minimized and therefore observed differences 
could be attributed to genetics or epigenetics. Notably, some studies showed that black 
African American children had lower SI compared to white children even prior to the 
onset of obesity (45,54–56) (Table 1.3), while other studies in both children and adults 
found no ethnic difference in SI (42,43,49,53,57–62). Again, methodological differences 
in quantifying SI may contribute towards these heterogenous findings. A lower SI found 
in black South African and African American populations without T2D might reflect 
differences in the underlying pathogenesis of T2D compared to white populations, but 
when T2D develops these differences are no longer apparent. We therefore need to 
explore the correlates of low SI in black African populations and whether a greater 
sensitivity to these correlates exist.  
1.5 ETHNIC DIFFERENCES IN HYPERINSULINAEMIA 
 
Ethnic differences have been observed in the insulin response to glucose, with 
hyperinsulinemia frequently found in black African populations (39,44–49,52,54,61). 
Tables 1.1, 1.2 and 1.3 summarizes ethnic differences in stimulated plasma insulin 
levels.  
Earlier studies emanating from South Africa, reported that compared to white adults, 
black men (63) and women (64) had a decrease in stimulated insulin response after an 
oral glucose challenge and lower C-peptide levels during the euglycemic period of a 
HIEG (40). However, these studies are conflicted with small sample sizes and one study 
used lean men that were manual labourers (63) and therefore external validity might be 
compromised. A study conducted in pre-menopausal women over a range of BMI found 
that black SA women had a greater acute insulin response to an intravenous glucose 
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load (AIRg) compared to their white counterparts (39). These findings were replicated 
in studies in African Americans. In fact, a meta-analysis that included 74 cohorts of 
which 19 included black African cohorts, including 1 South African cohort, found a 
greater AIRg in black African, compared to white and Asian individuals (997 ±36.2 vs 
396 ±7.5 vs 265 ±13.7 pmol/L, respectively), but this was restricted to normal weight 
individuals with normal glucose tolerance (52). However, a more recent report 
corroborated these results in overweight/obese women over a range of glucose 
tolerance, but no T2D (49). Chung et al, reported that compared to their white 
counteparts, pre- and post-menopausal African American women had an elevated 
insulin response to oral and intravenous glucose stimulation, as well as to a mixed meal 
test, which represents more physiological conditions. These findings have also been 
confirmed in healthy, normal weight children, with African children demonstrating an 
elevated AIRg compared to other ethnicities (45,56,58). The reason for this ethnic 
disparity in stimulated insulin response needs to be further explored. 
 
1.6 REASONS FOR HYPERINSULINEMIA IN BLACK AFRICAN POPULATIONS 
1.6.1 LOW INSULIN SENSITIVITY 
Majority of the studies that showed an elevation in stimulated insulin response in black 
African adults also reported a reduced SI (39,45–48,52,54). Based on the hyperbolic 
relationship between AIRg and SI, a negative feedback loop dictates that a change in 
one variable results in a reciprocal and proportional change in the other variable, to 
ensure euglycemia. Indeed, in those with normal glucose tolerance, an elevation in AIRg 
could be explained by a reduced SI (48). Haffner et al. suggested that a reduced SI, 
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independent of age, sex, BMI, waist-to hip ratio, physical activity and diet, could explain 
the higher fasting and early phase insulin response, in black Africans, as a 
compensatory mechanism to maintain euglycemia (48). However, it is also possible that 
hyperinsulinemia may precede the low SI found in black African populations.  
1.6.2 LOW INSULIN CLEARANCE  
Plasma insulin levels reflect the balance between insulin secretion and insulin 
clearance. Further, different methods, which will be discussed in detail in the method 
development chapter, are used to quantify insulin clearance. Some studies do not 
distinguish between hepatic and peripheral insulin clearance and reports the total insulin 
clearance, while others distinguish between hepatic and peripheral insulin clearance. 
Studies that evaluated insulin clearance in black African adults, using different 
methodologies, demonstrated a reduced clearance compared to white populations 
(Table 1.2) (44,49,50,59), with similar findings observed in children (56,58,65). While 
some studies only reported a reduced insulin clearance as the main contributor to a 
high insulin response (44,66), others showed that both reduced insulin clearance and 
high insulin secretion were contributors to hyperinsulinaemia (49,56). Further, a 
longitudinal study in dogs emphasized that both these factors are important to maintain 
high insulin responses but they do not occur simultaneously (67). Dogs were fed a high 
fat diet over 12 weeks and as SI deteriorated over the first 6 weeks, insulin secretion 
increased by 60%. However, from week 6 to 12, eventhough SI did not deteriorate 
further, the high level of insulin secretion could not be sustained. Rather, plasma insulin 
levels remained stable due to a reduction in hepatic insulin extraction. This suggests 
that a reduction in hepatic insulin extraction is a mechanism to alleviate the burden on 
the pancreatic β-cells, and may therefore protect against the development of T2D. On 
the contrary, a longitudinal study in African Americans and Hispanics found that a 
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reduced insulin clearance predicted the onset of T2D, independent from insulin 
secretion, adiposity, lifestyle factors and high-density lipoprotein cholesterol (68). This 
paradox allows us to speculate whether a reduced insulin clearance observed in black 
African populations may only provide temporary respite for the β-cells and that the 
hyperinsulinemia that ensues may be the factor that escalates the development of T2D.  
Nonetheless, the reasons for low hepatic insulin clearance in black African populations 
needs to be considered. Notably, a lower hepatic insulin clearance is present in African 
American children, compared to white children, even before the onset of obesity (58), 
perhaps indicating a genetic component. Hepatic fat has been shown to be a major 
correlate of low hepatic insulin clearance in studies conducted in white adults, without 
T2D (69,70), but the role in black African populations has not been well-studied. This is 
particularly relevant given that black Africans typically present with lower hepatic fat 
compared to their white counterparts (49,53). The two studies that examined the 
association between hepatic fat and hepatic insulin clearance in black African 
populations produced conflicting results, probably due to differences in study 
populations and methods of assessment. The first study conducted in African American 
women without T2D, found no association between hepatic fat and basal hepatic insulin 
extraction during a mixed meal tolerance test (49). In contrast, a UK study conducted in 
black men of West African descent with T2D found a trend for an association between 
hepatic fat and insulin clearance, determined in response to a hyperglycemic clamp 
(53). Although based on limited data, one may hypothesise that hepatic fat might not be 
an important factor in the low insulin clearance observed in black African adults without 
T2D. Further studies are required to confirm this hypothesis.  
Another factor to consider is the contribution of peripheral insulin clearance to 
hyperinsulinemia. The few ethnic comparison studies that measured peripheral insulin 
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clearance found no difference between African Americans and their white or Hispanic 
counterparts (58,59). Nevertheless, the proportion of total insulin cleared peripherally 
was greater in African American women compared to white women (59). Moreover, in 
black African men, peripheral insulin clearance was associated with glucose tolerance 
status, such that those with IGT had reduced peripheral insulin clearance compared to 
those with normal glucose tolerance (71). Based on these findings, the role of peripheral 
insulin clearance in the pathogenesis of T2D is of interest but it is a component that has 
been largely understudied. Further, although it has been shown that peripheral insulin 
clearance is associated with higher SI in black African men (71), the association with 
AIRg is not clear and also no previous studies have evaluated the relationship with β-
cell function.  
1.6.3 HIGH INSULIN SECRETION  
Black African premenopausal women without T2D, have both a greater first phase β-
cell sensitivity and insulin secretion rate (ISR) compared to white populations, but no 
ethnic differences are found in the second phase response (49,54). This indicates that 
in black African populations, the pancreatic β-cell might have a greater capacity to store 
insulin compared to white populations. Moreover, some studies have demonstrated that 
the high stimulated insulin response found in black African populations is excessive for 
the level of SI (47,56). The reasons for this are not clear. Whether, the unique phenotype 
found in black African women of less VAT and ectopic fat deposition and more 





1.7 IMPORTANCE OF HYPERINSULINEMIA  
 
Hyperinsulinemia, referring to an elevated insulin response due to elevated insulin 
secretion and/or reduced insulin clearance, may compensate for the low SI observed in 
black African populations, however, it could also precede low SI. Moreover, because 
obesity can be associated with both hyperinsulinemia (72) and reduced SI (30,73), it 
may confound these associations. In addition, lifestyle factors may also influence these 
two factors; accordingly, the study of children provides a good model to evaluate 
whether hyperinsulinemia precedes low SI, independent of obesity and other lifestyle 
factors. Compared to white children, normal-weight black African children demonstrated 
a high AIRg and first phase insulin secretion, despite similar SI (58). A similar finding 
was reported in older children, however obesity was already present (57). Accordingly, 
these findings suggest that hyperinsulinemia may be the primary event that may cause 
low SI in black African children.  
Indeed, an in-vitro study showed that insulin receptors in isolated cells develop 
diminished autophosphorylation, secondary to hyperinsulinemia (74). Furthermore, 
hyperinsulinemia may also induce obesity. Insulin is an anabolic hormone that 
stimulates the uptake of free fatty acids and glucose into adipose tissue depots to 
stimulate TGs synthesis and DNL, respectively (12). During DNL, insulin stimulates 
acetyl-CoA carboxylase to convert acetyl CoA to malonyl CoA. Further, during TG 
synthesis, insulin activates diacylglycerol transferase, the enzyme responsible for 
conversion of diacylglycerol to TGs. Additionally, insulin inhibits lipolysis through 
inactivation of hormone sensitive lipase, and inhibits fatty acid oxidation, which together 
promote TG storage (12) . Indeed, in mice models, knockout of insulin receptors in white 
and brown adipose tissue subsequently protected the mice from age and diet-induced 
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obesity (75). Further, in a longitudinal study (follow-up of a mean of 16.7 years) of 
normal glucose tolerant adults, hyperinsulinemia, high AIRg, defined by a FSIGT, was 
a risk factor for long term weight gain, especially in insulin sensitive individuals (76). 
Similarly in Pima Indian children that were followed up for a mean of 9.3 years, fasting 
hyperinsulinemia predicted weight gain independent of other factors known to influence 
weight gain (72). Based on this evidence it is plausible to hypothesize that in black 
African individuals, hyperinsulinemia may precede both obesity and low SI. Further 
support for this hypothesis is found from interventional studies that suppressed insulin 
secretion using insulin secretion inhibitors, such as octreotide, for 20 weeks in morbidly 
obese adults, without T2D (77). Lower plasma insulin concentrations were associated 
with a concomitant weight loss. Taken together, I hypothesise that in black African 
populations, hyperinsulinemia may be the primary event that increases the propensity 
for obesity and lowered SI, which then exacerbates hyperinsulinemia further through the 
hyperbolic relationship (Figure 1.1).  
 
SI – Insulin sensitivity, DI – Dispsosition index, HIE, Hepatic insulin extraction, ISR -Insulin secretion rate  
Figure 1.1: Proposed relationships between hyperinsulinemia, insulin sensitivity and 
obesity in Black African populations 
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Tests/ Variables 
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B: 13 (F),  
W: 14 (F) 
OB: 
B: 16 (F) 





B: 28±1; 38±0.9 
W: 31±2; 35±0.9 
FSIGT: 
SI x10-5  
(min-1/(pmol/l) 
AIRg – pmol 
















W: 78.2 ±41.0 
Ins/Glc0-30 
OB: B>W 
B: 507 ±65  
W: 248 ±65 
fIns (OB) B>W 
B: 90.6 ±7.2 
W: 52.5 ±7.7 















Periph SI -M/I 
Hep SI-
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Periph SI – low 
dose 
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Non-T2D B: 7 (M) 
W:8 (M) 






















Shires, 1985 (64) Non-T2D B: 10 (F) 
W: 8 (F) 
OB OGTT( tolbutamide 
and glucagon) 
HIE: Cpep AUC/Ins 
AUC 






Van der Merwe, 
2000 (40) 
Non-T2D B:10 (F) 





















Summary measures expressed as mean±Standard deviation, T2D – Type 2 Diabetes, B - Black, W - White, F – Female, M – Male, NW – normal weight, OB – Obese, BMI – body 
mass index, FSIGT – Frequently sampled intravenous glucose tolerance test, HIEG – hyperinsulinemic euglycemic clamp, OGTT – Oral glucose tolerance test, IV – Intravenous, 
HOMA-IR – Homeostatic Model Assessment of Insulin Resistance, SI, insulin sensitivity, AIRg – acute insulin response to glucose, EGP – Endogenous glucose production, fIns – 
Fasting insulin, M – glucose disposal rate,  AUC – Area-under-curve, Ins – insulin concentration, Glc – Glucose, C-pep – C-peptide concentration, HIE – hepatic insulin extraction, 
IUCL – Insulin urinary clearance, ND – Not done; FMI – Fat mass index 
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Participant characteristics  
Age (y); BMI (kg/m2) 
Tests/ Variables 
measured 












B: 25 (F), 
W: 32 (F) 
Pre-Menopausal 
B:25±3;%BF 36 ±11 
W:26±3; %BF 37 ±9 
FSIGT 
SI  
Β-cell sensitivityglc  (Φ)  























B: 18 (F), 

















































AIRg higher at 









B: 52 (F),  
W: 35 (F) 
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W: 38±7; 29.9±5.0 
Post-Menopausal: 
B: 53±4; 30.1±4.6 
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W:26.0±3.5; 25.2±4.3 
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W: 56.1±0.7; 27.4±0.5 
 (adj for age, sex, clinic, 











T2D B: 18, (M) 
W: 19 (M) 
B:54.9 ±9.3; 29.8±3.5 
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W:14 (M), 25 
(F) 
3 black African groups: AA, 
GI, NG vs W 
AA: 33.3±0.9; 28.3±0.9 
GI: 37.2±1.6; 29.3±0.7 
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B: 18 (F) 
W: 29 (F) 
B: 25 ±4; 27 ±6 
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B: 34 (F) 
W: 83 (F) 
B: 39±1.9, 31.4±0.8; 
W:44±0.9, 32.0 ±0.5 
FSIGT 
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Summary measures expressed as mean±standard deviation or median (interquartile range), T2D – Type 2 Diabetes, B: Black Africans living in USA, UK, unless otherwise 
specified such as in Osei1997: AA – African Americans, GI – Ghanaian immigrants, NG- Native Ghanaians; H – Hispanics, A – Asians, W – White, M – Male, F-Females, BMI – 
body mass index,  %BF – percent body fat, SI – Insulin sensitivity in x10-4 min-1/µU/mL, unless otherwise specified, AIRg – Acute insulin response to glucose in mU/L-1.min-1 , 
unless otherwise specified, IGI – Insulinogenic Index,  AUC – Area-under-curve, fIns – fasting insulin in µU/mL, unless otherwise specified, fC-pep – Fasting C-peptide, HIE – 
Hepatic insulin extraction, MCR – Metabolic insulin clearance rate; § - DI – Disposition Index, was not mentioned in paper and thus no statistical test was done, but it was 
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B: 6 (M), 6 (F) 
W: 7 (M), 4 (F) 
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B: 10.1±1.5; 21.5±4.7 
W: 10.8 ±1.9; 20.7±5 




















First phase ISR: 
B=W=H 















Non-T2D B: 34 (F), W: 
14 (F) 
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Β-cell sensitivity to 
glucose (φ)  
(Toffolo, 1995) 
 




B: 6.12 ±3.82 




B: 11766 ±16050 




















B: 32(M), 53(F) 
W:35(M),43(F) 
B: 14.6±0.2; 34.1±0.6 
W:14.8±0.2; 34.1±0.7 
OGTT: 






Early ISR 30min: 
B>W 













B:34 (M),21 (F) 
W:42 (M), 46 
(F) 
H:29 (M), 31 
(F) 
 
B: 7-12; 18±3  
W: 7-13; 18±3  
















B: 1026 ±737 
W: 585±365 
H: 1194 ±1119  





ISR late phase 
B<H, W<H 












Summary measures expressed as mean±standard deviation, T2D – Type 2 Diabetes, B- Black, W-White, H - Hispanics, F -  Female, M – Male, NW – normal weight, OB – Obese, 
BF – Body fat, FSIGT – Frequently sampled intravenous glucose tolerance test, HIEG – hyperinsulinemic euglycemic clamp, OGTT – Oral glucose tolerance test, HOMA-IR – 
Homeostatic Model Assessment of Insulin Resistance, SI, insulin sensitivity, AIRg – acute insulin response to glucose, ISR – insulin secetion rate, DI – Disposition index,  fIns – 
Fasting insulin, M – glucose disposal rate, AUC – Area -under curve, Ins – insulin concentration, Glc – Glucose, C-pep – C-peptide concentration, HIE – hepatic insulin extraction 
IC – Insulin clearance, ND – Not done; FMI – Fat mass index 
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1.8 ETHNIC DIFFERENCES IN THE DETERMINANTS OF INSULIN 
SENSITIVITY  
 
1.8.1 BODY COMPOSITION  
 
Dual X-ray absorptiometry (DXA) can distinguish between fat, bone and non-bone lean 
tissue and has therefore been used to measure not only total body fat and fat-free soft 
tissue mass but is also use to estimate regional fat mass such as trunk fat, leg fat, 
abdominal SAT (aSAT) and VAT (79). An advantage of DXA is that it has low levels 
of radiation and its accuracy is maintained across a wide range of body sizes, although 
adjustments may be required in obese individuals (80) and ethnic specific equations 
are required for the estimation of VAT and aSAT (81). 
Studies in predominantly white populations have found an inverse association 
between total body fat and SI (82,83). However, this relationship appears to be altered 
by ethnicity. A study conducted in African American and white American women with 
a wide range of age and BMI, found that body fat percent was inversely associated 
with SI, only in white women but not in African American women (54). Another study 
conducted in obese premenopausal African American women with normal glucose 
tolerance and IGT found that body fat percent was not associated with SI in a multiple 
regression model that contained age, lean body mass, SAT and VAT and total fat 
weight (84). However, the failure to show an association may be due to the collinearity 
commonly shown between these correlated variables. Regardless, a South African 
study found that body fat percent was inversely associated with SI in both black and 
white premenopausal women with normal glucose tolerance, but was stronger in white 
women (r=-0.498, p=0.008), compared to black women (r=-0.379, p=0.042) (85). 
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These findings might suggest that body fat percent may be a less important correlate 
of SI in women of African descent compared to white women. Perhaps muscle mass 
or body fat distribution may be more important contributors to SI in women of African 
descent.  
1.8.2 MUSCLE MASS  
Skeletal muscle is the major site of glucose uptake (86). Muscle mass may therefore 
be an important correlate of SI. A cross-sectional study conducted in predominately 
white adults (mean age 41 year old and mean BMI 25.6 kg/m2) reported an inverse 
association between skeletal muscle mass (normalized to total body weight) and 
insulin resistance (HOMA-IR) and the prevalence of diabetes (87). These findings 
were corroborated by a longitudinal study in older (mean age 51.6 years), normal-
weight (mean BMI 24.2 kg/m2) Japanese Americans without T2D (88). This study 
reported that a lower baseline thigh muscle mass predicted insulin resistance, 
determined be HOMA-IR and the quantitative SI check (QUICKI), after 10 years of 
follow-up (88). The reasons why low skeletal muscle mass is associated with insulin 
resistance and T2D is not clear but could due to lower mitochondrial oxidative capacity 
(89), or reduced secretion of myokines that are important in glucose and lipid 
metabolism (90). However, in a study conducted in African American and white women 
without T2D a greater muscle mass was associated with lower SI and a greater muscle 
mass partly explained the lower SI in African Americans compared to their white 
counterparts (91). These discrepant findings may be explained by the method used to 
determine muscle mass and whether it represents fat free muscle mass or general 
muscle mass that may still contain extramyocellular lipids as in the latter study. 
Intriguingly, a higher total body skeletal mass has been reported in African American 
women across all ages compared to white, Hispanic and Asian women (92). 
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Contrastingly, in South African studies, no difference was found in fat-free soft tissue 
mass (muscle mass) between obese black and white premenopausal women 
(40,42,85). Rather, sarcopenia was prevalent in older black South African women 
which was associated with lower levels of physical activity (93). These findings may 
suggest that black populations from Southern Africa, compared to those from West 
African descent, may be more susceptible to lower muscle mass, which may 
predispose to lower SI. However, no study assessed the direct association between 
fat-free mass and SI in black obese South African women.  
Furthermore, skeletal muscle is not homogenous and consist of different fiber types 
with different glucose disposal and fat oxidative capacity, which may influence SI.  
Three different muscle fiber types have been identified based on histochemistry 
methods (94). Type I fibers, also referred to as slow twitch fibers based on a slower 
contractile ability, have greater oxidative potential and greater mitochondrial density, 
compared to other fiber types. Type IIb fibers are also referred to as fast twitch fibers 
based on a greater contractile ability, are better at utilizing glycogen as fuel, compared 
to Type I fibers, and are therefore also referred to as glycolytic fibers. Type IIa is an 
intermediate muscle fiber type with fast twitch fibers, but with greater oxidative 
capacity compared to type IIb fibers. A greater proportion of type I fibers is associated 
with a greater SI in those without T2D (95–97). Moreover, obese adults without T2D 
have more Type I fibers compared to those with T2D (98). Compared to Type II fibres, 
Type I fibers have higher protein levels of insulin receptor, GLUT4, hexokonase II and 
glycogen synthase, which infers greater glucose uptake ability which likely explains 
the positive association with SI (98). Interestingly, ethnic differences in muscle fiber 
type have been observed, with lower levels of type I fibers found in African Americans 
compared to their white counterparts (99), which may in part, explain the lower SI 
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found in this population. However, African Americans are mainly of West African 
descent (99) and may therefore have a different muscle mass and muscle fiber type 
distribution to those black populations of Southern African descent.  
 
1.8.3 OVERVIEW OF ADIPOSE TISSUE AND NON-ADIPOSE TISSUE DEPOTS 
 
The accumulation of fat occurs when an energy surplus exists due to energy intake 
exceeding energy utilization (100). Excess energy from either dietary fat or 
carbohydates is stored as TGs in adipose tissue depots (26). A schematic diagram of 
the various adipose tissue depots relevant to this thesis is depicted in Figure 1.2. The 
adipose tissue can be divided into SAT (representing 80% of total fat) and VAT depots. 
SAT depots can be further divided into peripheral and aSAT depots (101). Peripheral 
fat depots include the arms and legs (102), of which the gluteal-femoral (gynoid) depot 
is of great interest. The landmarks for delineating leg fat, using dual-energy X-ray 
absorptiometry (DXA), are two diagonal lines passing through the right and left femoral 
neck forming a “V” and that meets in the midline between the legs (103). The gluteal-
femoral region (gynoid), a subdivision of the leg, extends from the greater femoral 
trochanter downwards to the middle of the thigh (104) (Figure 1.3). Accumulation of 
fat in non-adipose tissue depots is termed ectopic fat and can be found in skeletal 
muscle, liver, pancreas and the heart (101). However, this thesis will focus only on 
ectopic fat accumulation in the first three organs. These various adipose tissue depots 
differ with regards to their size and ability to expand (32), which may explain their 





VAT – Visceral adipose tissue, aSAT – Abdominal subcutaneous adipose tissue 












Figure 1.3: Dual-energy X-ray absorptiometry landmarks for delineation of leg and 
gynoid regions (Source MRC DAPA measurement toolkit website: 
https://www.measurement-toolkit.org/anthropometry/objective-methods/whole-body-
dexa-scan [Accessed 29 Jan 2020] 




The SAT depots act as a buffer by storing excess free fatty acids as TGs (105). A 
generalised or partial absence of adipose tissue, such as in those with lipodistrophy, 
is associated with insulin resistance (106). This emphasizes the importance of the SAT 
depot for safe storage of excess free fatty acids. Contrastingly, insulin resistance is 
also associated with excessive accumulation of fat in adipose tissue depots, explained 
by the expandibility hypothesis. This hypothesis proposes that adipose tissue has a 
limit to the amount of fat that can be stored without adverse metabolic effects (27). 
Individual variability occurs in the ability to expand adipose tissue, which may be 
regulated by genetic and environmental factors (107). Adipose tissue that has reached 
its storage capacity may become ‘dysfunctional’, characterized by hypertophic 
adipocytes that have outgrown their vascular supply and therefore becomes hypoxic 
(105). Further, this ‘dysfunctional state’ is marked by release of free fatty acids instead 
of the safe storage of TGs, increased secretion of pro-inflammatory cytokines (27), 
reduced secretion of insulin-sensitizing adipokines, and increase secretion of anti-
insulin-sensitizing adipokines (108). The increased mobilization of free fatty acids may 
be redirected to visceral and ectopic sites such as skeletal muscle, liver and pancreas 
(109).  
1.8.4 PERIPHERAL SUBCUTANEOUS ADIPOSE TISSUE 
 
Studies have consistently shown that higher peripheral fat associates with lower 
insulin resistance across a wide range of age, BMI and ethnicity (82,110–115). A study 
conducted in premenopausal black South African women showed that DXA-
determined leg fat mass correlated negatively with HOMA-IR (43). Studies conducted 
in predominately white populations using the gold-standard HIEG echoed these 
findings (82,114). The one study conducted in young-to-middle aged adults (82) and 
53 
 
the other in older (46-75 year old) women (114) showed that peripheral adipose tissue 
was associated with higher SI. The positive association between peripheral adipose 
tissue (determined both by CT (114) and DXA (110,112,113)), and SI exists 
independent of central fat depots in overweight to obese adults. A possible reason for 
this observed finding could be due to the a higher lipoprotein lipase activity of lower 
body fat depots, compared to abdominal depots, which indicates a greater uptake of 
free fatty acids (116,117). This will enable peripheral fat depots to store fat more 
readily and prevent the release of fatty acids into the circulation (118) where it could 
be diverted to ectopic sites and therefore protects against insulin resistance. 
Moreover, a lower inflammatory profile of peripheral fat depots, compared to aSAT, 
observed in white adults, may contribute towards the beneficial association with SI 
(119). 
The peripheral SAT depots, in particular the gynoid region, seem to be the preferential 
storage depot of black African women. Indeed, a greater gynoid fat mass (adjusted for 
total fat mass) has been found in black South African women compared to white 
women matched for body fat (120). Few studies have been conducted in black African 
populations that assessed the association between leg/gynoid fat mass and SI 
(43,115,120). Mixed results have been found with a protective association observed 
in overweight African American premenopausal women (115) and in overweight-to-
obese South African premenopausal women (43) but a detrimental effect in another 
small South African study (120). The beneficial effect of leg/gynoid fat mass on SI may 
depend on the the expandibility of this depot and when the storage limit has been 
reached, it may become dysfunctional and cease to be protective. Notably, the gynoid 
fat depot of the black South African women in the latter study showed reduced 
expression of lipogenic and adipogenic genes which may indicate that the storage 
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capacity had been reached (120). Nevertheless, a longitudinal study reported that a 
reduction in relative gynoid fat mass over time was independently associated with 
lower SI at follow-up (121). Evidence points to leg/gynoid fat mass as being protective 
against deteriorating SI in both white adults and those from African descent. However, 
we are left with a conundrum as to the reason for a low SI in black African populations 
despite greater gluteo-femoral depots. Interventional studies in black South African 
women are therefore warrated to investigate this further.   
1.8.5 ABDOMINAL SUBCUTANEOUS ADIPOSE TISSUE 
 
The aSAT depot does not only differ from the peripheral SAT depot by location, but 
also in lipolytic potential. Abdominal SAT depots are more lipolytic compared to 
peripheral SAT (118,122). Abdominal SAT depot is also distinct from VAT and is 
characterized by larger adipocytes (123,124) and higher LPL-activity (124), which 
suggests a greater ability to store fat compared to VAT. Indeed, aSAT is a much larger 
fat depot compared to VAT. Moreover, aSAT is the main contributor to systemic free 
fatty acids, which may be linked to peripheral insulin resistance through their effects 
on peripheral (muscle) insulin signaling (125). However, discrepant findings have been 
reported, with studies showing a negative (82,126), positive (111) and no association 
(114,127) between aSAT and SI. Similarly, studies conducted in black African 
populations produced contradictory results. No association was found in some studies 
from USA (54,84) and from South Africa (43), while a negative association was found 
in another study from USA (128). The reasons for these disparate findings are not 
clear, but could relate to differences in sample size, or analysis strategy (adjusting for 
multiple body fat measures or only BMI). Alternatively, the inability to distinguish 
between deep aSAT and superficial aSAT (129), which may have different functions 
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(85,130) could influence the association of total aSAT with SI. Indeed, an American 
study conducted in lean and obese adults, ethnicity not mentioned, with normal 
glucose tolerance,  found that deep aSAT (r-0.51, P<0.001), but not superficial aSAT 
(r-0.29, p>0.05), was associated with SI, independent of total body fat and VAT (83). 
Moreover, the association between deep aSAT and SI (r-0.64) was similar to the 
association between VAT and SI (r-0.61), which may indicate that the deep aSAT 
depot may be more similar to VAT in function. However, the inflammatory profile of 
these depots may not be the reason for the above findings since a study conducted in 
black and white South African women, found a similar inflammatory profile between 
deep and superficial aSAT, which was distinct from the VAT depot (130). Conversely, 
another SA study found that both deep and superficical aSAT was negatively 
associated with SI in both black and white women (85). Although deep aSAT was a 
stronger correlate of lower SI in black women compared to superficial aSAT, superficial 
aSAT may still be detrimental to SI if its storage capacity has been reached. Notably, 
black African populations have greater aSAT depots compared to their white 
counterparts of which superficial aSAT, compared to deep SAT, is the largest 
contributor (85). Clearly, the evidence linking aSAT to lower SI is inconclusive, which 
may be explained by the heterogeneity in the fat storage threshold of this depot 
together with the concomitant extent of fat accumulation in non-SAT depots.  
1.8.6 VISCERAL ADIPOSE TISSUE 
 
Shen et al.identified that VAT can be located within 3 main body cavities: intrathoracic, 
intraabdominal and intrapelvic (131). The VAT depot most commonly linked to T2D 
and cardiovascular disease is intra-abdominal VAT, in particular omental and 
mesenteric fat (129). Despres et al. proposed various theories as to why VAT is 
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associated with deteriorating SI (132). One of these theories is the portal vein theory 
which proposes that VAT secretes free fatty acids directy into the portal vein because 
it is highly lipolytic and resistant to the effects of insulin. The liver is therefore directly 
exposed to the high flux of free fatty acids and through its lipotoxic effects may result 
in hepatic and peripheral insulin resistance. Another theory, is that VAT is highly 
immunogenic and able to secrete inflammatory cytokines, such as IL-6 and TNFα that 
have been implicated in insulin resistance. A further theory is that VAT is a marker of 
dysfunctional SAT that has reached its fat storage capacity (132).  
The association between VAT and SI has been extensively studied 
(82,83,85,111,114,126,128,133–142). A negative association between VAT and SI 
has been found consistently in normal weight (133,136), overweight and obese (134–
136,138,139) adults without T2D. Although these were select populations, studies that 
included adults over a wide range of BMI reported a similar relationship between VAT 
and SI (83,139–141). While an association is apparent between VAT and SI regardless 
of the level of BMI, a large population-based study did report that BMI modifies this 
association with a stronger association found in obese compared normal-weight adults 
(126). In contrast, one study conducted in predominantly white adults (mean age 36.6 
years) found that VAT was not associated with SI, if adjusted for aSAT (82). 
Nevertheless, the negative association between VAT and SI found in cross-sectional 
studies have been reiterated by a longitudinal study conducted in Japanese Americans 
(135). This study reported that baseline VAT was positively associated with HOMA-IR 
and negatively associated with Matsuda SI index after 10-11 years of follow-up, even 
after adjusting for baseline BMI, total fat and aSAT.  
Studies in populations of African descent are also generally supportive of the 
relationship between VAT and SI. For example, studies including African American 
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men and women (128,137) or only women (84) confirmed a negative association 
between VAT and SI. However, a South African study found no association between 
VAT and SI in black premenopoasual women over a range of BMI, while a negative 
association was observed in white women (85). Notably, a recent study reported that 
the accumulation of VAT was a predictor of T2D in middle-aged black South African 
women after 13 years of follow-up (143). This study showed that over the follow-up 
period VAT increased by a greater margin (41%) compared to that of aSAT (16%). 
These findings were echoed by an earlier South African study reporting that 
premenopausal black women were more prone to VAT (increased by 28%) than aSAT 
(8%) accumulation after 5.5-years of follow-up (121). The heterogeneity in findings in 
black African populations regarding the association between SI and VAT might be 
explained by the level of VAT. A curvilinear association has been described between 
SI and VAT such that at higher VAT, no changes in SI are observed (144). Therefore, 
no association will be apparent if VAT is beyond a certain point. However, overweight 
and obese black African women have lower VAT, compared to Hispanic (128) and 
white women (39), but are more insulin resistant. Perhaps indicating that black African 
populations might have a greater sensitivity to VAT accumulation. Further research is 
required to explore this phenomenon in black African populations.  
1.8.7 SKELETAL MUSCLE FAT 
The accumulation of fat in non-adipose tissue sites such as the skeletal muscle have 
been associated with reduced SI (82,145–150). The mechanism that excess fat in the 
muscle could lead to insulin resistance is based on the lipotoxicity theory (24). Fatty-
acid derivatives such as long-chain fatty acyl CoA and ceramides interfere with the 
insulin signalling pathway (24,151). Lipid intermediaries activate PKC, which 
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phosphorylates IRS-1 on a serine residue. This renders IRS-1 unable to activate PI3K, 
which is an important step in the translocation of GLUT4 to the plasma membrane, as 
well as for glycogen synthesis. In addition to a defect in the insulin signalling pathway, 
earlier research in obese individuals with and without T2D has also implicated defects 
at the level of the insulin receptor such as reduced numbers and reduced kinase 
activity (152). Chronic hyperinsulinemia may be considered a plausible explanation for 
this finding (153). 
Despite studies using different methods to determine skeletal muscle fat content, 
including CT (82), muscle biopsy and histochemistry methods (149,150) and MRS 
(145–148), a consistent negative association has been found with SI. However, the 
location of the fat in the muscle is important because intramyocellular lipids (IMCL) 
were found to be a stronger correlate of insulin resistance compared to 
extramyocellular lipids (EMCL) (147). MRS is therefore the optimal method to 
differentiate between IMCL and EMCL. Another aspect to consider is the fibre 
composition within muscle, as discussed in section 1.8.2, which may confer differential 
associations with SI. Indeed a study conducted in lean offspring of parents with T2D 
found that soleus IMCL, but not tibialis anterior IMCL, was the main correlate of 
reduced SI (147). Further, the association between IMCL content and SI may also be 
modified by the underlying fatty oxidation capabilities such that a positive association 
is observed when fat oxidation is high compared to a negative association when fat 
oxidation is low, which is also termed the ‘athlete’s paradox’ (154). 
Ethnicity may also alter the relationship between skeletal muscle lipid content and SI, 
but conflicting evidence exists. In a study that compared soleus IMCL content, 
measured by MRS, between African Americans and European Americans (21 and 46 
years of age), IMCL content and SI were similar between the groups (60). However, 
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IMCL correlated with SI in white and not African American adults, which led the authors 
to suggest that IMCL might not be pathological in African Americans. Another 
American study in obese adolescents, showed that although soleus IMCL was lower 
in African Americans compared to Hispanics and white individuals, SI was similar in 
all the groups (155). A South African study found no difference in soleus IMCL content 
between obese black and white women, but only in black women was soleus IMCL 
content correlated with a lower SI. Potential reasons for the discrepancies in findings 
could be that Ingram et al.(60) included men and women over a wide range of BMIs 
(21-46 kg/m2), while the South African study only focused on obese women. 
Nevertheless, cross-sectional studies show that black African populations may be 
more sensitive to the accumulation of IMCL (42,155). Although another study found 
that IMCL was only associated with SI in white but not African American women and 
girls (156). Future interventional studies that manipulate IMCL such as an exercise or 
dietary interventions, may provide greater insight into this association between SI and 
skeletal mucle fat in black African women.  
1.8.8 HEPATIC FAT 
 
The liver plays an important role in glucose and lipid homeostasis both in conditions 
of low and excess energy intake (157). Postprandially, when energy sources are high, 
insulin will inhibit EGP and activate glycogen synthase to ensure glucose is converted 
to glycogen and stored. However, after maximal glycogen storage capacity has been 
reached, the excess glucose will be converted into free fatty acids via DNL. These free 
fatty acids can be esterified and stored in the liver as TGs or secreted as very low-
density lipoprotein (VLDL) and transported to adipose tissue and other tissue. Free 
fatty acids can also enter the mitochondria and undergo β-oxidation in the liver (158). 
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Under normal physiological conditions, minimal fat is stored in the liver. However, 
hepatic TG accumulation may occur if the net carbohydrate and free fatty acid flux into 
the liver is increased. Excess carbohydrates and free fatty acids may be derived from 
the diet or from increase fatty acid secretion from adipose tissue (159), a consequence 
of adipose tissue that exceeded its storage capacity as discussed previously. Further, 
the liver itself may increase TG synthesis. Hyperglycemia may stimulate lipogenesis 
through activation of the transcriptional factor, carbohydrate response element-binding 
protein (ChREBP) (159). Another mechanism that may explain hepatic fat 
accumulation is when fatty acid oxidation is decreased. This may occur as another 
consequence of dysfunctional adipose tissue which secrete less adiponectin (160). 
Hepatic fat accumulation associates strongly with hepatic insulin resistance in cross-
sectional studies in non-obese (161,162) and obese individuals (163,164), without 
T2D and in those with T2D (165). Furthermore, in obese adults with non-alcoholic fatty 
liver disease (NAFLD), hepatic fat accounted for 34% of the variability in hepatic insulin 
resistance (163). It is possible that hepatic insulin resistance may cause hepatic fat 
accumulation, but evidence is also available that suggests hepatic fat accumulation 
causes hepatic insulin resistance. Insulin resistance in the liver is characterized by an 
inability of insulin to suppress EGP, while DNL remains intact. Elevated glucose levels 
can stimulate pancreatic insulin secretion (166). Subsequent increased insulin levels 
stimulate DNL which promotes lipid accumulation in the liver. In support, targets have 
been found where these 2 pathways diverge downstream from the insulin receptor 
(166) which explains the molecular basis for insulin’s dual action in the liver. On the 
other hand, hepatic fat may also cause hepatic insulin resistance and the possible 
mechanism is the accumulation of lipid intermediaries such as diacylglycerol, that 
interrupts the insulin transduction pathway, which has been shown in human (167) 
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and mice (168) studies. Notably, discrepant findings of the association between 
hepatic fat and hepatic insulin resistance have been found in black populations. A 
significant positive association was found in non-obese, young Jamaicans without T2D 
(169) and in obese pre-menopausal South African women without T2D (42), whereas 
no association was observed in black men of West African descent residing in the UK 
whom have T2D (53). The reason for the inconsistent findings are not clear and 
whether differences in the measurement of hepatic fat or hepatic insulin resistance or 
population characteristics such as T2D status may explain it, requires further study. 
Further, ethnic discrepancies have been noted in hepatic fat accumulation with lower 
levels observed in black African populations compared to other ethnicities 
(42,53,155,170–172). However, despite black African populations exhibiting lower 
hepatic fat, they may have similar whole body SI compared to white populations (42) 
but only in the black Africans where hepatic fat associated with lower SI. This may 
indicate a greater sensitivity of SI to the effects of hepatic fat, but further research is 
required to explore the direction of causality in black Africans. 
The association between hepatic fat accumulation and peripheral insulin resistance, 
and whether the development of hepatic insulin resistance may precede this 
association requires further consideration. An elegant murine study was able to 
investigate the chronological effect of a high fat diet over 16 weeks on muscle, liver 
and adipose tissue SI as well as associated fat accumulation in these organs (168). 
Notably, hepatic insulin resistance occurred prior to muscle insulin resistance and was 
associated with an increase in hepatic fat content. Interestingly, the insulin 
suppression of lipolysis was not altered, only glucose uptake into the adipose tissue 
was reduced, which coincided with hepatic insulin resistance. Similar findings were 
observed in lean men after 5 days of high fat diet, such that hepatic insulin resistance 
62 
 
occurred prior to any changes in peripheral SI (173), however, adipose tissue SI was 
not measured. Based on these limited studies, it appears that hepatic insulin 
resistance seems to precede peripheral SI and is associated with increased dietary fat 
intake and hepatic fat accumulation, rather than increased free fatty release from 
adipose tissue.  
Hepatic fat accumulation may therefore not only induce hepatic insulin resistance but 
may also have an impact on systemic insulin resistance. Indeed, an association 
between hepatic fat and peripheral insulin resistance has been reported 
(163,165,174–177). These findings were obtained regardless of the method used to 
quantify hepatic fat. These methods varied from a liver biopsy (175) to magnetic 
resonance spectroscopy (MRS) (174,177). However, these studies were conducted 
mainly in white individuals. Due to the ethnic differences in adipose tissue distribution 
and ectopic fat deposition, these findings may not be applied to black Africans.  
 
1.9 INSULIN SECRETION 
 
Causal factors that have been implicated in the impairment of insulin secretion are a 
combination of reduced β-cell glucose sensitivity, glucotoxicity, lipotoxicity, 
inflammation and β-cell exhaustion (178). β-cell exhaustion occurs when the demand 
for insulin is high. This involves increases in the synthesis and packaging of insulin 
into storage vesicles, which can strain the endoplasmic reticulum and result in an 
increase proinsulin:insulin ratio. Nevertheless prior to β-cell failure and the 
development of IGT, normal plasma glucose levels are maintained through increasing 
plasma insulin levels (179). 
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Studies use various terms to describe β-cell function such as insulin response or 
insulin secretion. However in this thesis the insulin response refers to the fasting or 
stimulated plasma insulin levels and reflects both insulin clearance (hepatic and 
peripheral) and insulin secretion. Insulin secretion will refer to measures that reflect 
fasting or stimulated plasma C-peptide levels or the ISR, derived from C-peptide 
modelling. Importantly, the ability to maintain euglycemia depends on the ability to 
match the insulin response or insulin secretion to the prevailing level of SI. Indeed,  a 
hyperbolic relationship between the AIRg and SI, derived after a FSIGT, has been 
described (180). The product of AIRg and SI is also known as the disposition index 
(DI) and remains constant when the insulin secretory response completely 
compensates for the level of SI. In this thesis, DI will be used as an index of β-cell 
function. Of note, DI is an overall measure of insulin action because it encompasses 
both the insulin response and SI. A deterioration in DI will occur when the first phase 
insulin secretion/response is unable to fully compensate for the level of SI, which will 
result in IGT and eventually T2D. Importantly, defects in β-cells function have been 
observed early in the pathogenesis of T2D (181,182). In addition, the sensitivity of the 
β-cells to the stimulus of glucose may also affect β-cell function. This is a measure of 
insulin secretion in response to the incremental change in glucose. Indeed, β-cell 
glucose sensitivity was a predictor of deteriorating glucose tolerance in healthy 
Europeans (183). 
 
1.10 ASSOCIATIONS OF HEPATIC FAT WITH INSULIN CLEARANCE, 




Accumulation of fat in the liver has been associated with reduced insulin clearance 
and a higher insulin response (184). The exact mechanisms for this are not known but 
in vivo studies in rats (185) and dogs (186) have shown that free fatty acid infusion 
into the portal vein was associated with reduced hepatic insulin clearance. However, 
these results were not replicated in non-obese adults without T2D (187). The human 
study infused glycerol into the systemic circulation, which may explain the lack of 
association with hepatic insulin clearance.  
Majority of studies conducted in humans that assessed the association between 
hepatic fat and insulin clearance found a negative association (69,70,165,188), but not 
all (189) (Table 1.4). Different methods were used to quantify hepatic insulin 
clearance. Two studies used mathematical modelling that was able to distinguish 
between hepatic and peripheral insulin clearance (49,189). Others used the metabolic 
clearance rate formula that provides an estimate of total insulin clearance (69,188) or 
the C-peptide to insulin ratios (53,70) to approximate hepatic insulin clearance.  
Populations of African descent have shown reduced insulin clearance (44,49,50,59), 
although paradoxically have a lower hepatic fat than white populations (49,155) 
(42,171). Indeed, ethnic differences have been observed in the association between 
hepatic fat and insulin clearance. A study conducted in pre- and post-menopausal 
women without T2D found that hepatic fat was associated with lower basal hepatic 
insulin clearance only in white women, but not African American women (49). These 
findings were mirrored in men with early T2D, (53). This study reported that under 
basal conditions, hepatic fat was associated with lower total insulin clearance only in 
the white men but not in the black men of West African descent, while under stimulated 
conditions no association was found in both groups (53). However, no studies in Africa 
have measured both hepatic fat and hepatic insulin clearance and assessed their 
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relationship. Studies are therefore required to determine whether findings from other 
black populations residing in USA and UK are translatable to those living in Africa. 
 
Table 1.4: Studies, including ethnic comparison studies, that assessed the association 
between hepatic fat and insulin clearance 



















MRS FSIGT:  
Polidori (2016) model 
MMT: 
Cpep AUC0-30m/ 
Ins AUC0-30m and 
Piccinini (2016) model 
Basal HIE: 
B: No ~ 









M + F, Non-T2D 








MRS OGTT:  
1-(Ins AUC/Cpep AUC) 
HIE: 
Negative ~ 








T2D: 54 yo, NW 
+OB 
MRS HIEG  
Insuin infusion rate/ 
steady state [Insulin] 
Total IC: 
Negative ~ (å 





B (n=18), W 
(n=18) 
M, T2D,  MRI Hyperglycemic clamp:  




Basal total IC: 
B: No ~ 
W: Negative ~ 
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Total IC: 
B: No ~ (neg 
trend) 
W: No ~ 
Kotronen, 2007 
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MRS HIEG: 
Insulin infusion rate/ 
steady state [Insulin] 
Total IC 
Negative ~ 
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steady state [Insulin] 
and Cpep AUC/Ins AUC  
 
Total IC: 





2018 (USA) (189) 
NAFLD (n=13): 











(BMI matched ) 
CT OGTT + HIEG 







HF – Hepatic fat, IC – Insulin clearance, HIE – Hepatic insulin clearance, ~ - associations, å – adjusted, B – Black, 
W – White, H – Hispanic, NAFLD – Non-alcoholic fatty liver disease, T2D – Type 2 Diabetes, M – Male, F – Female, 
NW – Normal-weight, OB – Obese, OW – Overweight, HIEG – Hyperinsulinemic euglycemic clamp, FSIGT – 
frequently sampled intravenous glucose tolerance test, MMT – Mixed meal tolerance test, OGTT – Oral glucose 
tolerance test, AUC – Area-under-curve, [] -Concentration, MRTInsulin – Mean residence time of insulin, VAT – 
Visceral adipose tissue 
 
Hepatic fat accumulation may also affect the secretion of insulin from the pancreas, 
as explained by the Twin-cycle hypothesis (190). This hypothesis postulates that 
hepatic fat increases due to a positive energy balance that leads to hepatic insulin 
resistance. This will result in increased glucose production by the liver and elevated 
plasma glucose levels. Consequently, basal insulin secretion will increase, which will 
further increase hepatic fat through the effect of insulin on DNL. Increased VLDL 
secretion transports TGs to the rest of the body. Due to its proximity to the liver, the 
pancreas is susceptible to fat accumulation. This process culminates in both elevated 
plasma glucose and free fatty acids causing a reduction in β-cell function and β-cell 
glucose sensitivity. Additionally, an in vitro study showed that hepatokines secreted by 
fatty livers can induce inflammation in both the β-cells and the fat cells within the 
pancreas, that results in reduced insulin secretion in response to glucose (191). This 
study also highlighted that in cell culture, pancreatic fat does not alter insulin secretion 
on its own, but only after being exposed to free fatty acids and fetuin-A. However, 
studies have shown a lack of association between hepatic and pancreatic fat 
(192,193), which may indicate that other mechanisms may be involved in the 
interaction of pancreatic fat accumulation on insulin secretion and β-cell function.  
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1.11 ASSOCIATION BETWEEN PANCREATIC FAT AND INSULIN 
SECRETION/B-CELL FUNCTION 
 
Various mechanisms have been proposed to explain the reduction in insulin secretion 
and/or failure of β-cell function in the progression to T2D. The β-cells experience 
increased stress when demand for insulin is high, such as in black African populations 
that present with hyperinsulinemia. Endoplasmic reticulum and oxidative stress 
ensues, which may lead to reduced β-cell function (194). This results in incomplete 
folding of pro-insulin. Moreover, elevated blood glucose, known as glucotoxicity, has 
been shown to reduce insulin secretion (195). Another factor to consider is β-cell 
exhaustion, which occurs when continuous high insulin secretory responses depletes 
the available pool of insulin and results in a reduced insulin response. However, this 
seems to be transient, with studies showing an improvement in insulin secretion after 
the pancreas has been rested with drugs (i.e diazoxide) known to inhibit insulin 
secretion (196). In addition, the harmful effects of lipids and lipotoxicity on the β-cells 
is another factor to consider. Lipid intermediaries such as ceramides induce β-cell 
apoptosis (197). However, controversy exists regarding whether fat accumulation in 
the pancreas directly influences the β-cells ability to secrete insulin or whether it is just 
a marker of adipose tissue dysfunction. The lipotoxic effect on β-cells has been 
demonstrated in in vitro (198,199) and animal studies (200). One in vitro study 
revealed that prolonged exposure of the β-cell to free fatty acids can lead to decreased 
insulin gene expression, decreased stimulated insulin response and an increase in the 
apoptosis rate (198). Another in vitro study showed that β-cell death via apoptosis is 
due to endoplasmic reticulum stress that activates inflammatory pathways (199). A 
study conducted in rats demonstrated that chronically elevated systemic free fatty 
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acids correlated with fat in the pancreatic islet cells and with reduced glucose 
stimulated insulin secretion (200).  
In contrast to the in vitro studies, studies in humans have found no consensus on the 
association between pancreatic fat and insulin secretion or β-cell function. Table 1.5 
summarizes human studies that evaluated the association between pancreatic fat and 
insulin secretory function and β-cell function (51,191–193,201–211). These studies 
used different definitions of insulin secretion. Some used plasma C-peptide levels, 
which is more reflective of insulin secretion, while others used plasma insulin levels, 
which reflects both insulin secretion and insulin clearance (insulin response). In 
children without T2D, one multi-ethnic Canadian study reported an inverse association 
between the insulin response and pancreatic fat (206), while a bi-national study from 
Sweden and Austria found no association (203). The latter study adjusted for BMI as 
well as other fat depots such as VAT, SAT and hepatic fat, while the first study did not, 
which may explain the disconcordant findings. In adults without T2D but over a range 
of glucose tolerance, an inverse association was only observed in those with IGT 
(191,208) or with elevated hepatic fat (207), while no association was found in normal 
glucose tolerant women with a history of gestational diabetes (202) and in adults with 
or without T2D (192,193,201,210). Insulin response/secretion was derived after an 
oral glucose tolerance test (OGTT) for most of previously mentioned studies, except 
Van der Zijl et al. who used a HIEG method. A study that evaluated whether the 
association between insulin secretion/response and pancreatic fat differed between 
ethnicities found an inverse association only in white men, but not black African men 
with T2D (211). Contrastingly, a positive association was found between AIRg, derived 
from a FSIGT, and pancreatic fat in both black African and white adults without T2D. 
However, the association in black Africans had a steeper slope, while an inverse 
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association was found in Hispanics (209). Studies that investigated the association 
between pancreatic fat and β-cell function (insulin secretion/response normalised to 
the level of SI) also found discrepant results. In one study, there was an inverse 
association in those without T2D, while those with T2D showed no association (192). 
No association was found between pancreatic fat and β-cell function in black Africans 
and Hispanic teenagers and young adults without T2D, independent of ethnicity (204). 
Another ethnic comparison study found a positive linear association in black African 
women, while in white and Hispanic women a non-linear association was noted (51). 
This study grouped lean and obese women with and without T2D together. Taken 
together, significant associations between pancreatic fat and insulin 
response/secretion were only apparent in those with IGT or elevated hepatic fat, but 
not in those with normal glucose tolerance or with T2D. Further, ethnicity seems to 
influence the nature of these associations, such that in black African populations a 
greater positive association was evident between both the insulin response and β-cell 
function and pancreatic fat, compared to Hispanics, which may be due to lower 
pancreatic fat deposition observed in black African populations. All these studies were 
cross-sectional and therefore it is difficult to evaluate causality. A longitudinal study 
that followed Japanese adults for 5 years found no association between pancreatic 
fat, determined by CT, and T2D onset (212). However, interventional studies that 
induced substantial weight loss either through dietary restriction (~15 kg weight loss) 
(213) or after bariatric surgery (13.6%) (214) in individuals with T2D, found that the 
first phase insulin response improved concomitant with a reduction in pancreatic fat. 
Although the association of pancreatic fat with insulin response and β-cell function has 
been studied across various populations, no study has been conducted in black 
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Africans living in Africa to determine whether pancreatic fat follows similar patterns to 
those in black populations residing in other continents. 
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Table 1.5: Studies that evaluated the association between pancreatic fat and insulin secretion and/or β-cell function 





Association (~) PF with 
insulin secretion 




Germany; White M+F, adults 
OW/OB 
Non-T2D, T2D MRS OGTT No ~ No ~  
Cohen, 2014 (206) Canada; White, Black, 




Non-T2D MRS/MRI OGTT Neg ~ * 
(å sex, puberty, ethnicity) 
Neg ~ 
(å sex, puberty, ethnicity) 








OGTT Neg ~ * (IGT) 
No ~ (NGT) 
- 








OGTT Neg ~ (IGT/IFG) 
No ~ (NGT) 
- 
Hakim, 2018 (211) UK; Black, White 
 
M, T2D MRI MMT, HIEG 
 
 
Black: No ~ 
White: Neg ~  












OGTT Neg ~ * 









MRS OGTT No ~ * No~  







FSIGT - No ~  
(å ethnicity, sex, VAT, SAT, 
HLC, BF, FFA) 
Lingvay, 2014(51) USA; Black, White, 
Hispanics  
 
F, adults Non-T2D, T2D MRS 
 
FSIGT - Combined non-T2D/T2D 
Black: Neg ~(linear) 







M+F, adults Non-T2D MRS OGTT No ~ - 











No ~ No ~ 
72 
 









OGTT No ~ 
(å age, BMI, VAT, SAT, HLC) 
No ~ 
(å age, BMI, VAT, SAT, HLC) 
Szczepaniak, 2012 
(209) 






Non-T2D MRS FSIGT Black: pos ~ * 
White: pos ~ * 
Hispanic: neg ~ * 












Neg ~ (Non T2D) 
No ~ (T2D) 
å (BMI, fglc, TG) 










HIEG No ~ No ~ 
(å age,BMI) 
Insulin secretion – measures derived using plasma C-peptide levels, * - plasma insulin levels were used to measure insulin response, B-cell function – insulin secretion/response normalized to the 
level of insulin sensitivity;  PF – Pancreatic fat, M – Male, F- Female, OW – Overweight, OB -Obese, NonT2D- Non- Type 2 Diabetes, IGT – Impaired glucose tolerance, IFG – Impaired fasting 
glucose, OGTT – Oral glucose tolerance test, FSIGT – Frequently sampled intravenous glucose tolerance test, MMT – Mixed meal tolerance test, HIEG – Hyperinsulinemic euglycemic clamp, å – 
Adjusted, Neg– Negative association, Pos – Positive association, HF – Hepatic fat content, SAT – Abdominal subcutaneous adipose tissue, VAT – Visceral adipose tissue, BMI – Body mass index, 
fglc – fasting glucose, TG – triglycerides, FFA – fat free fatty acids 
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1.12 ROLE OF BODY FAT DISTRIBUTION ON INSULIN RESPONSE OR ß-
CELL FUNCTION 
 
Based on the expandibilty hypothesis, if the maximum expandibility of SAT is reached, 
an increase in VAT may be observed (27). Accordingly, the effect of VAT, or the VAT-
aSAT ratio on the insulin response or β-cell function should also be considered. 
Indeed, a negative association between DI and VAT has been found in black African 
(54,128) and white adults (189). However, this was not a consistent findings with no 
association found in other studies conducted in both black African and white adults 
(45,140) as well as in black African children (55). Reasons for these discrepant 
findings may be the level of VAT or the direction of association between VAT and the 
components of DI. As mentioned, DI is a composite measure of both SI and AIRg and 
therefore the association between VAT and SI, as discussed in section 1.8.6, may also 
explain the above findings. For example if a negative association is found between SI 
and VAT and a positive association between AIRg or ISR and VAT, no association 
between DI and VAT may be apparent due to matched compensation. Further, aSAT 
was not associated with DI (45,128,165,215) in black African and white populations, 
when VAT was also placed in the model. The lipolytic and immunogenic profile of VAT, 
compared to aSAT may explain these findings. 
Another consideration is that VAT may associates directly with AIRg or ISR and thus 
requires further mentioning. Interestingly, ethnic differences have been observed such 
that a positive association was found between AIRg and VAT in white adults 
(83,114,140,215), while a negative association has been observed in African 
American adults after adjusting for SI, but no association was found between AIRg and 
74 
 
VAT-aSAT ratio (128). However, another study in African American women found no 
association between AIRg and VAT or aSAT in a multivariate model, but collinearity 
could have occurred through the inclusion of body fat weight and body fat percent into 
the same model. In addition, the association of VAT or VAT-aSAT ratio with β-cell 
function were not examined in this study. Importantly AIRg reflects both insulin 
clearance and ISR and how these components relate to VAT or aSAT is also of 
interest. Although a positive association has been found between insulin secretion 
[derived after both an OGTT (140) and FSIGT (138)] and VAT in white populations, no 
evidence is available in black African populations. In addition, women of black African 
descent have lower VAT compared to white women (61,85) which may contribute 
towards the ethnic specific association between VAT and the insulin response. Finally, 
none of these studies incorporated whether the association between the insulin 
response and VAT or VAT-aSAT ratio could be mediated through insulin clearance, 
which may be an important compensatory mechanism in black African women.  
Further, associations between insulin secretory function and VAT are confounded by 
ectopic fat accumulation in the liver and pancreas, since it has been postulated that 
VAT accumulation may precede ectopic fat deposition in the liver and pancreas (132). 
One ethnic-comparison study found that in African American adults, VAT was not 
associated with AIRg, independent from pancreatic fat such that VAT did not add 
significantly to the model. A similar finding was found in white individuals, while in 
Hispanics, VAT, together with hepatic and pancreatic fat were all independent 
predictors of AIRg (209). Another study conducted in African American and Hispanic 
adolescents and younger adults (13-25 year old) reported that VAT confounded the 
associations between hepatic and pancreatic fat and between pancreatic fat and 
inflammatory markers, but did not directly ascertain whether VAT associates with AIRg 
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or DI independent from hepatic and pancreatic fat. Therefore further studies are 
needed to establish whether fat partitioning observed in African Americans are similar 
in black populations living in Africa and whether VAT is a more important correlate of 
insulin secretory function compared to hepatic and pancreatic fat. 
 
1.13 EXERCISE TRAINING  
 
Physical inactivity is a risk factor for the development of obesity and T2D (216). Low 
levels of physical activity have been reported in African American women with 57% 
engaging in less than an hour a week of walking for exercise (217). Whereas in a 
cross-sectional South African study conducted on urban black women, 67% were 
deemed physically active according to the Global Physical Activity Questionnaire 
(218). Nevertheless, majority of the physical activity time was attributed to low 
intensitiy activity, accumulated during walking, which is used as a mode of transport 
(219). Moreover, this low intensity activity might explain the low cardiorespiratory 
fitness observed in the black South African women, which was below the 5th percentile 
for females between 30-39 year of age (219). Similarly, in the USA, the National Health 
and Nutrition Survey reported that African American women across a range of BMI 
(20-49 year old) had lower VO2max (32.9 ml/kg/min) compared to white (35.9 ml/kg/min) 
and Hispanic women (36.0 ml/kg/min) and with increasing obesity the decline in 
VO2max was more pronounced in the African American women (220). Further, low 
cardiorespiratory fitness has also been associated with insulin resistance in black 
South African women (219). Clearly, obese women of African descent would benefit 
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from an exercise intervention that has been shown to improve both cardiorespiratory 
fitness and SI.  
Lifestyle interventions that include exercise together with diet are a cornerstone in the 
management of T2D (221), but also in the prevention of T2D (222–224). Large 
population-based diabetes prevention studies have shown that a combination of diet 
and increased physical activity in those with IGT can reduce the risk of T2D by 58% 
(224) in the US Diabetes Prevention Program, by 43% (225) in the Finnish Diabetes 
Prevention Study and by 42% (222) in the Chinese Diabetes Prevention Study (Da 
Qing). Interestingly, in the Da Qing study, exercise without dietary intervention reduced 
the risk of T2D by 46% (222). The importance of exercise training and its metabolic 
benefits in improving glucose homeostasis has been noted and hence The American 
Diabetes Association recommends 2.5 hours of moderate aerobic activity per week 
for the prevention of T2D (100). 
While a healthy diet is an important component of a healthy lifetsyle and the prevention 
of obesity and T2D, this thesis has focused solely on the effect of exercise training on 
improving metabolic outcomes. The impact of diet on obesity and insulin resistance is 
beyond the scope of this thesis and will therefore not be discussed further.  
 
1.13.1 OVERVIEW OF THE EFFECT OF EXERCISE ON GLUCOSE AND FAT 
METABOLISM 
 
It is important to provide a brief overview of the effect of exercise on glucose and fat 
metabolism including glycogen depletion to identify the cellular mechanisms that may 
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explain changes in SI and hyperinsulinemia in response to exercise training (Figure 
1.4). 
During exercise, the muscles require fuel to sustain contractions. The type of fuel, 
whether glucose or fat, depends on the intensity of exercise, session duration, 
exercise modality, diet prior to exercise, duration since last meal and the ability to 
oxidize fat (226). During exercise, glucose disposal and utilization in the muscle can 
occur independent from insulin. Muscle contraction initiates the uptake of glucose 
through an insulin-independent pathway, AMP kinase signalling, that result in 
increased GLUT4 translocation to the plasma membrane (227). The glycogenolysis 
pathway will dominate to further supplement the availability of glucose with less 
glucose converted to glycogen. This will deplete the glycogen stores in the muscle. If 
more glucose is required, the liver will assist by increasing glucose production either 
through breakdown of glycogen or through EGP under the influence of glucagon. Upon 
entering the cell, glucose will be phosphorylated to glucose-6-phospate by hexokinase 
(HK). Glucose-6-phospate will undergo a series of metabolic reactions (indicated by 
an asterisk* in figure 1.3) to be converted to pyruvate and then to acetyl Coenzyme A 
(if oxygen is available), which will be transported into the mitochondria for complete 
oxidation (228). During moderate intensity and longer duration of exercise, fat 
oxidation will increase. (226). In the fasted state, free fatty acids will be derived from 
adipose tissue lipolysis under the influence of epinephrine (228). Further, during 
exercise, insulin levels are low and therefore DNL in the liver will be inhibited and VLDL 
secretion reduced (229). 
Some of the mechanisms that may explain the improvement in SI after exercise 
training are an increase in GLUT4 transporters in the cell membrane (230) and 
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improved phosphorylation of insulin receptor substrates and other key molecules in 
the insulin signalling cascade (231). In addition, glycogen depletion may also 
contribute to an exercise-induced improvement in SI (232). Moreover, exercise training 
may increase mitochondrial biogenesis and enhance mitochondrial function in both 
skeletal muscle (233) and adipose tissue (234), with an augmentation in oxidative 
capacity. In particular, an improvement in fatty acid oxidation (235) may occur either 
through the increased uptake of FFAs, via fatty acid transporter proteins, into the cell 
and/or the improvement of FFAs transport into the mitochondria via the carnitine 
palmitoyl transferase 1 and 2 (CPT1/2) complex and/or through the upregulation of 
enzymes involved in β-oxidation.  
 
AMPK- Adenosine monophosphate activated protein kinase,  CPT1/2 - Carnitine palmitoyl transferase 1 and 2, 
DNL – De novo lipogenesis, EGP – Endogenous glucose production, FFA – free fatty acids Glc – glucose, GDP – 
Guanosine-5-diphosphate, GTP – Guanosine-5- triphosphate, HK – Hexokinase, ,  LPL – Lipoprotein lipase, TBC1D1 
– Rab-GTPase activating protein TGs – triglycerides,  
Figure 1.4: Overview of glucose and fat metabolism during exercise, schematic 
adapted from Brouwers et al (2017) (229) and Richter et al (2013) (230) 
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1.13.2 FACTORS AFFECTING THE INSULIN SENSITIVITY RESPONSE TO EXERCISE 
TRAINING 
 
The effect of exercise on SI has been extensively studied with systematic reviews 
already published in those with and without T2D (227,236–238). Therefore, in this 
section, a brief overview of factors that can influence the SI response to exercise 
training will be given followed by a discussion on the effect of exercise training on SI 
in black populations of African descent.  
An acute exercise bout increases SI, an effect that can last up to 72 hours (239). 
However, to sustain the insulin-sensitizing effects of exercise for longer, a chronic 
exercise training program is required, which may lead to adaptations that promote a 
greater glucose disposal (238). The underlying metabolic health of a study population 
and the volume and intensity of an exercise training intervention may influence the 
insulin sensitizing responses to exercise training. It has been reported that those who 
are more insulin resistant show greater improvements in SI (240). In support, Madsen 
et al. showed that only those with T2D showed an improvement in SI compared to no 
improvement in those without T2D. Further, the effect of volume and intensity of 
exercise training on SI have been studied in a randomized controlled trial (241). 
Overweight-obese older adults (mean age >50yo) without T2D participated in a 6-
month intervention of either a low volume/moderate intensity or low volume/high 
intensity or a high volume/ high intensity exercise training compared to a control group. 
SI improved significantly in all 3 groups, but the greatest improvement (~85%) was 
seen in those groups with a longer exercise duration (~170 minutes/week) compared 
to the low volume/low intensity group (~40%) (~115 minutes/week). In addition, greater 
improvements in SI are found with increasing exercise dose, however this study did 
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not demonstrate a minimum or maximum threshold for an improvement in SI (242). 
Another aspect to consider is the effect of high intensity interval or sprint interval 
training compared to moderate intensity continuous training on SI. While, both sprint 
interval training and moderate intensity continuous training over 12 weeks, in non-
obese men, increased SI similarly, in the sprint interval group this was accomplished 
with a lower time commitment of 30 mintutes per week compared to 150 minutes per 
week (243). However, in another study in obese girls, 12 weeks of high intensity 
interval training increased SI to a greater degree compare to moderate intensity 
exercise (244). Nevertheless, high intensity training may not improved SI in all 
populations (245). 
The mode of exercise training is another factor to consider when evaluating the effect 
of exercise training on the improvement of SI. The effect of resistance training on SI in 
adults without T2D has been studied less extensively compared to the effect of aerobic 
exercise. A study that randomized young (18-35 years old), normal-weight women 
either to a resistance training group, an aerobic training group or a control group for 6 
months found that SI improved similarly in both the exercise groups, but not in the 
control group (246). Similarly, a study in older overweight/obese men found that SI 
improved regardless of the mode of exercise after 12 weeks (247). Contrastingly, in 
older women (54-78 years old), no improvement in SI  was found in both the resistance 
or aerobic exercise training groups after 6 months (248). However, this study attributed 
the lack of improvement in SI to the frequency of exercise which was 3 times per week. 
Another study conducted in overweight adults (18-70 years old) reported that a 
combination of resistance and aerobic training was more effective in improving SI and 
sustaining this improvement after 14 days of no exercise, compared to either type of 
exercise on its own (249). A mechanism to explain the improvement in SI after 
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resistance training may be an increase in skeletal muscle mass. However, limited 
evidence exists in those without T2D. For example, after 8 months of resistance 
training in overweight-obese adults without T2D, lean body mass increased 
significantly but no changes in SI were observed (249). However, resistance training 
has shown to improve key mediators of uptake of glucose in both insulin-sensitive and 
insulin-resistant muscles such as the GLUT4 protein content and enzymes in the 
insulin signalling cascade, which may occur independent of muscle mass changes 
(250). Taken together, these studies suggest that both aerobic and resistance training 
can improve SI, and a combination is recommended for the prevention and treatment 
of T2D (100). 
The majority (235,242,249,251–271), but not all (271–277) exercise-training studies 
show an improvement in SI. The discrepancies observed in these studies may perhaps 
be explained by the impact of exercise training on body composition and body fat 
distribution. An improvement in SI after exercise training may be mediated through a 
reduction in body weight. Indeed, most studies that did not report a significant 
reduction in body weight also did not report a change in SI (253,271,274,275). 
However, a study conducted in adults with T2D that participated in 2 weeks of sprint 
interval or moderate-intensity continuous training reported an improvement in SI 
without a concomitant reduction in weight (252). Nonetheless, this study also 
demonstrated a reduction in body fat mass, VAT and SAT. Lack of change in body 
weight or BMI may not always correlate with body fat changes. Therefore it is important 
to evaluate the effect of exercise training on fat-free soft tissue mass, body fat mass, 
as well as on regional fat depots when assessing the impact on SI.  
The VAT depot has been shown to be an important correlate of insulin resistance in 
cross-sectional studies, as well as in a recent longitudinal study (143). Therefore a 
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reduction in VAT may contribute to an improvement in SI after exercise training. 
Moreover, VAT responds more readily to adrenergic-stimulated lipolysis induced by 
exercise (278) and thus may be preferentially reduced after exercise training. Indeed, 
studies that measured VAT and reported an improvement in SI also observed a 
concomitant reduction in VAT (235,251,269,271). However, these studies also 
reported concomitant reductions in aSAT (235,251,269,271) and body fat mass 
(235,251,271), which could also explain the improvement in SI. However, studies that 
assessed the contribution of VAT to the improvement in SI, independently from body 
fat mass and/or other body fat depots have shown conflicting results. One study 
reported that VAT was not an independent predictor of SI when accounting for 
reductions in body fat mass, aSAT and subfascial thigh fat (235), while another study 
found that VAT contributed to the improvement in SI, independently from other fat 
depots (251). However, differences in study populations may have contributed to these 
discrepancies, the latter study (251) included both overweight and obese participants 
while the former study (235) included only obese individuals. Importantly, both these 
studies combined exercise training with calorie restriction. Nevertheless, a Danish 
study randomized obese adults without T2D into an exercise training without calorie 
restriction group, a calorie restriction only group or an exercise training combined with 
calorie restriction group. They showed that in the exercise training alone group, the 
relative reduction in VAT was greater compared to the reduction in body fat mass, but 
in all 3 groups, the reduction in VAT correlated closely with the reduction in body fat 
mass (273). This study did not perform a multivariate analysis to determine the 
independent contribution of a reduction in VAT to SI but reported that after exercise 
training alone, the reduction in VAT, aSAT and the gluteal-femoral depot were similar. 
The evidence with regards to whether a reduction in VAT may be a more important 
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correlate of an improvement in SI after exercise training above a reduction in body fat 
mass or other regional fat depots is inconclusive.  
Few exercise-intervention studies that evaluated the effect of exercise training on SI 
have been conducted in black African populations (Table 1.6). Two studies that 
reported an improvement in SI, conducted the FSIGT <72 hours after the last exercise 
bout (279,280); the results may therefore reflect the effect of an acute exercise bout 
rather than chronic adaptation. Ortmeyer et al. included African American and white 
post-menopausal women, but found no interaction by ethnicity and therefore reported 
results in the combined group (281). In this study, an improvement in SI was found 
after 6 months of high-intensity aerobic exercise training combined with calorie 
restriction that coincided with a reduction in body weight, VAT and SAT. A study 
conducted in pre-menopausal, overweight-obese African American women without 
T2D reported no change in SI after 14 weeks of high-intensity interval training (245). 
In addition, no improvement in VO2peak and no change in body weight and SAT were 
observed, but a reduction in VAT was noted. Notably, there is a dearth of randomized-
controlled exercise intervention studies in populations of black African descent that 
are able to assess the independent effects of exercise training on SI together with body 
composition and body fat distribution, and crucially, no exercise intervention study has 







Table 1.6: Summary of exercise intervention studies from USA that included African 
Americans individuals and measured insulin sensitivity 
Study Participants Study 
groups 
Exercise intervention: Dx, 
volume, intensity, mode 
SI Method ∆ SI Other changes 
Arad, 2015 
(245) 








High Fat Diet 
10d prior to 
testing 
14 weeks,  
Three 24 min sessions/week 
75-90% HRR,  
















7 consecutive days 
65% HRR 


























No Δ: VO2peak 
























↓: BW, BF, 
VAT, SAT 
Dx – Duration of exercise training, SI – Insulin sensitivity, Δ – Change,F- Female, M – Male, OW – Overweight, OB 
-Obese, NonT2D- Non- Type 2 Diabetes, IGT – Impaired glucose tolerance, B – African American, H – Hispanic, W 
– White, CON – control group, EX- exercise group, HRR – Heart rate reserve, HIT – High intensity training, HIEG – 
Hyperinsulinemic euglycemic clamp, BW – Body weight, BF – Body Fat, SAT – Abdominal subcutaneous adipose 
tissue, VAT – Visceral adipose tissue, IMAT – intramuscular fat, IC – insulin clearance, ↑ - increase, ↓- decrease 
 
1.13.3 EFFECT OF EXERCISE TRAINING ON HYPERINSULINEMIA 
 
The preservation of the insulin response and β-cell function is critical in preventing or 
delaying the onset of T2D and therefore investigating the effect of exercise training on 
these key components is warranted. During an acute bout of exercise, insulin secretion 
will depend on the intensity of the exercise (282). During both low and moderate 
intensity exercise, insulin secretion is inhibited to allow the liver to produce more 
glucose under the influence of glucagon. This ensures euglycemia while glucose is 
taken up by the muscle, via an insulin-independent pathway. Similarly, during high 
intensity exercise, insulin secretion is reduced, however, the rate of glucose production 
is much higher compared to lower intensity exercise. During the post-exercise period, 
glucose uptake reduces more than glucose production which results in hyperglycemia. 
85 
 
Insulin secretion will therefore increase during this period to normalize glucose levels 
(282). However, whether chronic adaptations occur in the insulin response to glucose 
after exercise training, as well as whether the exercise-induced changes in both the 
insulin response and β-cell function differ according to diabetic status requires 
discussion. Studies that reported on the effect of exercise training on insulin response/ 
secretion or β-cell function are summarized in Table 1.7. 
Studies that have shown an improvement in SI after exercise training also reported a 
reduction in the insulin response (251,260,264,265,280,283,284). The majority of 
these studies were conducted in those without T2D (251,260,265,283). T2D status 
may modify the exercise-induced change in the insulin response because those with 
T2D may have already impaired insulin responses. Indeed, a study conducted in those 
with T2D, differentiated between low and moderate insulin secretors and found that 
after 3 months of exercise training, the moderate secretors had an increased insulin 
response, whereas in the low secretors showed no change (285). Interestingly, in this 
study the insulin response was augmented in the moderate secretors without an 
improvement in SI. Moreover, in those with T2D the residual insulin response is 
therefore an important factor in the exercise training response and can perhaps 
explain discrepant findings in those with T2D. For example, after 8 weeks of high 
intensity training in those with and without T2D, no changes occurred in the insulin 
response (263). While in another study conducted in those with T2D and prediabetes 
reported a reduction in the insulin response after 12-16 weeks of moderate-high 
intensity training (284). Further, the mechanism responsible for a lowered insulin 
response after exercise training could be due to lower insulin secretion. A study that 
evaluated both the insulin response and the insulin secretory capacity, derived from 
C-peptide measures, after 12 weeks of vigorous training in obese prediabetic adults, 
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found that only the insulin response decreased but not the insulin secretory response, 
indicating an increase in insulin clearance only (284). However, in Heiskanen et al, the 
ISR, obtained through C-peptide deconvolution and normalized to glucose 
concentration (0-30min), decreased after exercise training in both those with T2D and 
those without (252).  
As previously mentioned, the insulin response normalized to the prevailing level of SI 
is a better marker of β-cell function. The β-cell function in response to exercise will 
therefore depend on the net change in SI and the insulin response. An increase in β-
cell function was observed in studies that reported an increase in SI  together with a 
reduction (264,284) and no change in insulin response (263). These studies indicate 
that the degree of change in SI is an important contributor to the improvement in β-cell 
function. Exercise intensity and volume also influences the degree of change in SI and 
β-cell function. Compared to low volume/high intensity and high volume/high intensity 
exercise training, low volume and moderate intensity exercise training resulted in the 
biggest increase in β-cell function in adults without T2D due to a large increment in SI 
and no change in the insulin response (261). In addition, combining aerobic and 
resistance training will sustain increases in β-cell function for at least 14 days post-
exercise compared to aerobic or resistance training alone (249), due to an increase in 
SI that only reduced by less than 50% after detraining. Indeed, the influence of 
exercise training on the insulin response and β-cell function seems to be driven by 
changes in SI. Black African populations frequently present with hyperinsulinemia and 
a reduction in the acute insulin response was found in African American women after 
acute exercise (280), but not in African American and Hispanic adolescents (279). 
However SI increase after exercise training in both the latter 2 studies  
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The effect of exercise training on insulin clearance requires further mention, especially 
since this may be a mechanism through which exercise training may reduce the insulin 
response. Although studies in Table 1.7 evaluated the effect of exercise training on 
insulin response or β-cell function, they did not evaluate the effect on insulin clearance. 
Nevertheless, two other studies assessed the effect of exercise training on insulin 
clearance (245,286). One study, in which ethnicity was not mentioned, was conducted 
in overweight-obese adults with IGT and reported that insulin clearance did not change 
after 12-weeks of combined aerobic and resistance training, but increased after using 
metformin or metformin in combination with the exercise training program (286). In 
contrast, SI improved to a greater extent in the exercise training group compared to 
both the metformin groups. This study speculated that exercise training does not affect 
insulin clearance unless combined with metformin. The other study conducted in pre-
menopausal African American women without T2D found no change in insulin 
clearance after 14 weeks of high-intensity interval training (245). Nevertheless, both 
these studies determined the insulin clearance after a hyperinsulinemic euglycemic 
clamp, which compared to a FSIGT derived measure, correlates poorly with direct 
measures of insulin clearance (287). More studies are therefore necessary to assess 
the effect of exercise training on insulin clearance derived from FSIGT measures in a 
black African population who typically present with lower insulin clearance compared 
to white populations (59) 
In the following sections the effect of exercise training on ectopic fat will be discussed 
to determine whether these changes may explain changes in SI and hyperinsulinemia.
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Table 1.7: The effect of exercise training on insulin response/secretion and β-cell function 
Study 
(Country) 
Participants Study groups Exercise intervention: Dx, 




∆ Insulin response/ 
secretion 
















age, sex, BMI, 
race) 
8 months 
RES:180min/wk, 8 Exercises, 








16-24hrs post Ex 
RES: No ∆ 
AER: ↓  
AER+RES: No ∆ 
16-24hrs post Ex 
RES: No ∆ 
AER: No ∆ 
AER/RES: ↑ 
14 days post Ex 
AER: ↓ (trend) 
AER+RES:↑ (trend) 
↑ VO2max (AER> 
other groups) 
↑SI (AER+RES only) 






Black, F, 51±2yo, 
OB, NonT2D,  






Yes ↓  ND ↑ SI, 






M+F, 36yo, OB, 
Non-T2D,  
EX (n=9) 8 weeks, five 60min 
sessions/wk, 60 min, Mod-
intensity aerobic exercise 
OGTT - AUCIns 
Post-Ex: 36-48h  
Yes ↓ ND ↑: VO2max, SI, 
FAO 











EX (n=9) vs 
NoEX (n=7) 
Low secretors: 
EX (n=5) vs 
NoEX (n=3): 
 










Ins and Cpep  
responses 
EX: 
Mod secretors: ↑ 
Low secretors: no ∆ 
NoEX 
Mod secretors: no 
∆ 
Low secretors:  
ND ↑VO2max 






White, 40-55yo:  







2 weeks, SIT: 4-6 sessions 30s 
cycle/4min rest 
CT:  6 sessions of 40-60min, 




T2D: ISR basal ↓  
NonT2D: ISR early↑  
T2D/NonT2D: 
ISR/Glc0to30min ↓  
ND ↑VO2max 
↑SI 




(SIT vs CT 
combined) 
Kahn, 1992 
(USA)(265)   
M, 61-82yo, FM 
19.4%, NonT2D 
EX (n=13) 6 months, five 45min 
session/wk,  
80-85%HRR 







AIRg Yes ↓ 
AIRmax ↓ 
Glc sensitivity No ∆ 
No ∆ ↓BW, BF 
↑VO2max 
↑SI 
































EXCR: 5 sessions/wk, aerobic 
exercise, ↑ energy 
expenditure by 12.5% and 




↓ (all 3 
intervention 
groups) 
ND ↑SI (EXCR, LCD) 











8 weeks, 3 sessions/wk, High 
intensity interval training 
10x6s cycle 




IGI: No Δ 
T2D: Yes↑ 
NonT2D: No Δ 
T2D: ↓2h glucose, 
HOMA-IR 
T2D and nonT2D: 












12 weeks, 5 sessions /wk, 






(1st and 2nd phase) 
Cpep/Glc: No Δ 
(1st and 2nd phase) 
↑  































8 months,  





Lo/Mod No Δ 
Lo/Vig ↓ 










Hi/Vig (n=64) Lo/Vig: 65-80% VO2peak, 
113min/wk 













EX (n=105) 12-16 weeks, 4-5 
sessions/wk, ~60min/d, 





1st and 2nd phase 
↑  
1st and 2nd phase 
↑SI, VO2max 
↓;BMI, BF 
Dx – Duration of exercise training, Δ – Change, F- Female, M – Male, OW – Overweight, OB -Obese, NonT2D- Non- Type 2 Diabetes, IGT – Impaired glucose tolerance, RES – 
Resistance training group, AER – Aerobic training group, CON – control group, EX- exercise group, CR – Calorie restriction, EXCR – Exercise and calorie restriction group, LCD – 
Low calorie diet, SIT – Sprint interval training, CT – continuous training, Lo/Mod – low volume moderate intensity exercise group, Lo/Vig – low volume, vigorous intensity 
exercise group, Hi/Vig – High volume, vigorous intensity exercise group, HRR – Heart rate reserve, Wmax – maximum work load, HR – Heart rate, HIT – High intensity training, 
FSIGT – Frequently sampled intravenous tolerance test, OGTT, Oral glucose tolerance test, HIEG – Hyperinsulinemic euglycemic clamp, AIRg – Acute insulin response to glucose, 
DI – Disposition index, IGI – Insulinogenic index, AUCIns – Area-under-curve Insulin, GSIS – Glucose stimulated insulin secretion, ND – Not done, SI – Insulin sensitivity, BW – 
Body weight, BF – Body Fat, SAT – Abdominal subcutaneous adipose tissue, VAT – Visceral adipose tissue,  PF – Pancreatic fat, FAO – fatty acid oxidation, DAGs – diacylglycerol, 
HF- Hepatic fat, HOMA-IR Homeostatis Model assessment of Insulin Resistance, ↑ - increase, ↓ - decrease
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1.13.4 EFFECT OF EXERCISE TRAINING ON SKELETAL MUSCLE FAT 
 
During exercise the main source of lipids used in oxidation, are from plasma long-
chain fatty acids derived from VAT and SAT lipolysis, 10% from intramyocellular 
lipids and less than 5% from VLDL (288). The net effect of exercise training on 
lipids depends on the metabolic status, lean vs obese, trained vs untrained as well 
as the diet before and during exercise (289). Another important factor to consider 
is the intensity of exercise, with maximal fat oxidation occurring during moderate 
intensity exercise. Further, the longer the duration of exercise, the more reliant the 
muscle will be on lipids as a fuel source (226). A recent study also highlighted that 
the type of exercise is important, with an increase in IMCL observed with 2 weeks 
of sprint interval training (4-6 30 second cycling sessions with 4 minutes of 
recovery), but no change observed with 2 weeks of moderate-intensity continuous 
training program (40-60 minutes), regardless of the metabolic status of the 
participants (290). 
Considering all the factors that may influence the exercise response of 
intramuscular fat, it is not surprising that studies have reported mixed results. Table 
1.8 summarizes studies that evaluated the effect of exercise training on 
intramuscular fat and SI. Studies in those without T2D reported no changes 
(251,253,270,273,274,283,291), an increase (277,292,293) and a decrease (294) 
in intramuscular fat. The discrepancies between these studies may be explained 
partly by the exercise duration. The studies that showed a change in intramuscular 
fat ranged from 2 weeks to 16 weeks, while the studies that did not report a change 
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range from 4 weeks to 6 months. As most studies used a moderate intensity 
aerobic exercise training, the exercise intensity and mode were unlikely 
explanations for the discrepant findings . Another important factor to consider are 
the methods use for intramuscular fat assessment, namely histochemistry after a 
muscle biopsy or magnetic resonance spectroscopy (MRS), which are able to 
distinguish between IMCL and EMCL content, with one study using magnetic 
resonance imaging (MRI) that measures total intramuscular fat. Although the 
above-mentioned studies focused on those without T2D, differences in study 
population can still occur. For example, an increase in IMCL was observed in 
studies that included young males (BMI was not mentioned) (277), or lean older 
adults (293). However, the third study that showed an increase in IMCL was 
conducted in older adults that were overweight or obese (292). 
Findings from studies that were conducted on those with T2D also lacked 
consistency. One study, using a combination of aerobic and resistance training, 
reported an increase in IMCL, (270), while a decrease was observed in another 
study using only aerobic exercise training (291). No change in IMCL was reported 
in another 12-week study that used combined aerobic and resistance training with 
a concomitant Paleolithic diet (295). The reason for the heterogeneity in findings 
is not clear but differences in the intervention duration, the study population and 
diet may contribute to the discrepant findings. 
No study found an association between the changes in intramuscular fat and 
changes in SI, although an improvement in SI occurred in most of the studies 
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(251,253,270,273,283,291,292,294–296). Two studies (274,293) that did not 
report an improvement in SI, used HOMA-IR as a surrogate marker of SI and the 
other study used an insulin tolerance test (277). In addition, two of the studies were 
of a shorter duration, 2 weeks (277) and 4 weeks (293). Importantly, an 
improvement in SI  was observed in studies without a concomitant change in 
intramuscular fat (251,253,270,283,291,295). This suggests that changes in 
intramuscular fat content are not essential for improvements in SI.  Perhaps 
changes in lipid intermediaries such as diacylglycerols (292), improvements in 
oxidative capacity (283,291,294,296,297), or metabolic flexibility (270) may be 
more important correlates of SI improvements. However, majority of these studies 
investigating the effect of exercise training on both SI and skeletal muscle fat were 
conducted in predominately white populations. In addition, no study focused only 
on premenopausal women. A gap therefore remains, to evaluate the effect of 
exercise training on both SI and skeletal muscle fat in black South African 
premenopausal women known to have a greater sensitivity to skeletal muscle fat 
accumulation compared to their white counterparts (42). 
1.13.5 EFFECT OF EXERCISE ON HEPATIC FAT 
 
Studies that evaluated the effect of exercise training on hepatic fat showed mixed 
results, which were dependent on cohorts with and without NAFLD). A recent 
systematic review showed that the majority of studies reported a reduction in 
hepatic fat after exercise training (298). However, these studies were mostly 
conducted in those with NAFLD and/or T2D (256,257,272,299–303). Notably, the 
94 
 
studies that did not show any change in hepatic fat content after exercise were 
conducted in those without NAFLD (253,304). Although, one study reported that 
after 12 weeks of a combined aerobic and resistance training the reduction in 
hepatic fat in those without NAFLD (relative Δ -28.3%) and those with NAFLD 
(relative Δ -34.5%) were similar (256). Further, an increase in hepatic fat has also 
been observed after exercise training (295). This study was conducted in adults 
with T2D that combined exercise training with a Paleolithic diet. However, this 
increase was driven by 3 subjects whereas most of the group (n=10) showed a 
reduction in hepatic fat. It seems that exercise training is beneficial to reduce 
hepatic fat in those with NAFLD and T2D. However, in those without NAFLD, the 
effect of exercise training on hepatic fat is more variable. In those that showed a 
reduction in hepatic fat, the effect was modest and larger reductions were 
observed with longer duration of exercise training (6 months) that were combined 
with calorie restriction. 
Although a reduction in hepatic fat after exercise training coincided with an 
increase in hepatic and peripheral SI, no association was found between these two 
factors (251,256). The change in hepatic fat was rather associated with changes 
in either body weight, VAT or total body fat mass (251,256,305). Although an 
association between hepatic fat and SI has been reported in cross-sectional 
studies, this association is not so apparent in intervention studies, probably due to 
the heterogenous response of hepatic fat to exercise training (295). While cross-
sectional studies to evaluate the association between hepatic fat and SI have been 
conducted in black South African women (42,171), interventional studies are 
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needed to provide greater insight into the causality of hepatic fat on SI in this 
population. Furthermore exercise intervention studies have not addressed whether 
changes in insulin clearance and hyperinsulinemia can be explained by changes 
in hepatic fat in black African populations. 
1.13.6 EFFECT OF INTERVENTIONS ON PANCREATIC FAT 
 
Intervention studies have been performed to assess the role of pancreatic fat on 
β-cell function, with a focus to reverse T2D. These studies induced weight loss 
either through bariatric surgery (13.6%) (214) or low calorie diets (15%) (213). Both 
these studies reported a change in pancreatic fat from 6.6 to 5.5% 8 weeks after 
bariatric surgery (214) and from 8.0 to 6.2% after 8 weeks of low calorie diet (213), 
which in both these studies coincided with an improvement in acute insulin 
response in those with T2D. Contrastingly, those without T2D, had a comparable 
weight reduction to those with T2D after bariatric surgery, but had no reduction in 
pancreatic fat and no improvement in the acute insulin response (214). This could 
indicate that a reduction in pancreatic fat might be needed for an increase in acute 
insulin response. Notably, in those without T2D, the acute insulin response was 
not impaired and may be the reason why no change was observed. Interestingly, 
in the intervention study, the importance of a reduction in pancreatic fat on β-cell 
function was only observed in those with T2D, while in cross-sectional studies an 
association was only apparent in those without T2D (Table 1.5). 
The effect of exercise training on pancreatic fat has only been studied once before 
in a Finnish population and included adults with T2D and healthy men (252). The 
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participants completed 2 weeks of either high intensity interval training or moderate 
intensity continuous training. A similar reduction in pancreatic fat was found in both 
the healthy men (from 4.4 to 3.6%) and in those with T2D/prediabetes (from 8.7 to 
6.7%). However, this also coincided with a reduction in SAT and VAT, but body 
weight was not altered after the intervention in both groups. While β-cell measures 
improved similarly in both the healthy men and those with T2D it was not 
associated with reduction in pancreatic fat.  
Pancreatic fat has never been assessed in a black South African population. 
Importantly, a cross-sectional study showed that in black South African women 
both skeletal muscle and hepatic fat accumulation was associated with lower SI. A 
study is therefore justified to explore the response of pancreatic fat to exercise 
training and whether this change will be associated with changes in the insulin 
response and β-cell function in this cohort who are at high risk for T2D. 
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↑ No Δ HOMA-
IR 
ND ↑FAO but not 
associated with 
ΔIMAT 










EXPD: 12 weeks, 




resistance training + 
paleolithic diet  
MRS – soleus, 
tibialis anterior 
(IMCL) 




HepSI No Δ 
AT-SI ↑ 
(HIEG) 




No Δ: Adipose 







23yo, BMI 22.6, 
highly trained 
EX (n=8) 2 weeks- 1 rest day, 
aerobic (2h) and 
interval training (45 




↑ No Δ 
(ITT)  
48h post Ex 














6 weeks, 3/wk, 20 
min, 60-80% of 






Perip SI ↑ 
HepSI ↑ 
(HIEG) 
72h post Ex 
ND ↓Circulating FFA 






EX: 66yo, OB 




12 weeks, 5/wk, 60 
min 










No ↓BW, BF 
Dx – Duration of exercise training, Δ – Change, IMAT – intramuscular fat, SI – Insulin sensitivity, F- Female, M – Male, OW – Overweight, OB -Obese, NonT2D- 
Non- Type 2 Diabetes, IGT – Impaired glucose tolerance, NGT – Normoglucose tolerant, RES – Resistance training group, AER – Aerobic training group, CON – 
control group, EX- exercise group, CR – Calorie restriction, EXCR – Exercise and calorie restriction group, LCD – Low calorie diet, SIT – Sprint interval training, 
CT – continuous training, Lo/Mod – low volume moderate intensity exercise group, Lo/Vig – low volume, vigorous intensity exercise group, Hi/Vig – High 
volume, vigorous intensity exercise group, HRR – Heart rate reserve, Wmax – maximum work load, HR – Heart rate,  HIT – High intensity training, FSIGT – 
Frequently sampled intravenous tolerance test, OGTT, Oral glucose tolerance test, HIEG – Hyperinsulinemic euglycemic clamp, IMCL – intramyocellular lipid 
content, ISI – Insulin sensitivity, HOMA-IR Homeostatis Model assessment of Insulin Resistant, ND – Not done, Periph – Periperal, Hep -Hepatic, BW – Body 
weight, BF – Body Fat, SAT – Abdominal subcutaneous adipose tissue, VAT – Visceral adipose tissue, FAO – fatty acid oxidation, DAGs – diacylglycerol, FFA – 
free fatty acids, EX – exercise, ↑ - increase,  ↓ - decrease
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1.14 RATIONALE FOR THIS STUDY 
 
Although great strides have been made to unravel the mechanisms involved in the 
pathogenesis of T2D in black African women, who have a high risk for developing 
T2D (306), the underlying mechanisms still remain poorly understood. Evidence 
has evolved to show that ethnic differences exist in the pathogenesis of T2D with 
black African women frequently having a lower SI and higher insulin response 
compared to their white counterparts (39,48,49). Despite both a lower hepatic 
insulin clearance and higher insulin secretion being observed in black African 
populations compared to other ethnicities, the relative contributions of these two 
factors to a high insulin response is still under debate. Further, how peripheral 
insulin clearance relates to hyperinsulinemia and β-cell function has not been 
previously reported. 
Intriguingly, black African women may also demonstrate an insulin response that 
exceeds the level of SI  with a notably higher β-cell function, compared to white 
women (47,56). Clearly, exploring the correlates of these key components in black, 
obese South African women is warranted. Previous studies in Africa have focused 
mainly on the correlates of SI (42,43,121,143,171) and all, but one, used HOMA-
IR to quantify SI (43,121,143,171). In addition, while the insulin response and DI, 
have been described before in black South African women (39), its correlates were 
not evaluated. Notably, black African women exhibit a unique phenotype that 
contrasts to the established pathophysiology of insulin resistance typically shown 
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in white populations. Compared to their white counterparts, black African women 
have less VAT (43), an established determinant of insulin resistance (141), and 
more peripheral SAT (43), typically regarded as protective (110). Further, black 
African women have less hepatic fat and equivalent intramuscular fat compared to 
their white counterparts (42). However, the majority of evidence are derived from 
cross-sectional studies, from which causality cannot be inferred. Moreover, 
although two longitudinal studies were conducted on black South African women 
to determine how changes in body fat distribution predict IGT/T2D onset (143) or 
reduced SI (121), only fasting indices were used.  
Further, studies exploring the correlates of insulin secretory function and β-cell 
function in black African populations have reported ethnic differences in the 
association between body fat distribution, pancreatic and hepatic fat and the insulin 
response and β-cell function (49,51,54,128,209). Nevertheless, correlates of both 
hepatic and peripheral insulin clearance have rarely been studied in black African 
populations. 
Importantly, an intervention that perturbs SI and hyperinsulinemia and/or body fat 
distribution and ectopic fat will provide greater insight into the role of these 
components in the pathophysiology of T2D in African populations. Indeed, exercise 
training has been shown to alter body composition and regional and ectopic fat 
distribution, as well as SI, insulin secretion and clearance. Exercise training 
therefore provides an ideal model to understand how changes in regional and 
ectopic fat distribution relate to changes in SI and hyperinsulinemia and how this 
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may contribute towards the pathogenesis of T2D in black African populations. It is 
particularly relevant given that women of black African descent exhibit lower levels 
of cardio-respiratory fitness compared to white populations. A sedentary lifestyle 
may contribute towards this lower cardio-respiratory fitness (219), although it may 
not be the only explanation for this phenomenon in black Africans. Nevertheless, 
only few studies have evaluated the effect of exercise training on SI, insulin 
response and insulin clearance and regional and ectopic fat depots in African 
Americans. Importantly, no exercise intervention study has previously been 













CHAPTER 2: AIMS AND HYPOTHESES 
 
2.1 OVERALL AIM 
The overall aim of this PhD was to investigate the correlates of low SI and 
hyperinsulinemia, characteristic in black African populations. This was assessed 
by using a cross-sectional design and an exercise intervention study, with 
emphasis on the role of ectopic fat deposition (skeletal muscle, hepatic and 
pancreatic fat), body fat distribution and body composition.  
2.2 CROSS-SECTIONAL STUDY 
2.2.1 AIM 
In a sample of obese black South African women, the aims of the study were to: i) 
identify the correlates of DI by examining the relationships between DI and its 
direct (SI and AIRg) and indirect components (hepatic and peripheral insulin 
clearance and ISR), and to assess the associations of ectopic fat (skeletal muscle, 
hepatic and pancreatic fat) and body fat distribution with the variance in DI; ii) 
explore the correlates of the insulin response (insulin secretion and clearance) and 
SI; and iii) assess the relationships between the various regional adipose tissue 





 To evaluate the associations between DI and its direct components 
(SI and AIRg) and its indirect components (insulin secretion, hepatic 
and peripheral insulin clearance). 
 To determine the relative contribution of insulin secretion and hepatic 
and peripheral insulin clearance to AIRg, independent of SI. 
 To determine the relationship of DI with body fat distribution and 
ectopic fat depots. 
 To determine the associations of SI and hyperinsulinemia with body 
fat distribution and ectopic fat. 
 To determine the associations between various ectopic fat depots 
and body fat distribution.  
 
2.2.3 HYPOTHESES 
  The main correlates of a higher DI in obese black South African women will 
be a higher AIRg, which will be associated with a higher ISR, while a lower 
hepatic and higher peripheral insulin clearance will also contribute to the 
variance in DI, but to a lesser extent. 
 A higher ISR will be the primary contributor to higher AIRg above lower 
hepatic and higher peripheral insulin clearance, independent of SI 
 A higher DI will be associated with lower VAT, skeletal muscle, hepatic and 
pancreatic fat.  
 The above associations will be explained by: 
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o  a higher AIRg and ISR associated with lower VAT, hepatic and 
pancreatic fat 
o A higher SI associated with lower VAT, hepatic and skeletal muscle 
fat.  
o Whereas hepatic insulin clearance will not be associated with VAT 
and hepatic fat and peripheral insulin clearance will not be 
associated with skeletal muscle fat accumulation 
 VAT will be positively associated with hepatic and pancreatic fat, and 
hepatic fat will be positively associated with pancreatic and skeletal muscle 
fat.  
2.3 EXERCISE INTERVENTION STUDY 
2.3.1 AIM 
The aim is to evaluate the effect of 12-week combined aerobic and resistance 
exercise training on SI, hyperinsulinemia and DI and whether changes in these 
metabolic outcomes can be explained by associated changes in body composition, 
body fat distribution, skeletal muscle, hepatic and pancreatic fat. 
2.3.2 OBJECTIVES 
 To determine the changes in SI, insulin response, insulin secretion, insulin 




 To examine the changes in body composition, body fat distribution, skeletal 
muscle, hepatic and pancreatic fat after 12-weeks of exercise training 
compared to the control group. 
 To explore if changes in SI are associated with changes in body composition, 
body fat distribution, skeletal muscle and hepatic fat. 
 To determine if changes in insulin response, secretion and clearance are 
associated with changes in hepatic and pancreatic fat. 
 To examine if changes in DI are associated with changes in pancreatic fat.  
2.3.3 HYPOTHESES 
 Exercise training will increase SI and reduce AIRg, which will also be 
associated with a reduction in insulin secretion.  
 Exercise training will increase DI due to a greater change in SI compared to 
AIRg. 
 Exercise training will reduce VAT as well as skeletal muscle, hepatic and 
pancreatic fat.  
 The increase in SI will be associated with reductions in VAT, skeletal muscle 
and hepatic fat. 
 The reduction in AIRg and insulin secretion will be associated with 
reductions in pancreatic fat, hepatic fat and VAT.  
 The increase in insulin clearance will be associated with a reduction in 
hepatic fat. 




CHAPTER 3: PERSONAL CONTRIBUTION 
TOWARDS PHD 
 
3.1 RECRUITMENT AND SCREENING 
I was integrally involved in the recruitment and screening of the participants. 
3.2 MEASURING OF INSULIN SENSITIVITY, SECRETION AND 
CLEARANCE 
A FSIGT was used to obtain glucose, insulin and C-peptide blood samples at 
various time points. As a medical doctor, I was responsible for all aspects of the 
FSIGT, including calculations, infusions, blood sampling and monitoring. The 
minimal model was used to estimate SI, insulin response and DI. I ran the models 
and did standard checks. Mathematical modelling was used to estimate ISR, 
hepatic and peripheral insulin clearance. I ran three different models to find the 
best fit for the data.  
3.3 ECTOPIC FAT QUANTIFICATION 
 
MRS and MRI were done to measure fat in the liver, pancreas, soleus and tibialis 
anterior muscles. I was integrally involved in generating the spectral peaks in LC 
Model (MRS) for skeletal muscle, hepatic and pancreatic fat quantification, in 
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assessing the most appropriate method for ectopic fat quantification for this thesis 



















CHAPTER 4: METHOD DEVELOPMENT 
 
4.1 ECTOPIC FAT QUANTIFICATION 
 
A 3 Tesla whole-body human MRI scanner (MAGNETOM Skyra; Siemens Medical 
Solutions, Erlangen, Germany) was used to perform both the MRI and MRS 
sequences. Quantifying the fat fraction, using MRI-Dixon and MRS, relies on the 
chemical shift technique based on the different resonate frequencies of the 
hydrogen protons in water and fat.  
4.1.1 MRS 
 
MRS signals are derived from the specific resonance frequencies of hydrogen 
protons which are depicted as a metabolite peak (307). Water and fat are identified 
by their resonance frequencies expressed as parts per million (ppm). Although, fat 
and water both have hydrogen protons, the resonance frequencies differ based on 
the configuration of the protons in the compound. Water has 2 symmetrical 
hydrogen protons that exhibit a single resonance frequency peak (Figure 4.1). 
However, fat has different configurations of the hydrogen protons depending on 
the fatty acid chain (e.g. methylene (CH2) or methyl (CH3) groups) and therefore 
exhibit distinct peaks (Figure 4.2). Due to more water in the tissue, the water peak 
is much larger than the fat peaks and therefore needs to be suppressed to visualize 
the fat peaks (307).  
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The resonance frequencies of CH2 and CH3 are at 1.3 ppm and 0.9 ppm, 
respectively. They are the largest fat peaks due to the abundance of these 
moieties, and therefore these peaks were used for the fat measurement in the liver 
and pancreas. The area under each peak is directly proportional to the 
concentration of proton species in the compound. The fat peak is expressed in 
relation to water. The fat fraction is expressed as 
  
    
.  
In skeletal muscle, MRS can distinguish between IMCL and EMCL content. IMCL 
and EMCL have different locations and orientations towards the magnetic field and 
therefore, differences in resonance frequencies occur. The CH2 and CH3 peaks for 
IMCL are found at 1.3 and 1.5 ppm, respectively, and at 0.9 and 1.1 ppm, 
respectively for EMCL. 
 
Figure 4.1: Graphical display of the chemical configuration of water and its 
spectral peak  
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MRS data was acquired using the point-resolved spectroscopy sequence 
(PRESS) with the following parameters: relaxation time (TR)/echo time (TE) 
3000/33 ms, bandwidth 2000 Hz, 10 averages for the abdominal scans and 80 
averages for the calf scans. The voxel dimensions were 20×20×20 mm3 for liver, 
15×15×15 mm3 for pancreas and 15×15×15 mm3 for both soleus and tibialis 
anterior muscles (Figure 4.3). 
 
Figure 4.2: Graphical display of the chemical configuration of methylene and 





Soleus muscle Tibialis anterior muscle 
 
 
Figure 4.3: MRS voxel placement in the liver (top, left picture), pancreas (top, right 
picture), soleus (bottom, left picture) and tibialis anterior (bottom, left picture) 
muscles 
 
4.1.2 MRI - DIXON  
The Dixon method refers to the separation of fat and water based on the difference 
in resonance frequency between water and fat. During the Dixon MRI sequence, 
the fat (F) and water (W) signals are separated by acquiring images at different 
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TEs. The TE where both the fat and water signals are in the same direction is 
called in-phase (𝐼𝑃𝑠𝑖𝑔𝑛𝑎𝑙 = 𝑊𝑠𝑖𝑔𝑛𝑎𝑙 + 𝐹𝑠𝑖𝑔𝑛𝑎𝑙) and the TE where the fat and 
water signals are in opposite directions, with the water signal dominating, is called 
opposed phase (𝑂𝑃𝑠𝑖𝑔𝑛𝑎𝑙 = 𝑊𝑠𝑖𝑔𝑛𝑎𝑙 − 𝐹𝑠𝑖𝑔𝑛𝑎𝑙) (Figure 4.4).  Based on these 
two phases, fat ( 𝐹𝑠𝑖𝑔𝑛𝑎𝑙 = ) or water only (𝑊𝑠𝑖𝑔𝑛𝑎𝑙 =
) images can be obtained. Further, by combining the fat and water 
only images the fat fraction signal can be acquired (𝐹𝑠𝑖𝑔𝑛𝑎𝑙 = ) 
(308). 
 
Figure 4.4: In- and Opposed phases of MRI-Dixon technique 
We used a three-point Dixon volume interpolated breath-hold gradient recalled 
echo sequence: TR 3.97 ms, TE1 1.23 ms, TE2 2.46 ms, flip angle 9 degrees, 
number of averages 1, bandwidth 1040Hz/px, field of view 450 X 366 mm, matrix 
size 195 x 320 x 144 and a slice thickness of 2 mm. 
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After the images were acquired the hepatic, pancreatic and skeletal muscle fat 
were quantified using a MATLAB algorithm to separate the water and fat signals 
and to create a fat fraction map calculated as the fat signal over the sum of the 
water and fat signals. OsiriX (Pixmeo SARL, Geneva, Switzerland) software was 
used to manually draw a ROI in the liver (Figure 4.5) and skeletal muscle (Figure 
4.6) and HOROS V1.1.7 (HOROS Project) software was used to manually draw a 
ROI in the pancreas.(Figure 4.7) The ROI was drawn on the in-phase image due 
to better visualization of anatomy. The ROI was then copied to the fat fraction 
image where the average pixel value from the ROI were converted to a fat fraction 
(fat fraction=pixel value from ROI/65535; a value between 0 and 1 was obtained 
where 0 in no fat and 1 is only fat) (309). 
 
.  
Figure 4.5: Region of interest in right lobe of liver in fat fraction image (left picture) 





Figure 4.6: Region of interest in tibialis anterior (orange ROI 1) and soleus (green- 
ROI 2) muscles in a transverse image through the calf in both the in-phase (left) 
and fat fraction (right) images. 
 
4.1.2.1 HEPATIC FAT 
A rectangular ROI (5.5 cm width, 7.5 cm height) was drawn on one slice, in the 
right lobe of the liver (Figure 4.5) by a single reviewer that was blinded to group 
allocation. This single ROI was duplicated on 3 superior and 3 inferior slices from 
this initial slice, taking care to avoid ducts and blood vessels. The average from 
the seven slices were calculated together with standard deviations. 
Studies have shown that the right lobe, compared to the left lobe, correlated better 
with a liver biopsy when evaluating hepatic steatosis (310). However, this 
difference is less obvious in those without NAFLD (311). Also, the fat fraction 
variability was found to be less in the right lobe (1.15%) compared to the left lobe 
(1.74%) and the left lobe tends to underestimate the hepatic fat content (310). This 
supports our rationale of estimating the fat fraction only in the right lobe of the liver. 
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Pilot analysis was completed using one subject to compare the liver fat fraction 
obtained by the in-house MATLAB algorithm with the fat fraction obtained from the 
build-in Phillips scanner mDixon QUANT algorithm and almost identical values 
were obtained. This confirmed that our in-house MATLAB algorithm was adequate 
to determine fat fractions. 
 
4.1.2.2 SOLEUS AND TIBIALIS ANTERIOR SKELETAL MUSCLE FAT 
 
Various methods have been used to identify ROIs in skeletal muscle (312–319) . 
The most recent studies (320,321) use a single slice to determine the fat fraction 
in the thigh and calf muscles. Hogrel et al. reported that a single slice provided a 
good representation of the fat in the thigh muscle compared to using 7 slices, but 
the slice should include the largest cross-sectional area of the muscle of interest 
(315). However, Hogrel et al. included non-obese male and females across a wide 
spectrum of age. The mean BMI (kg/m2) was 21.4 and 22.6 for younger (20-30 yo) 
and older females (70-80 yo), respectively (315). In contrast, another study also 
conducted in non-obese population reported that fat infiltration in calf muscles were 
inhomogeneous (317).  
Due to inconsistency in the literature regarding number of slices, we opted to use 
7 consecutive slices over a 14 mm area (slice thickness 2 mm). The largest 
diameter of the muscle was found visually by scrolling up and down the sagittal 
image and confirmed using the measurement tool in OsiriX. An irregular shape 
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ROI was drawn by a single reviewer using the method adapted from Machann et 
al. (322) (Figure 4.6). The ROI captured the intramuscular fat and excluded the 
fatty septa between muscles.  
A pilot study was performed on 5 randomly selected participants to determine the 
best method of drawing the ROI. Initially an ROI was drawn individually on each of 
the seven slices, then an ROI was drawn on the most proximal slice and copied to 
the 6 distal slices and lastly an ROI was drawn on the middle slice (of the 7 
identified slices) and copied to 3 slices superior and inferior to this slice. The latter 
method produced the most consistent result with smaller standard deviations and 
thus less variability. The ROI was therefore, duplicated on 3 superior and 3 inferior 
slices and the average was calculated. Calculation of the fat fraction was 
performed by the MRI physicist that was blinded to group allocation. 
 
4.1.2.3 PANCREATIC FAT 
 
Pancreatic fat quantification is technically challenging due to the small size of the 
organ and due to irregular borders especially in those with type 2 diabetes. Various 
methods referring to the number of slices used, number of ROIs drawn, manual vs 
automated methods and with or without thresholding, have been used to determine 
the fat fraction in the pancreas (176,202–204,208,213,323). 
In our study, pancreatic fat was determined by drawing one circular 1cm2 ROI in 
the head, body and tail of the pancreas (Figure 4.7) using HOROS V1.1.7. A single 
reviewer, blinded to group allocation, drew the ROI and calculated the fat fraction. 
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An ROI was drawn on both the water and fat images and the following formula was 
used to calculate the fat fraction, (Fat fraction= ). The fat fractions 
from the pancreas head, body and tail were averaged to obtain the mean fat 
fraction for the whole pancreas. This method consisting of several smaller ROIs, 
compared to one big ROI encompassing the whole pancreas, is used to avoid 
inclusion of VAT (211). Also, greater precision was achieved with using the 3 









Figure 4.7: Region of interest in head (top picture), body (middle picture) and tail 
(bottom picture) of the pancreas, in the fat fraction images (left pictures) and in-




4.1.2.4 ABDOMINAL VAT AND SAT 
 
MRI and computed tomography (CT) are considered the gold standard in 
determining abdominal VAT and SAT. However, CT exposes individuals to ionizing 
radiation whereas MRI does not. Further, while DXA is a more cost-effective 
method compared to MRI, it has been found to underestimate VAT by ~30% in 
older men (325). MRI fat quantification was therefore used in our study. Further, 
because MRI fat quantification can be expressed as an area (cm2) derived from a 
single slice or multiple slices, or as a volume (cm3), requiring multiple slices, we 
needed to determine whether to use a single slice or multiple slices. VAT quantified 
by a single slice, located at approximately the level of L3, showed excellent 
correlation with VAT volume (r>0.95) in black and white men and women (326) but 
this was based on cross-sectional data. However, after weight loss in overweight 
and obese adults, the reduction in VAT and SAT was poorly estimated using a 
single slice compared to using multiple slices (327). Further, after a 6-month 
exercise intervention in premenopausal women with a wide range of BMI, using 
multiple slices was more precise in detecting a reduction in VAT compared to using 
a single slice (328). We, therefore, calculated the VAT and SAT volumes, using 
multiple slices. Firstly, the slice at the L4-5 vertebral position was located, and VAT 
and SAT were manually delineated using HOROS V1.1.7 (Figure 4.8). The area 
of VAT and SAT in this slice was measured. The same method was repeated in 
the 15th slice proximal from the first slice and then repeated 3 more times. The 
volume of VAT and SAT over a 15cm region of the abdomen was determined using 
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the following formula: 𝑉 = (𝑡 + ℎ) ∑ 𝐴 , where t – thickness of each slice, h – 
between slice interval, N – number of total slices, Ai – cross-sectional area of each 
slice. The sum of the cross-sectional areas of 5 slices were multiplied with 3 (2 
mm(t) + 28 mm (h) = 30 mm or 3 cm) (327). 
 
 
Figure 4.8: Abdominal subcutaneous adipose tissue (left picture) and visceral 
adipose tissue (right picture) delineation on a transverse MRI scan through 
abdomen 
4.1.2.5 VALIDITY OF MRI METHODS TO DETERMINE HEPATIC, SKELETAL MUSCLE AND 
PANCREATIC FAT AND SAT AND VAT 
 
The 3-point Dixon method has been validated before using a fat/water phantom 
and was found to be accurate and reproducible even at low levels of fat in liver, 
pancreas and skeletal muscle (329). Coefficients of variation for hepatic, skeletal 
muscle and pancreatic fat, and SAT and VAT quantification previously published 
are 10-17%, 3.2%, 3.5%, 3.5% and 8.8%, respectively (309,318,324,330). 
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4.1.3 COMPARING BASELINE AND CHANGES IN HEPATIC AND PANCREATIC 
FAT BETWEEN MRS AND DIXON MRI METHODS 
 
In order to choose the best method to quantify hepatic and pancreatic fat we  
investigated the discrepancies between the 2 fat quantification methods in relation 
to baseline and change in hepatic and pancreatic fat contents. Simple correlations 
and a Bland Altman analysis were done on baseline data. The baseline MRI and 
MRS hepatic fat data were non-normally distributed and even natural log 
transformation was unable to normalize the data. However, after exclusion of 2 
outlying values visible in figure 4.8 A and outside the 95% limits of agreement in 
figure 4.8 C, natural log transformation was able to normalize the data. While a 
significant linear association was found between natural log transformed MRI and 
MRS hepatic fat, poor agreement was found between the 2 methods as illustrated 
by the line of perfect agreement (Figure 4.8 B). This was confirmed in the Bland 
Altman analysis that showed that on average the MRI-derived hepatic fat was 
higher compared to MRS values (mean difference: 𝑒 . =2.23). There was also a 
significant systematic bias between these 2 methods with the line of perfect 
agreement (red dotted line at zero) outside the 95% confidence interval 
(antilog:1.97 to 2.51) of the average difference between MRI and MRS-derived 
values (Figures 4.8 D). 
Pancreatic fat at baseline determined by MRS varied considerably from 0.72% to 
67.5%, while the range for MRI-determined pancreatic fat (mean of the fat in the 
body, head and tail of the pancreas) was 4.7% to 12.9% (figure 4.9 A). MRI and 
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MRS pancreatic fat needed to be natural log transformed to achieve a normal 
distribution. A significant linear association was found between MRI and MRS, but 
again poor agreement was found (Figure 4.9 B). The Bland Altman analysis 
showed that on average MRI-derived pancreatic fat was higher compared to MRS-
derived pancreatic (mean difference: 𝑒 . . =0.98) and that a systematic bias 
existed with the line of perfect agreement outside the 95% confidence interval of 
0.84 to 1.14 (antilog) (Figure 4.9D). 
The relative changes in hepatic and pancreatic fat, in response to the 12-week 
intervention, determined by MRI and MRS are shown in Figure 4.10. In the 
exercise group, MRI-determined hepatic fat was reduced (Δ -13.1%) while the 
MRS-derived values showed an increase (Δ 33.6%). A similar discrepancy was 
observed in the control group, albeit in opposite directions. Further, in the exercise 
group, pancreatic fat determined by both MRI and MRS showed a reduction, but 
greater variability occurred in the MRS measures. In the control group, 
contradictory results were obtained and again the MRS-derived pancreatic fat 
showed great variability.  
Taken together, a systematic bias existed between MRI and MRS derived 
measures of hepatic and pancreatic fat at baseline and the relative changes in 
hepatic and pancreatic fat in response to the 12-week intervention showed 
contradictory findings between these two methods. Fat derived from MRS showed 
outlying values and considerable variability. A possible reason could be that the 
MRS sequences require longer scanning times compared to MRI sequences and 
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movement of the voxels could have occurred when breath-holding was 
inadequate. We therefore included only the MRI-derived hepatic, pancreatic, as 
well as skeletal muscle fat in our pre-post analysis. The baseline analysis included 
MRI-determined hepatic and pancreatic fat, but skeletal muscle fat determined by 
both MRS and MRI was included because only MRS can discriminate between 
IMCLand EMCL content. MRS- determined skeletal muscle fat will also be less 
affected by breathing compared to pancreas and the liver.  
 
Figure 4.9: Comparison of baseline hepatic fat derived from MRI and MRS in A) 
scatterplot of untransformed data, B) Correlation of transformed data with 
regression line (black) and line of perfect agreement (green), C) Bland Altman plot 
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of untransformed data with limits of agreement, and D) Bland Altman plot of natural 
log transformed data (ln) with mean difference and 95% confidence interval. 
 
 
Figure 4.10: Comparison of baseline pancreatic fat derived from MRI and MRS in 
A) scatterplot with untransformed data, B) Correlation of transformed data with 
regression line (black) and line of perfect agreement (green), C) Bland Altman plot 
of untransformed data with limits of agreement and D) Bland Altman plot of natural 





Figure 4.11: Comparing the relative changes between MRS and MRI with regards to 
(A) Hepatic fat and (B) Pancreatic fat in the control and exercise groups 
 
4.2 DETERMINATION OF INSULIN SENSITIVITY, INSULIN SECRETION AND 
INSULIN CLEARANCE 
 
4.2.1 INSULIN SENSITIVITY 
 
Various methods are available to measure SI. The HIEG clamp, developed by de 
Fronzo and Andres (331), is the gold standard. It gives a direct measure of peripheral 
SI under steady-state conditions, but it is labour intensive and costly. 
The minimal model developed by Bergman and Cobelli (332) is an indirect method of 
measuring SI and requires glucose and insulin plasma levels obtained during a FSIGT. 
The FSIGT is less labour intensive than the clamp method and steady state conditions 
are not required. Additionally, glucose effectiveness (Sg), AIRg and the DI can also be 
calculated. A disadvantage of the FSIGT is that it cannot distinguish between hepatic 
and peripheral SI because it unable to isolate endogenous glucose produced by the 
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liver from exogenous glucose (333). Nevertheless, a good correlation has been found 
between FSIGT and hyperglycemic clamp-derived SI (r=0.88, p=0.001) and insulin 
response (r=0.75, p=0.005) in normo-glycaemic women (334). 
The minimal model calculates SI, a measure of the fractional disappearance of glucose 
for a given insulin concentration by uncoupling the glucose and insulin responses. This 
minimal model encompasses a glucose (describes glucose dynamics) and insulin 
(describes insulin dynamics) minimal model (332). The following parameters are 
derived from this model (Figure 4.11): (a) At 0 min of the FSIGT test, glucose is 
injected into a single compartment with a subsequent rise in the plasma glucose 
concentration (G(t)) from baseline glucose (GB). (b) This results in glucose stimulating 
its own uptake (Sg) and a simultaneous triggering of the pancreatic β-cells to release 
endogenous insulin into the interstitium (remote insulin compartment). Insulin levels 
(I(t)) increase from baseline insulin levels (IB). (c) After insulin enters the interstitium it 
can then promote glucose uptake. The action of insulin (X) is proportional to the 
interstitial insulin. The uptake of glucose is a composite measure of both the hepatic 
and peripheral glucose uptake, as well as the inhibition of hepatic glucose production. 
(d). Exogenous insulin is infused at 20 min at a time that Sg is declining, and therefore 
the glucose uptake after 20 min is assumed to be due to insulin. The movement of 
insulin into the interstitium and out of the interstitium is noted as P3 and P2, 
respectively. Other measures obtained from the minimal model are: AIRg, the 
incremental area under the insulin curve in response to intravenous glucose over the 
first 10 minutes, and thus reflects the first phase insulin response; DI, a measure of 
the insulin response to glucose relative to the prevailing level of SI (AIRg x SI) which 
gives an index of whether the insulin response is adequate for the level of SI (180). A 
graphical output from the minimal model is shown in figure 4.12. The fractional 
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standard deviation (FSD) was used as a measure of how well the parameters derived 
from this model were estimated. 
 
Figure 4.12: Schematic illustration of the minimal model that is used to determine 




Figure 4.13: Output from the Minimal Model. Green – Insulin response, Blue – 




















4.2.2 INSULIN SECRETION 
 
AIRg, is a measure that reflects glucose-stimulated plasma insulin levels and not 
insulin secretion per se. Plasma insulin levels reflects both insulin secretion and insulin 
clearance. Insulin is secreted by the pancreatic β-cells into the portal circulation and 
during first pass through the liver up to 70% and 54% of insulin is degraded in the liver 
under fasting and stimulatory conditions, respectively (18). As a result, the amount of 
insulin that reaches the systemic circulation can be up to half to two-thirds less than 
the amount secreted by the pancreas. Nevertheless, C-peptide is co-secreted with 
insulin, in equimolar quantities, by the pancreas and is not degraded by the liver. In 
addition, C-peptide has a longer half-life (30-35 min) compared to insulin (5-10 min) 
and has therefore been used to estimate insulin secretion. 
C-peptide deconvolution is used to determine ISRs by using peripheral C-peptide 
levels, but the clearance kinetics of C-peptide must be known. The kinetics of C-
peptide after administration of synthetic human C-peptide in adults with and without 
T2D was described by Faber et al. (335). Subsequently, Eaton et al. (336) proposed 




Figure 4.14: Schematic of two-compartment C-peptide model for estimating insulin 
secretion rate  
This method of estimating ISR was a 2-step process. Firstly, the kinetic parameters 
(k1, k2, k3) need to be obtained. Therefore, synthetic human C-peptide was 
administered to diabetic patients with no endogenous C-peptide secretion. Information 
obtained from these C-peptide decay curves was used to determine the kinetic 
parameters (k1, k2, k3) by solving equations using non-linear least squares regression. 
Secondly, stimulated endogenous insulin and C-peptide levels were obtained using 
an OGTT. The kinetic parameters, together with the plasma levels of C-peptide are 
then used as inputs into the following formula for the calculation of the ISR  
𝑆(𝑡) =  −𝑒  𝑘1𝐶(𝑡1)𝑒  + 𝑘1𝑘2 ∫ 𝑒 𝐶(𝑠) 𝑑𝑠 +  𝐶(𝑡) + (𝑘1 + 𝑘3)𝐶(𝑡)  
(336). However, this method required two sets of experiments and the administration 
of human biosynthetic C-peptide, which can be costly and time-consuming. 
Subsequently, the Van Cauter and Polonsky group showed that standard kinetic 
parameters can be used, taking into account sex, age and body surface area, to 
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determine ISR without obtaining individual kinetic C-peptide parameters (337). 
Following this, various other models have been proposed to measure ISR such as a 
one-compartment model that combines the kinetics of insulin and C-peptide into one 
model (338). Nevertheless, after validating the use of peripheral C-peptide levels 
under various conditions, it was found that the two-compartment C-peptide model was 
better at estimating ISR compared the one-compartment model (339). Hence, in our 
study the two-compartment C-peptide model was used with standard kinetic 
parameters, to obtain an estimate of ISR.  
 
4.2.3 INSULIN CLEARANCE 
 
Direct measures of estimating hepatic insulin clearance such as using hepatic vein 
and artery catherization are not feasible in humans due to its invasive nature (340). 
An indirect measure of hepatic insulin clearance uses the ratio of plasma C-
peptide/insulin levels. The use of this ratio depends on the following assumptions: C-
peptide and insulin must be secreted in equimolar amounts, C-peptide must not be 
degraded by the liver, the clearance of C-peptide must be constant over a range of 
physiological conditions (341). These assumptions have been tested and shown to be 
reliable, but only under steady-state conditions and are thus not a reliable proxy for 
hepatic insulin extraction under non-steady state conditions (342). In addition, this 
measure has not been validated to my knowledge in a black African population and in 
response to an insulin-modified FSIGT. Accordingly, C-peptide/insulin ratio was only 
used in our study during fasting conditions that reflect a steady-state condition, and 
not during the FSIGT. 
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Mathematical modelling is another method to estimate insulin clearance. The following 
models have been used with FSIGT data, and can estimate hepatic insulin clearance 
either as a constant (71,343) or that varies over the course of the FSIGT (18). We first 
used the latter model in our study. This model combined the two-compartment C-
peptide model with a new one-compartment minimal model of insulin delivery and 
kinetics (18) (Figure 4.14). This model assumed that above a certain threshold of 
plasma glucose levels (h), insulin is secreted (ISR) into a central compartment (CP1). 
The insulin secreted is in response to the rapid change in glucose concentration 
(Glucosemax-Glucoseo) and is proportional to the insulin in an already available pool in 
the β-cells (X). After this initial phase, new insulin is provided (Y) to the releasable pool 
in the β-cell after a delay, and is controlled by the glucose concentration. X reflects the 
balance between ISR and new insulin provided to the releasable pool (Y). C-peptide 
and glucose plasma levels during the FSIGT are used as the input into this model. The 
one-compartment model of insulin, estimates the post-hepatic insulin delivery rate 
(IDR), normalized to the volume of distribution (Vd), using insulin kinetics that reflects 
both secretion and extraction of insulin. The other parameters from this model are the 
constant rate of insulin disappearance (n), exogenous insulin delivered between 20-
25 min and the insulin level above basal (Insulin) in the accessible compartment. After 








Figure 4.15: Schematic illustration of the combined two-compartment model of C-
peptide and one-compartment model of insulin from Toffolo et al. (18) to determine the 
insulin secretion rate (ISR), insulin delivery rate (IDR) and hepatic insulin extraction 
Each participant’s glucose, insulin and C-peptide data were analysed using WinSAAM 
mathematical software programme (344). This software program estimates the 
parameters necessary to solve the model followed by checking how well the model fits 
the data. Depending on the fit of the model, the parameters might need to be adjusted 
or specified up front using Bayesian constraints to optimize the fit. A FSD of <0.5 
indicates that the model fits the data well and that the parameters are well estimated. 
Examples of modelled C-peptide, insulin, ISR and hepatic insulin extraction graphs 
are shown in figure 4.15. 
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Figure 4.16: Graphical output from the Toffolo model showing the C-peptide and 
insulin observed data (closed triangles) over time with the model predicted values 
(black solid line). The model estimated insulin secretion rate (ISR) and hepatic insulin 
extraction (HIE) over time in the bottom graphs 
 
In 18 participants, the Toffolo model were unable to estimate key parameters. We, 
therefore, could not use the ISR and hepatic insulin extraction derived from the Toffolo 
model. Possible reasons why the Toffolo model fitted our data poorly were the 
complexity of the model, estimated 11 parameters, or the model was not applicable to 
our population that have high insulin and C-peptide levels in response to glucose.  
Subsequently we choose a simpler model with less estimated parameters and that 
has been used in black men of African descent (71), as well as in black African 
American children (58) and women (59). This model was first described by Polidori et 
al. and can estimate both hepatic and peripheral insulin clearance (71). This model 
assumes that hepatic insulin delivery comes from 2 sources, the portal vein (which 
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reflects endogenously secreted insulin - ISR) and from the systemic circulation (Figure 
4.17). The insulin delivered to the liver from the systemic circulation is assumed to be 
equal to the hepatic plasma flow multiplied by the plasma insulin concentration. 
Polidori et al. assumed that the hepatic plasma flow was constant (0.576 L/min/m2) 
(71). Hepatic plasma flow quantification requires invasive techniques which are not 
feasible in majority of settings. However, to determine whether the changes in hepatic 
insulin extraction is due to cellular changes and not changes in hepatic blood flow, 
hepatic blood flow therefore needs to be considered. A study that inserted 3 catheters 
- in the hepatic vein, subclavian vein and the brachial artery - and used a continuous 
infusion of indocyanine dye, determined that hepatic blood flow increased after an oral 
glucose load but did not changed significantly after an intravenous glucose infusion 
(345). This finding may justify using a constant hepatic plasma blood flow with a FSIGT. 
However, the previous mentioned study used healthy, lean males, so the validity of 
the assumption of constant hepatic blood flow in our study population (obese, black 
African females) cannot be certain. ISR are obtained from C-peptide deconvolution. 
Insulin can either be degraded peripherally by tissues such as the kidney, muscle and 
adipose tissue or by the liver. Peripheral insulin degradation is assumed to be 
proportional to plasma insulin levels with the parameter CLp. Lastly, the model 
assumes that hepatic insulin clearance can either follow linear or saturable kinetics. 
The linear model assumes a constant hepatic insulin clearance and is explained by 
the fractional hepatic extraction (HIE) parameter, while the saturable model assumes 
hepatic insulin clearance varies with the ISR and plasma insulin levels which are 
explained by the maximal insulin degradation rate (Vmax) and the hepatic insulin 




Figure 4.17: Graphical display of the Polidori model (adapted from (71)), ISR – insulin 
secretion rate, HPF – hepatic plasma flow, Ins – Insulin, HIE – hepatic insulin 
extraction, CLp – peripheral insulin clearance 
 
WinSAAM was used to estimate the parameters of both the linear (volume of 
distribution (Vd), HIE, CLp, ISR) and the saturable models (Vd, Vmax, Km, CLp, ISR). 
The Polidori model only looks at the disposal of insulin and not the effect of glucose 
on insulin. Therefore, only the insulin and C-peptide levels over the FSIGT are used 
as inputs into the model. Both the linear and saturable models were run on all 
participants. An FSD was obtained for the estimated parameters to ensure parameters 
were well estimated. The model that fits the data the best was chosen as the preferred 
model. The Akaike Information Criterion (AIC) was used to determine the best fit (346): 
𝐴𝐼𝐶 = 𝑁 𝑋 ln + 2𝑛  with N - Number of insulin time points, n – number of 
parameters estimated + 1, SSR - Sum of squares of residuals with SSR= 
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∑ 2(   )  . The model with the lowest AIC was chosen as the 
preferred model. An additional measure was used to determine how well the model 
fitted the data, the normalized root mean square error (NRMSE) = 
100 𝑋 
√ /
. The NRMSE normalizes the square root of SSR to the 
change in insulin concentration (71). 
The linear model provided a single parameter to explain hepatic insulin clearance 
(HIE) (post-glucose load) compared to two parameters (Vmax and Km) provided by 
the saturable model. In order to compare hepatic insulin extraction between subjects 
as well as before and after the intervention, the output from the linear model was used. 
Prior to the intervention (baseline), both the linear and saturable model were run on 
43 participants (excluded: 2 did not have a FSIGT test) and the linear and saturable 
models were preferred in 26 (60.5%) and 14 (32.6%), respectively, whereas in 3 
participants no model could be resolved. Both models were run on 35 participants that 
completed the intervention but 5 had to be excluded from pre- and post-intervention 
analysis because no pre-FSIGT test was done (n=1), or no model was resolved on 
pre-FSIGT data (n=3), or the post FSIGT test was prematurely halted at 50 minutes 
(n=1). In a further 2 participants, the preferred pre-and post-intervention models was 
discrepant and therefore the insulin clearance parameters could not be compared. In 
20 (linear model) and in 8 (saturable) participants the same model was preferred for 






CHAPTER 5: METHODS 
 
The methods in chapter 5 have been published in part (347): 
Goedecke JH, Mendham AE, Clamp L, Nono Nankam PA, Fortuin-de Smidt MC, Phiri 
L, et al. An Exercise Intervention to Unravel the Mechanisms Underlying Insulin 
Resistance in a Cohort of Black South African Women: Protocol for a Randomized 
Controlled Trial and Baseline Characteristics of Participants. JMIR Res Protoc. 2018 
Apr 18;7(4):e75.  
 
5.1 RESEARCH DESIGN 
 
We performed a randomised controlled exercise intervention study. Participants 
meeting all inclusion criteria were block (2-4 participants) randomised (Microsoft Office 
Excel, 2013) into an exercise (n=23) and control group (n=22). The CONSORT 
participant flow diagram is shown in Figure 5.1. The schematic overview of all testing 
procedures is shown in Figure 5.2. All testing procedures occurred before and after 
the intervention. Post-intervention FSIGT was performed ≥72 hours after the last 











Fig 5.2. Schematic overview of testing procedures and timelines (Adapted from 
Goedecke et al, 2018)  
5.2 STUDY PARTICIPANTS 
 
Black South African women were recruited from a low socioeconomic community in 
Cape Town. Recruitment and testing occurred from July 2015 to December 2016 
through advertisements and flyers distributed in local communities and universities. 
Inclusion criteria were: obese (BMI 30-40 kg/m2), both parents of isiXhosa descent 
(self-reported), 20-35 years old, stable weight (<5 kg change in weight in the last 6 
months), using injectable contraception (depot medroxyprogesterone acetate, 400 
mg) for a minimum of 2 month prior to testing. Participants were excluded if they had 
any known diseases (e.g. HIV, hypertension, diabetes (random blood glucose 
>11.1mmol/L, HbA1c >6.5%)), were pregnant or lactating, smoking or had any other 
orthopaedic or medical problems that prevented or restricted exercise participation. 
University of Cape Town Human Research Ethics Committee provided ethical 
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permission (HREC REF:799/2015) (Appendix A). The trial was registered in the Pan 
African Clinical Trial Registry (PACTR201711002789113). Written informed consent 
(Appendix B) was obtained prior to screening and testing procedures. 
5.3. SCREENING PROCEDURES 
 
Volunteers completed a screening questionnaire (Appendix C) that collected 
information on ancestry, weight gain, current level of physical activity, contraception 
use, smoking history, medical and surgical history, current medication usage and HIV 
status. Weight was measured with no shoes and minimal clothes using a digital 
calibrated scale to the nearest 0.1kg. Height was measured with a stadiometer to the 
nearest 0.1cm. The BMI was calculated as weight (kg) ÷ height (m)2. Blood pressure 
was measured using an automated blood pressure monitor (Omron 711, Omron 
Health Care, Hamburg, Germany) with an appropriately sized cuff. The participant had 
to remain seated for at least 5 minutes after which blood pressure was measured three 
times at 1-min intervals. The participant was excluded if the mean blood pressure was 
≥140/90 mmHg. An HIV Rapid test was performed to ensure all participants were HIV-
negative. The participants received pre-and-post HIV test counselling and were 
referred to the local clinic if HIV test was positive. Blood samples were also drawn to 
test for Hb (to exclude anaemia), and to measure random blood glucose and HbA1c 
(to exclude diabetes). A physical activity readiness questionnaire (PARQ) was 
completed by each participant to assess their risk of taking part in the exercise 
intervention. They answered “no” to all questions for inclusion into the study. A 
pregnancy test will also done to exclude any participants who were not aware that they 
were pregnant. Reasons for participant exclusions were: a positive HIV test (n=2), 
unwillingness to further participate in the study (n=21), a BMI <30 kg/m2 (n=12), BMI 
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>40 kg/m2 (n=12), too young (n=1), not on contraception (n=15) and taking medication 
(n=1). Participants that met all the inclusion criteria and none of the exclusion criteria 
were enrolled in the study.  
 
5.4 EXERCISE INTERVENTION 
 
The exercise group participated in a 12-week aerobic and resistance training 
intervention. A biokineticist facilated and supervised every session. The exercise 
session duration progressed from 40-60 min, 4 days per week. Table 5.1 display the 
session duration and the resistance exercise training (repetitions, sets and weights 
used) progression. The programme included aerobic-based exercises (dance, 
running, skipping and stepping) performed at a moderate-vigorous intensity (75-80% 
maximal heart rate, HRpeak). Aerobic-based exercises were done continuously moving 
from one exercise to another with no prescribed rest in between. Resistance exercise 
training consisted of progressive (body weight, bands and free weights) strengthening 
exercises (squats, lunges, bicep curls, push-ups and shoulder press) to achieve a 
prescribed intensity of 60-70% HRpeak. The prescribed resistance training intensity was 
a guide to ensure that the repetition tempo was maintained. The program was 
designed to use low weights with high repetition. Body weight and resistance band 
exercises were done during the first 2 weeks. Free weight strengthening exercises 
were added to body weight and resistance band exercises in the following weeks 
(Table 5.1). A heart rate monitor (Polar Electro, Kempele, Finland) was used to ensure 
participants achieved the desired exercise intensity and attendance was recorded for 
each session. The relative intensity of the exercise program did not change but as the 
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cardiorespiratory fitness of participants increased, the duration and intensity of the 
activities increased (Table 5.1). The control group was instructed to continue with 
habitual activity and not to initiate any exercise programs during the study period. Both 
the control and the exercise group were asked to continue with habitual dietary 
patterns which was monitored on a monthly basis. The participants were not blinded 
to the aims of the study. They were informed that the aim of the study was not to 
induce changes in body weight, but rather changes in health status. Weight loss was 
therefore not anticipated by the participants. 
 
Table 5.1: Details of the combined aerobic and strength exercise training program 
Weeks 1 2 3 4 5 6 7 8 9 10 11 12 
Session 
frequency 
4 times a week 
Total session 
duration (min) 
40  40 40 40 45 45 50 50 55 55 60 60 
Aerobic training             
Session 
duration (min)  
30 30 28 28 33 30 35 32 37 37 40 40 
Intensity 75-80% HRpeak 
Strength training 
Session 
duration (min)  
10 10 12 12 12 15 15 18 18 18 20 20 
Reps and sets 10 x 3 15 x 3 10 x 3 15 x 3 10 x 3 15 x 3 20 x 3 20 x 3 10 x 3 15 x 3 10 x 3 15 x 3 
Weights - - 1kg 1kg  1.5kg 1.5kg 1.5kg 1.5kg 2kg 2kg 2.5kg 2.5kg 
Intensity 60-70% HRpeak 
Min – minutes, HR – heart rate, Reps – repetitions, Weights – refers to the weight of the dumbbells 
 
5.5 STUDY MEASUREMENTS 
 
5.5.1 CARDIORESPIRATORY FITNESS 
144 
 
Peak oxygen consumption (VO2peak) was measured using a walking treadmill-based 
(C, Quasar LE500CE, HP Cosmos, Nussdorf-Traunstein, Germany), graded exercise 
test adapted for sedentary participants that are not familiar with gym-based equipment 
(348). The test started at 3 km/h at 2% gradient and the gradient was increased by 2% 
after every 2 minutes until a gradient of 16% were reached. Thereafter, the speed and 
gradient were increased alternatively (0.5 km/hour and 1%, respectively) to volitional 
exhaustion. VO2peak was measured by assessing ventilation and oxygen and carbon 
dioxide concentrations in the expired air using a metabolic gas analysis system 
(CPET, Cosmed, Rome Italy) and the heart rate was monitored continuously (Polar 
Electro Oy, Kempele, Finland) to determine peak heart rate (HRpeak).  
5.5.2 QUANTIFICATION OF SI AND Β-CELL FUNCTION 
Prior to the testing day, participants slept overnight at the laboratory and consumed a 
standardized meal, typical of their usual intake, at 20h00 (Energy: 2,456 kJ, 21 g 
protein (14% energy), 49 g carbohydrate (33% energy) and 32 g fat (48% energy)), 
followed by an overnight fast (10-12 h). In the morning, fasting blood samples were 
drawn for measurement of HbA1c, insulin, glucose and C-peptide, and the FSIGT was 
performed. Glucose (50% dextrose; 11.4 g/m2 X body surface area) was infused at 0 
min over a 60 s period followed at 20 min by an infusion of human insulin (0.02 unit/kg; 
NovoRapid, Novo Nordisk Limited, Cape Town, RSA) over 5 min at a constant rate. 
Thirty-two blood samples were drawn for the measurement of insulin, glucose and C-
peptide at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 
80, 90, 100, 120, 140, 160, 180, 200, 220, 240 time points over 240 min, following the 
start of glucose administration. SI, AIRg and DI (SI X AIRg), glucose effectiveness 
(minimal model of glucose kinetics) (332), ISR (337) and hepatic and peripheral insulin 
clearance (71) were derived from mathematical modelling. The incremental area-
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under curve (AUC) above baseline for ISR, glucose, insulin and C-peptide were 
calculated using the trapezoidal rule. The first 10 minutes and the entire period of the 
FSIGT are referred to as the first phase AUC and the total AUC, respectively. 
5.5.3 BIOCHEMICAL ANALYSES 
HbA1c was analysed using high-performance liquid chromatography (Meharini 
Diagnostics, Florence, Italy). Plasma glucose was measured using a colorimetric 
assay (Randox (Pty) Ltd, Gauteng, South Africa). Serum insulin and C-peptide were 
determined by an immunochemiluminometric assays (IMMULITE 1000 immunoassay 
system, Siemens Healthcare (Pty) Ltd, Midrand, South Africa). Pre- and post-
intervention samples for each participant were analysed in the same run. Coefficient 
of variation for assays ranged from 6 to 8.5%. 
5.5.4 ANTHROPOMETRY AND WHOLE-BODY FAT COMPOSITION 
Anthropometric measurements included weight, height, hip and waist circumferences 
using standardized methods (103). Whole body composition was measured by dual-
energy x-ray absorptiometry (DXA; Discovery-W®, software version 12.7.3.7; Hologic, 
Bedford, MA) in the mornings after an overnight fast, for the analyses of total body fat 
mass, fat-free soft tissue mass, trunk, and leg fat mass. All values are expressed as a 
percentage relative to sub-total fat mass (whole body minus the head).  
5.5.5 ECTOPIC FAT, SAT AND VAT QUANTIFICATION  
A standardized meal (Energy: 2553 kJ, protein: 20.9 g; carbohydrates: 83.0 g; fat: 22.2 
g) was consumed 2-4 h prior to skeletal muscle, hepatic and pancreatic fat and SAT 
and VAT volume determination. Image acquisition and post-processing of MRI and 
MRS images were described in detail in Chapter 4.  
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5.5.6 PHYSICAL ACTIVITY AND DIETARY MONITORING 
Energy expenditure of both the exercise and control groups was estimated using 
accelerometery (ActiGraph GTX3+, LLC, Pensacola, Florida, worn on the right hip 
for 24 hours a day over a 7-day period) at baseline, 4, 8 and 12 weeks. The activity 
counts from the ActiGraph were collected from 3 orthogonal axes. The vector 
magnitude was calculated as the square root of the sum of the 3 squared vectors 
( √𝑋 + 𝑌 +  𝑍 ) (349). Activity counts were categorized into sedentary, light, 
moderate and vigorous based on cutpoints from Matthews et al. (350). Data were 
recorded in 60 second epochs. Non-wear days were defined as 60 continuous 
minutes without any counts (351). Physical activity data were analyzed using the 
ActiLife Software version 6 (ActiLife software; Pensacola, Florida, USA). Energy 
expenditure was compared between the exercise (non-exercise days) and the 
control group. Dietary intake was measured by a registered dietician using a 24-hour 
dietary intake recall and a 3-day dietary record (2 weekdays and one weekend day) 
at baseline, 4 and 8 and 12 weeks. The South African Food Composition Database 
System (SAFOOD, the South African Food Composition Database, Version 2016, 
South African Medical Research Council, Parow, Cape Town, South Africa) was 
used for the nutrient intake analysis (352).  
5.6 STATISTICAL ANALYSIS 
 
Data was analysed using STATA 12.0 (College Station, TX, USA). The distribution of 
continuous variables was evaluated using histograms, standardized normal probability 
plots and the Shapiro Wilk test. Normally and non-normally distributed data were 
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expressed as mean ± standard deviation (SD) and median and interquartile range 
(25th-75th percentiles), respectively. 
Baseline data 
The study population was divided into tertiles based on the DI: DILow, DIintermediate and 
DIhigh. Differences between DI tertiles was determined using one-way ANOVA with a 
Bonferroni post hoc test or Kruskal Wallis test with the Dunn post hoc test for normally 
and non-normally distributed data, respectively. Pearson (normally distributed 
variables) and Spearman (non-normally distributed variables) correlation analysis 
were conducted to firstly assess the associations between DI and its direct 
components (SI, AIRg), indirect components through AIRg (first phase ISR, hepatic 
insulin extraction), peripheral insulin clearance and secondly to assess associations 
of all the aforementioned DI components with body composition, body fat distribution 
and ectopic fat deposition. This thesis did not correct for multiple comparisons and 
thus a possibility exists of obtaining false positive associations. However, this thesis 
wanted to explore all the possible significant underlying associations between these 
various component and therefore wanted to minimize false negative associations. 
These variables are highly correlated and therefore correcting for multiple 
comparisons may be to stringent. Linear regression was performed with the 
transformed DI (square root) as dependent variable and natural log transformed 
ectopic fat variables and VAT as independent variables. Additionally, linear regression 
was also used to assess the relative contribution of first phase ISR and hepatic insulin 
extraction to AIRg, with and without adjusting for SI). 
Pre- and Post-intervention Analysis 
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A per protocol analysis was performed using participants that had both pre- and post-
intervention data available (n=20 in exercise and n=15 in control group). Mixed model 
analysis was performed to determine the main effect between groups (exercise and 
control groups) and within groups (before and after intervention) and cumulative effect 
of between and within group factors (interaction), with Fisher’s least significant 
difference post-hoc test. The random effects refer to inter-subject variability, while the 
fixed effects refer to differences between the groups (control vs exercise). Mixed 
model analysis was also used for the diet and energy expenditure data to determine 
differences between the control and exercise groups at baseline, week 4, 8 and 12 
and to determine within group differences (between baseline and week 4, 8 and 12). 
Linear regression was used to determine the associations between changes in main 
outcomes and changes in possible predictors firstly, in the combined group and 
secondly, to check for an interaction by intervention group (control vs exercise group). 
If the homoscedasticity or the normality of residuals assumptions were not met, robust 
regression was used. In order to check whether the variation in the exercise training 
compliance influenced our study findings we calculated a composite measure, the 
exercise dose (AU), which is the product of the number of sessions (maximum = 48 
sessions) attended and the mean %HRpeak attained over the 12-week training period. 
The exercise dose was converted into a categorical variable with the following 
categories: No exercise (n=15) (control group), moderate exercise dose (n=10) (≤ 
median (3070.6), total number of sessions (range) 25-42, %HRpeak 78.3-83.4) and high 
exercise dose group (n=10) (> median (3070.6), total number of sessions 38-49, 
%HRpeak 75.5-83.1). Whether the exercise dose modified the changes in metabolic 
outcomes, regional and ectopic fat deposition were assessed using mixed models. 
Linear regression was used to assessed whether exercise dose modified the 
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associations of the metabolic outcomes with regional and ectopic fat deposition. A p-
value of <0.05 was regarded as significant. The sample size calculation was based on 
the change in SI as one of the primary outcomes of this study. Based on the mean 
change (±SD) in SI (x10-5 min/pmol) determined by FSIGT, in the control group (Δ-
0.35 ±1.7) and exercise group (Δ 1.7±2.5) (261) with a power of 80% and a 
significance level of p<0.05, 18 participants per group were needed. The number 









6.1.1 PARTICIPANT CHARACTERISTICS: OVERALL AND BY DI TERTILES  
 
A hyperbolic association was evident between AIRg and SI in the whole group and by 
each of the DI tertiles (Figure 6.1).  
 
Figure 6.1: Hyperbolic association between insulin sensitivity (SI) and acute insulin 
response to glucose (AIRg) in all participants (A) and by disposition index (DI) tertiles 
(B)  
The participants’ characteristics described by DI tertiles are displayed in Table 6.1. In 
the whole cohort the participants had a median age of 23 years (range 20 to 35 years) 
and were obese (BMI 33.9 ±2.8 kg/m2). The median pancreatic, hepatic, total soleus 
and tibialis anterior fat were 7.3 (6.2-9.3)%, 4.9 (4.4-5.8)%, 10.2 (8.8-11.6)% and 4.2 
(3.2-5.7)%, respectively.  
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Table 6.1: Characteristics of participants by disposition index tertile 
 DILow (≤5073.4) DIIntermediate (>5073.4 -
≤7933.2) 
DIHigh (>7933.2) P value 
n=15 n=13 n=15  
Age and anthropometry      
Age (years) 24 (21-28) 22 (21-28) 23 (21-24) 0.455 
Body weight (kg) 85.1 ±8.8 87.8±6.3 87.1 ±13.7 0.400 
Body mass index (kg/m2) 33.3 ±2.6 35.3 ±2.1 33.6 ±3.5 0.147 
Waist circumference (cm) 103.1 ±5.3 103.9 ±8.5 105.8 ±11.0 0.705 
Waist-hip ratio 0.89 (0.84-0.95) 0.89 (0.87-0.91) 0.90 (0.85-0.94) 0.899 
Body composition and fat distribution 
Body fat mass (%) 50.1 ±2.8 51.3 ±3.1 50.4 ±4.5 0.660 
Fat free soft tissue mass (kg) 36.9 (33.8-40.3) 37.4 (35.8-38.8) 38.7 (34.9-40.6) 0.791 
Trunk fat mass (%) 47.9 ±4.7 47.3±4.0 46.5 ±4.7 0.684 
Leg fat mass (%) 40.0 ±5.2 40.6 ±4.3 40.8 ±5.2 0.901 
Android fat mass (%) 8.5 ±1.4 8.1 ±0.8 7.9 ±0.8 0.284 
Gynoid fat mass (%) 18.5 ±1.8 18.7 ±2.0 18.4 ±2.5 0.942 
VAT (cm3) 1113.3 ±317.9  931.6 ±355.1 669.8 ±229.1* 0.002 
aSAT (cm3) 5303.9 ±1116.8 5741.4 ±1105.2 5629.1 ±2191.8 0.747 
VAT-aSAT 0.20 (0.16-0.24)  0.15 (0.11-0.21) ǂ 0.13 (0.09-0.15) * 0.003 
Ectopic fat     
Pancreatic fat (%) 8.0 (7.3-9.0) 7.4 (6.6-10.4) 6.2 (5.2-6.4) *† 0.006 
Hepatic fat (%) 5.6 (4.5-6.1) 5.9 (4.5-8.4)  4.5 (3.9-4.9) *† 0.023 
Soleus fat (%) 10.7 (10.1-11.4) 9.7 (8.8-11.6) 9.4 (6.8-10.3) 0.111 
Tibialis anterior fat (%) 4.1 (3.3-5.7) 4.2 (3.5-5.4) 5.0 (2.6-6.1) 0.953 
SIMCL (%) 2.9 (2.5-3.9) 2.9 (2.5-4.8) 2.1 (1.3-3.1) † 0.055 
SEMCL (%) 4.5 (4.2-12.8) 5.1 (3.6-4.5) 4.3 (3.6-5.6) 0.410 
TIMCL (%) 0.5 (0.3-0.8) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.288 
TEMCL (%) 2.9 (1.1-4.7) 2.6 (1.6-3.0) 2.5 (1.5-4.2) 0.815 
Fasting metabolic parameters 
Fasting glucose (mmol/L) 5.4 ±0.9 5.0 ±0.9 5.2 ±0.6 0.411 
Fasting insulin (pmol/L) 85.2 (63.9-119.1) 82.5 (78-113.7) 57.7 (38.6-88.5) 0.107 
Fasting c-peptide (pmol/L) 605.7 (572.6-744.8) 733.2 (491.5-835.8) 466.7 (382.3-787.8) 0.218 
C-peptide/insulinbasal 6.8 (6.3-8.4) 8.4 (6.4-9.3) 9.0 (7.7-10.9) 0.087 
ISRbasal (pmol/min) 78.7 (74.4-96.8) 94.7 (62.9-102.4) 62.4 (49.-104.6) 0.567 
HOMA2 IR% 2.1 (1.7-2.9) 2.0 (1.8-2.7) 1.4 (1.0-2.2) 0.149 
HOMA2 B% 134.6 (97.5-204.3) 182.6 (130.4-213.2) 108.7 (85.2-149.1) 0.133 
HbA1c and FSIGT-derived measures 
HbA1c 5.24 ±0.36 5.19 ±0.36 5.20 ±0.43 0.829 
Disposition index (AU) 3780 (2989-4527)  6596 (6070-7119) ǂ 9995 (9247-13882) *† <0.001 
SI (mU/l)-1
 
min-1 1.94 (1.1-2.8)  1.97 (1.4-3.1) 3.1 (2.2-4.5) *† 0.008 
AIRg mU l-1
 
min-1 2159 (1465-3159) 2909 (2544-4870) 3561 (4278-4514) 0.064 
Sg (min-1) 0.017 ±0.008  0.024 ±0.008 0.031 ±0.008 * <0.001 
ISRfirst phase(pmol/min) 2692 (1909-4023) 3624 (2826-4999) 4049 (2758-4877) 0.060 
ISRtotal (pmol/min) 4246 (3231-8095) 5589 (4813-7913) 4272 (3261-6500) 0.365 
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Mean (±standard deviation) for normally distributed variables and median (interquartile range) for non-normally distributed 
variables; DI – Disposition index, VAT – visceral adipose tissue, aSAT – abdominal subcutaneous adipose tissue, SIMCL- soleus 
intra-myocellular fat, SEMCL – soleus extra-myocellular fat, TIMCL – tibialis anterior intra-myocellular fat, TEMCL – tibialis 
anterior extra-myocellular fat,  ISR – insulin secretion rate, Homeostatic model assessment 2 of insulin resistance (IR) and beta 
cell function (B), SI – Insulin sensitivity, AIRg – acute insulin response to glucose, Sg – Glucose effectiveness, HIE – hepatic 
insulin extraction; CLp – peripheral insulin clearance. P value derived from ANOVA or Kruskal Wallis, Significant post hoc 
differences: * High DI compared to low DI; † High DI compared to intermediate DI; ǂ Intermediate DI compared to low DI with 
P≤0.05 deemed as statistically significant. § HIE and CLp numbers by DI tertiles: High (n=7), Intermediate (n=9) and Low (n=10) 
DI. 
 
No differences were found in fasting glucose or HbA1c between DI groups. The group 
with the highest DI, was the most insulin sensitive (post hoc p=0.006) and had the 
highest Sg (post hoc p<0.001) compared to those with the lowest DI. Moreover, over 
the whole FSIGT period the high DI tertile group had the lowest glucose AUC 
compared to the low DI tertile group (p=0.042) (Figure 6.2). AIRg and first phase ISR 
showed a gradual decline across DI tertiles (interaction p=0.060 and p=0.064, 
respectively). Interestingly, while no difference was observed in hepatic insulin 
extraction across the DI tertiles, peripheral insulin clearance declined moving from the 
highest to lowest DI tertile (post hoc p=0.005). While, groups did not differ in BMI, waist 
circumference, total fat mass, aSAT and peripheral fat mass, those with the highest 
DI had the lowest VAT and lowest VAT-aSAT ratio, as well as the lowest pancreatic 
and hepatic fat compared to those with the lowest DI. 
HIE (%) §  58.5 ±13.0 51.3 ±8.3  49.6 ±10.1 0.213 





Figure 6.2: Average time course and area under the curve for glucose, insulin and C-
peptide by disposition index (DI) tertiles. Insert shown is an enlargement of the 





6.1.2 DESCRIBING HOW DI AND ITS COMPONENTS RELATE TO EACH OTHER 
 
Various components contribute to DI and is the main outcome measure. This thesis, 
therefore, wanted to describe how DI relates to each of these components and how 
the components relate to each other. The correlation matrix of DI and its components 
is depicted in Table 6.2. As expected, DI was positively associated with both its 
immediate components: SI and AIRg, as well as with first phase ISR (rho 0.365, 
p=0.016). DI was also positively associated with peripheral insulin clearance (rho 
0.528, p=0.006), with a negative trend with hepatic insulin extraction (rho -0.305, 
p=0.079). Higher SI was associated with lower first phase ISR and a higher hepatic 
insulin extraction, but was not associated with peripheral insulin clearance. Further, 
higher first phase ISR was associated with lower hepatic insulin extraction and higher 
peripheral insulin clearance. However, the different insulin clearance components 
were not associated with each other (p=0.191). 
Further, this thesis determined the underlying correlates of a high AIRg, above the 
compensatory relationship with SI. Therefore, evaluating the relative contribution of 
insulin secretion and insulin clearance to high AIRg, firstly without and then adjusting 
for SI. This thesis started by evaluating the correlates of AIRg using simple 
correlations, which showed that a high AIRg was strongly associated with a high first 
phase ISR (rho 0.920, p<0.001)) and a low hepatic insulin extraction (rho -0.744, 
p<0.001), but was not associated with peripheral insulin clearance (p=0.236) (Table 
6.2). Secondly, linear regression models were used to determine the relative 
contributions of hepatic insulin extraction and first phase ISR to AIRg, with and without 
adjusting for SI (Table 6.3). Peripheral insulin clearance did not add significantly to the 
multivariable model and was therefore not included. In the univariate models, early 
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phase ISR and hepatic insulin extraction explained 70.7% and 55.3% of the variance 
in AIRg, respectively, while SI explained 32% of the variance in AIRg (data not shown). 
In the multivariable model, hepatic insulin extraction and early phase ISR were 
independently associated with AIRg and together accounted for 88.5% of the variance, 
with only a further 3.2% explained by the addition of SI to the model. 
Table 6.2: The relationships between disposition index (DI) and its components  
 DI SI AIRg ISRfirst phase HIE 












n=43 1   






n=43 1  




















Data expressed as Spearman correlation coefficient, rho (p value) with p ≤0.05 regarded as statistically significant; DI – 
Disposition index, SI – Insulin sensitivity, AIRg – acute insulin response to glucose, ISR - insulin secretion rate, HIE – hepatic 
insulin extraction, CLp – peripheral insulin clearance 
 
Table 6.3: The contribution of first phase insulin secretion and hepatic insulin 
extraction to acute insulin response to glucose in those with linear model preferred 
(n=26) 
Model Variables Ln AIRg    
β ± SE Partial beta P Model R2 
1. ln ISRfirst phase 1.14 ±0.12 - <0.001 0.787 
2. Hepatic insulin extraction (%) -0.014 ±0.002 - <0.001 0.553 
3. ln ISRfirst phase 0.883 ±0.112 0.687 <0.001 0.865 
 Hepatic insulin extraction (%) -0.007 ±0.002 -0.344 0.001 
4. ln ISRfirst phase 0.773 ±0.141 0.602 <0.001 0.877 
 Hepatic insulin extraction (%) -0.007 ±0.002 -0.347 0.001  
 ln SI -0.106 ±0.566 -0.136 0.165 
Data expressed as linear regression slope (β) ± SE (Standard error), Ln – natural log, AIRg – acute insulin response to glucose, 




6.1.3 ASSOCIATIONS OF DI AND ITS COMPONENTS WITH BODY FAT 
DISTRIBUTION AND ECTOPIC FAT 
 
This thesis explored body fat distribution and ectopic fat as correlates of DI. To 
appraise these associations, the relations of the components of DI with body fat 
distribution and ectopic fat were also evaluated. Firstly, DI was not associated with 
body fat percent (p=0.855). The associations of DI with ectopic fat depots are shown 
in Figure 6.3. A higher DI correlated with lower pancreatic fat and showed a tendency 
to associate with lower hepatic fat (p=0.076). A higher DI was also associated with a 
lower total soleus fat, as well as with both a lower soleus IMCL and EMCL, with a 
stronger association evident with soleus IMCL, than EMCL. DI was not associated with 
tibialis anterior fat, leg fat mass or aSAT (data not shown) but was associated with the 
VAT-aSAT ratio (β -167.4, p<0.001). In the univariate analysis VAT explained 32% of 
the variance in DI while soleus IMCL explained 18.7%, EMCL 10.9% and pancreatic 
fat explained 12%. Multivariable models were constructed to assess whether 
abovementioned associations occurred independent of age and fat mass percent. The 
addition of age and fat mass percent did not add significantly to the models as such 
the negative associations of DI with pancreatic fat (β -62.9, p=0.030), VAT (β -0.037, 
p<0.001), soleus fat (β -50.0, p=0.049), soleus IMCL (β -41.3, p=0.012) and soleus 
EMCL (β -32.0, p=0.047) remained.  
Additionally, to explore whether the associations between DI and the ectopic fat depots 
were independent from VAT, this thesis adjusted for VAT in bivariate regression 
models for each of the ectopic fat depots. (Table 6.4). When adjusting for VAT, the 
associations between DI and pancreatic fat and soleus IMCL were no longer 
significant, but soleus EMCL remained significantly associated with DI. However, 
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when soleus IMCL was also placed in the model with soleus EMCL and VAT, the 
association between DI and soleus EMCL was diminished (p=0.079). VAT remained 
a significant correlate of DI regardless of the ectopic fat depot placed in the model.  
 
 
Figure 6.3: Disposition index (DI) associations: with (A) pancreatic fat (B) hepatic fat, 
(C) visceral adipose tissue, (D) soleus fat (E) soleus intramyocellar fat (IMCL) and (F) 
soleus extramyocellular fat (EMCL) in those with low DI (solid black triangles), 
intermediate DI (open circles) and high DI (solid black square). Regression line 
indicates significant association (p<0.05) in the whole cohort, β - linear regression 









Table 6.4: Associations between disposition index and ectopic fat adjusted for visceral 
adipose tissue  
  Disposition index (square root) 
  β ± SE P value R2 
1. Ln Pancreatic fat 






2. Ln Hepatic fat 






3. Ln Soleus fat 






4. Ln Soleus IMCL 






5. Ln Soleus EMCL 






6. Ln Soleus IMCL 
Ln Soleus EMCL 








Data expressed as linear regression slope (β) and the standard error (SE). Pancreatic, hepatic, total soleus fat and soleus 
intramyocellular (SIMCL) and extramyocellular (SEMCL) fat were log transformed (Ln) 
 
Next, this thesis explored the associations between the components of DI and ectopic  
and regional fat. Firstly, the association with fat mass percent requires mention. None 
of the components of DI (SI, AIRg, first phase ISR, hepatic insulin extraction and 
peripheral insulin clearance) were associated with fat mass percent (p>0.05) (data not 
shown). Secondly, AIRg and first phase ISR, were not associated with pancreatic fat 
(rho -0.202, p=0.217 and rho-0.215, p=0.189, respectively), hepatic fat (rho 0.057, 
p=0.735 and rho-0.039, p=0.816, respectively) or soleus fat (rho-0.179, p=0.275 and 
rho-0.214, p=0.191, respectively). Additionally, hepatic insulin extraction was not 
associated with hepatic fat (rho -0.253, p=0.244) and peripheral insulin clearance was 
not associated with soleus fat (rho-0.036, p=0.872). Moreover, SI was not associated 
with fat deposition in the liver (rho-0.259, p=0.177), soleus muscle (IMCL rho-0.280, 
p=0.094 and EMCL rho-0.021, p=0.904) or tibialis anterior muscle (IMCL rho-0.184, 
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p=0.270 and EMCL rho-0.248, p=0.123). Rather, significant associations were found 
between the components of DI and central fat measures (Table 6.5). A lower SI was 
associated with higher VAT but not aSAT or VAT-aSAT ratio, while AIRg was not 
associated with VAT but rather with aSAT and VAT-aSAT ratio. However, when 
adjusting for SI, a higher AIRg was associated with a lower VAT and VAT-aSAT ratio 
but the association with aSAT was no longer significant. First phase ISR was not 
associated with any of the central fat depots, but after adjusting for SI, an inverse 
association emerged between first phase ISR and VAT, and a tended towards an 
association with the VAT-aSAT ratio (p=0.054). Further, hepatic insulin extraction was 
associated only with the VAT-aSAT ratio, and not with VAT, with and without adjusting 
for SI. Peripheral insulin clearance was not associated with central fat depots (VAT rho 
0.104, p=0.630 and aSAT rho 0.113, p=0.599).  
In terms of peripheral fat deposition, SI was positively associated with leg fat mass 
(%FM) (rho 0.411, p=0.007). However, both AIRg and first phase ISR were negatively 
associated with leg fat mass (%FM) (rho-0.395, p=0.010 and rho-0.425, p=0.005, 
respectively), but these associations were diminished to non-significance when 
adjusted for SI. Further hepatic insulin extraction and peripheral insulin clearance were 
not associated with leg fat mass (%FM), with or without adjustment for SI (data not 
shown).  
 
6.1.4. ASSOCIATIONS BETWEEN BODY FAT DISTRIBUTION AND ECTOPIC FAT 
 
Lastly, the associations between the various regional and ectopic fat depots were 
investigated to inform how these depots related to each other. VAT was positively 
associated with pancreatic fat and soleus IMCL, but not soleus EMCL, and showed a 
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positive trend with hepatic fat (p=0.06) (Table 6.6). Interestingly, aSAT was positively 
associated with hepatic fat and inversely associated with total soleus fat. Pancreatic 
fat was positively associated with hepatic fat (rho 0.540, p<0.001). None of the ectopic 
or regional fat depots were associated with fat mass percent (data not shown), except 
aSAT (r = 0.623, p<0.001). 
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Table 6.5: Correlations of the components of DI, insulin sensitivity, secretion and clearance, with central adipose tissue depots 
 Model 1  Model 2  






























































Unadjusted (Model 1) and in adjusted for SI (Model 2). Data expressed as the linear regression slope (P-value). SI – Insulin sensitivity, AIRg – acute insulin response to glucose, ISR- insulin secretion 
rate, HIE – hepatic insulin extraction, VAT – visceral adipose tissue, SAT – abdominal subcutaneous adipose tissue. Ln – natural log transformed variable 
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VAT (cm3) 1        
aSAT (cm3) 0.338 
(0.029) 
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Data expressed as correlation coefficient (p value). P≤0.05 is deemed statistically significant. VAT - Visceral adipose tissue; 





β-cell function is a critical factor in the pathogenesis of T2D. Nevertheless, the 
correlates of β-cell function, prior to onset of T2D, are incompletely understood, 
especially in black African populations who present with a phenotype of low SI, 
hyperinsulinemia and low ectopic fat deposition. This study not only showed 
associations between DI and its classic components, but we extend on existing 
evidence by demonstrating that DI was positively associated with peripheral insulin 
clearance. Notably, the major correlate of AIRg was first phase ISR above insulin 
clearance. Another key finding was that a higher DI was associated with lower VAT, 
pancreatic fat and soleus fat and a trend for lower hepatic fat. However, VAT emerged 
as the strongest correlate of DI, above and independent of the other ectopic fat depots. 
In addition, this thesis showed that AIRg, typically high in black African populations, 
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was associated with lower VAT deposition. This study further adds by showing that a 
lower VAT also associated with a higher ISR and lower hepatic insulin extraction. 
Thus, our findings suggest that VAT may be the main culprit in low DI in this cohort, 
not only through its association with a lower SI, but also through its relationship with 
the AIRg’s downstream components, ISR and hepatic insulin extraction. 
Our study, not only distinguishes between hepatic and peripheral insulin clearance, 
which has only been done in a few studies in adults without T2D (59,71,189), but also 
reported a positive association between DI and peripheral insulin clearance which to 
the best of my knowledge has never been shown before in any population. The reason 
for this relationship is unclear. Nevertheless, considering DI is based on the product 
of SI and AIRg, we can postulate two scenarios. Firstly, a higher DI may be due to 
hyperinsulinemia relative to the level of SI. However, hyperinsulinemia has been 
associated with lower insulin clearance in both adipose tissue (353) and skeletal 
muscle (354), due to reduced affinity of insulin receptors at these sites, and is therefore 
an unlikely explanation for our finding of a higher peripheral insulin clearance relative 
to higher DI. Secondly, a higher DI could be due to a greater SI in relation to the level 
of AIRg. In this scenario, a higher peripheral insulin clearance may be due to enhanced 
binding of insulin to insulin receptors in peripheral tissues. Although a positive 
association has been demonstrated between SI and hepatic insulin clearance (33), no 
association between insulin internalization, a measure of insulin clearance, and SI was 
observed in rat adipocytes (353), whereas the association between SI and insulin 
clearance in skeletal muscle is unknown. However, in support of the second scenario, 
we showed that those with the highest DI and peripheral insulin clearance were also 
more insulin sensitive, but only exhibited a slightly higher AIRg compared to those with 
lower DI and peripheral insulin clearance. Nevertheless, peripheral insulin clearance 
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was not associated with SI and AIRg, which may suggest that only when compensation 
between SI and AIRg is not matched, peripheral insulin clearance becomes more 
important. Further, we may also consider that the observed association between DI 
and peripheral insulin clearance is in compensation for a lower hepatic insulin 
extraction. However, we found no association between peripheral and hepatic insulin 
extraction, which is in accordance with Polidori et al. (71), who suggested that these 
components are differentially regulated. We also evaluated the associations of 
peripheral insulin clearance with ectopic fat deposition as possible explanation for the 
association with DI, but found that peripheral insulin clearance was not associated with 
soleus or tibialis anterior fat. Skeletal muscle fat has been associated with reduced SI 
(82), which may affect peripheral insulin clearance in the muscle. However, this 
requires further study, considering that the muscle is only secondary to the kidney in 
the proportion of insulin cleared in the periphery (17). 
Preservation of DI is critical for delaying the onset of T2D. Therefore,  we investigated, 
firstly, whether ectopic fat accumulation may explain the variance in DI. Secondly, we 
assessed the associations of ectopic fat with the components of DI, with a particular 
focus on hepatic and peripheral insulin clearance, which have not been studied 
together in this context before. Our study demonstrated that a higher DI was 
associated with lower pancreatic and soleus fat and a tendency towards a lower 
hepatic fat, but these associations were not independent from VAT. A similar 
observation was found in overweight African American and Hispanic adolescents (13 
to 25 years old) without T2D (204). In contrast a positive association between DI and 
pancreatic fat, adjusted for BMI and VAT, was shown in black African American 
women (51). However, this study included both participants with and without T2D, 
which may explain the discrepancy in findings. Further, two previous studies 
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conducted in black African adults without T2D assessed the association of AIRg and 
pancreatic fat, with one showing a positive association (209) and another showing no 
association (204). While our study is in accordance with the latter study, we also 
extend the literature by showing that pancreatic fat was not associated with first phase 
ISR determined by C-peptide deconvolution, or with hepatic insulin extraction. 
Differences in the accuracy of the techniques used to determine pancreatic fat and 
VAT may be considered to explain the lack of association between pancreatic fat and 
ISR and the diminished association between pancreatic fat and DI, after adjusting for 
VAT. However, the technique we used to detect pancreatic fat in this thesis showed 
good accuracy with a CV of 3.5% (324). Notably, a positive association was found 
between pancreatic fat and VAT in our study. Our findings may therefore suggest that 
pancreatic fat may only be a marker of VAT accumulation and may not be detrimental 
to DI in this cohort.  
The ability to maintain DI and prevent deteriorating glucose tolerance depends on the 
balance between AIRg and SI (180). However, there is no consensus on the 
mechanism of maintaining a higher AIRg, which is frequently observed in black African 
populations (39,45–47). Some studies reported that a lower hepatic insulin clearance 
alone is responsible for a higher AIRg (44,66), while others showed that both lower 
hepatic insulin clearance and higher ISR contribute towards a higher AIRg (47,58,59). 
Notably, AIRg may be out of proportion for the level of SI, and to assess the relative 
contribution of first phase ISR and insulin clearance to AIRg in this context, adjustment 
for SI is required. No association was found between AIRg and peripheral insulin 
clearance. Accordingly, a lower hepatic insulin extraction and higher first phase ISR 
were the main independent contributors towards a higher AIRg, independent of SI, but 
first phase ISR explained more of the variance in AIRg. Lowering hepatic insulin 
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clearance is an important compensatory mechanism to reduce the strain on the 
pancreatic β-cells, which has been shown in canines (67). However, this research has 
shown that a higher ISR can occur independent of a lower hepatic insulin extraction 
and lower SI. This may indicate that despite a lower hepatic insulin clearance, 
pancreatic β-cells continue to secrete insulin at a higher rate, which may be 
detrimental to the longevity of the β-cell in this cohort. Black African children present 
with hyperinsulinemia prior to obesity and a low SI (58), so whether a higher ISR is 
driven by a genetic predisposition or epigenetic alterations, remains to be determined. 
Although the inputs into these mathematical models may overlap, this is unlikely to 
explain the findings because three different models were utilized to estimate 
abovementioned variables; the two-compartmental model of C-peptide for ISR, the 
linear model from Polidori et al. for hepatic insulin extraction and the minimal model of 
insulin kinetics for AIRg and SI. Also, first phase ISR, hepatic insulin extraction and SI 
were independently associated with AIRg. Further, we also need to consider that a 
higher AIRg, independent from SI, may be explained by reduced insulin independent 
glucose uptake, measured by glucose effectiveness. We examined these associations 
in bivariate analyses and demonstrated a positive association between glucose 
effectiveness and AIRg or first phase ISR, independent from SI. This makes it unlikely 
that a higher AIRg, independent from SI, is due to reduced glucose effectiveness.  
This study further examined the associations between the components of AIRg and 
ectopic fat. Previously, reduced hepatic insulin extraction and increased insulin 
secretion have been associated with hepatic fat accumulation (184). The association 
between fasting hepatic insulin extraction and hepatic fat had been explored in African 
American women before (49). However, the association between stimulated hepatic 
insulin clearance, which is a more physiological response, and hepatic fat has not 
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been previously investigated in black African populations without T2D. We showed 
that hepatic fat was not associated with hepatic insulin extraction and insulin secretion 
in obese black South African women. Therefore, in black African populations, hepatic 
fat may not be an important correlate of alterations in hepatic insulin extraction and 
insulin secretion prior to T2D, and also not in those with early T2D (53). However, we 
should also consider that a lack of statistical power my explain this finding in our study 
since we only included those in whom the linear model was preferred. Instead, we 
found that a lower first phase ISR and higher hepatic insulin extraction was associated 
with higher VAT and VAT-aSAT ratio, respectively. This highlights a novel mechanism 
to explain the association between hyperinsulinemia and VAT and to the best of our 
knowledge, no previous study has evaluated the effect of central fat depots on hepatic 
insulin extraction. In addition, evidence on the associations between central fat depots 
and ISR, determined by C-peptide deconvolution are also limited in black African 
populations. A previous study showed ethnic and age differences between first phase 
ISR and VAT: a positive association in white women and a negative association in 
African American women and with a stronger negative association in post-menopausal 
African American women (54). However, we found that an inverse association 
between VAT and first phase ISR, independent of SI, was already evident in young 
pre-menopausal South African women. The negative associations between 
hyperinsulinemia indicators and VAT and VAT-aSAT ratio may reflect a reduced 
capacity of aSAT to store fat with a redirecton of fat to VAT and other ectopic sites, in 
line with the overflow hypothesis (109). Therefore, we should consider that VAT may 
only be a marker of ectopic fat accumulation and that VAT emerges as the strongest 
correlate due to a smaller measurement error in quantifying VAT compared to other 
ectopic sites. Nonetheless, possible reasons for the negative association between 
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VAT and ISR could be mediated through inflammatory (355,356) and/or lipotoxic 
pathways that involves lipid intermediaries rather than TGs (198). This may also 
explain why no association was found between ISR and pancreatic fat that reflects the 
TG content in the pancreas. Interestingly, black African women have lower VAT 
compared to other ethnicities (39,47,61), but they have a greater propensity to 
increase VAT over time, with the greatest increase occurring in the 20-29-year age 
group (357). Taken together, the ability to compensate for a lower SI with a higher 
insulin response may be compromised with an increase in VAT with increasing age 
and adiposity, and this inhibitory effect may start from a young age in black South 
African women. However, further studies are needed to confirm this hypothesis.  
This study also assessed the association between SI and ectopic fat and found no 
significant association between SI and skeletal muscle or hepatic fat. These findings 
suggest that these ectopic fat depots are not important contributors to SI in our study. 
However, considering that whole body SI was measured in this study this could have 
diluted the associations with hepatic and soleus fat. Indeed, a small South African 
study found that in black South African women, hepatic fat was associated with hepatic 
SI but not peripheral SI (42). Furthermore, total soleus fat and soleus IMCL were 
associated with peripheral SI, but not hepatic SI (42). Another reason that may explain 
the lack of association between SI and hepatic fat may be reduced statistical power. 
The liver scans from five participant could not be used due to technical challenges 
experienced during MRI acquisition. Nevertheless, lower SI was associated with 
higher VAT, which may contribute to a decline in DI in this cohort. 
A major strength of this study is that ISR and both hepatic and peripheral clearance 
were evaluated, determined using mathematical modelling, which has never been 
done before in an African cohort. Further we assessed pancreatic, hepatic and skeletal 
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muscle ectopic fat depots, as well as VAT and aSAT volumes using MRI. However, 
limitations of this study were that we did not determine glucose tolerance, and we did 
not distinguish between hepatic and peripheral SI. In addition, these findings are 
applicable to pre-menopausal, obese black South African women and may not be 
extrapolated to, all black South African women, men or other ethnicities. 
In conclusion, an original finding from this study was that DI was associated with 
peripheral insulin clearance, which may be explained by a greater SI, instead of 
hyperinsulinemia. Further, while both hepatic insulin extraction and insulin secretion 
contributed towards hyperinsulinemia, insulin secretion was more important. Ectopic 
fat was not an important independent correlate of DI and its components. Rather, a 
key finding was that higher VAT was the principal correlate of a lower DI, above other 
ectopic fat depots. Additionally, the associations of higher VAT on the downstream 
components of DI, a lower first phase ISR and higher hepatic insulin extraction, 
exposes a novel mechanism of low DI prior to T2D onset. Accordingly, the prevention 
of VAT accumulation, especially in young black African women may be an important 








7.1.1 COMPARING PARTICIPANTS AT BASELINE 
 
The exercise and control group participants were well matched at baseline. They 
consumed a similar diet and had similar levels of energy expenditure (Table 7.1). 
Further, they did not differ in age, cardiorespiratory fitness and metabolic outcomes 
(Table 7.2). Body composition, body fat distribution (Table 7.3) and ectopic fat 
deposition (Figure 7.2) also did not differ between the groups. 
 
7.1.2 EXERCISE ADHERENCE AND EFFECT OF EXERCISE ON CARDIORESPIRATORY 
FITNESS 
 
Mean number and percentage of exercise session attended were 38±6 (range 25-49, 
maximum number of sessions = 48) and 79% (range 52-100%), respectively, at a 
mean intensity of 79.6±4.0 %HRpeak. An improvement in cardiorespiratory fitness 
(VO2peak) was observed in the exercise group (2077±211 to 2278±231 ml/min, p<0.001 
and 24.9±2.42 to 27.6±3.39 ml/kg/min, p<0.001), while no change was observed in 
the control group (2099±282 to 2032±196 ml/min, p=0.286 and 23.9±2.97 to 23.0±2.64 
ml/kg/min, p=0.309). The change in the exercise group was significantly different from 
the change in the control group for the absolute (interaction p=0.001) and relative 




7.1.3 DIETARY AND PHYSICAL ACTIVITY  
 
Energy intake, macronutrient composition of the self-reported diets, and total energy 
expenditure (non-exercise days in the exercise group) did not differ within or between 
groups at 4, 8 and 12 weeks (Table 7.1).  
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Table 7.1: Energy intake and energy expenditure (non-exercise days for exercise group) over 12-week intervention 
 Control Exercise Group
@time 
 Baseline Week 4 Week 8 Week 12 Time 
@group 
Baseline Week 4 Week 8 Week 12 Time 
@group 
Joint P 





















(% of total EI) 
31.0 ±5.6 29.2 ±5.1 29.5 ±7.3 27.8 ±6.4 0.379 30.4 ±6.1 31.0 ±6.0 31.3 ±5.5 32.2 ±5.9 0.719 0.188 
Protein  
(% of total EI) 
14.3 ±1.9 13.2 ±2.3 13.8 ±2.8 13.6 ±2.1 0.642 13.2 ±2.5 13.9 ±2.9 13.4 ±2.0 13.7 ±3.0 0.761 0.578 
Carbohydrate  
(% of total EI) 





















Mean (±SD) for normally distributed variables. Non-normally distributed variables are described with median (interquartile range) and were log-transformed prior to mixed model analysis. EI – Energy 
intake. Time@group p value – reflects the interaction between time points within each group. Group @Time joint p value reflects the interaction between groups at each time point combined 
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7.1.4 EFFECT OF EXERCISE TRAINING ON METABOLIC OUTCOMES  
 
Results of metabolic outcomes pre- and post-intervention are shown in Table 7.2. SI 
improved in the exercise group (post hoc p=0.005), improving in 15 out of 19 
participants, with no change in the control group (post hoc p=0.711) (Figure 7.1). 
Nevertheless, exercise training did not alter the AUC of glucosetotal (group x time 
p=0.529). Similarly, the AUC for insulin (group x time p=0.853) and C-peptide (group 
x time p=0.956) over the entire FSIGT period did not change (Figure 7.2). Accordingly, 
no changes were observed in AIRg (Figure 7.1), ISR, hepatic and peripheral insulin 
clearance. As SI improved with no reciprocal change in AIRg, DI increased after 
exercise training (post hoc p=0.028). 
This thesis further assessed whether the changes in SI, AIRg and DI differed by 
adherence to the exercise intervention, characterized as the exercise dose (Figure 
7.3). The exercise group where split into moderate and high exercise dose groups, 
compared to the control group. Notably, a significant increase in SI was only observed 
in the high exercise dose group compared to the control group (p=0.009). Although 
the moderate exercise dose group showed a similar increase in SI (median change 
(25-75th percentile) 0.59 (0.01 to 0.95) compared to the high exercise dose group 
(median change 0.53 (0.35 to 0.75) (p=0.132), there was greater variability in 
response. Equally, a significant increase in DI was only observed in the high exercise 
dose compared to the control group (p=0.009). However, no significant changes were 
observed in AIRg after the intervention regardless of the exercise dose.    
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Table 7.2. Age and metabolic outcomes of participants before and after the 12-week intervention period 
 Control group  Exercise group C/Eǂ Group Time Group 
x Time 
 Pre Post Pre Post p value 
Age (years) 23 (21-27) -  22 (21-24) - 15/20 0.748 - - 
HbA1c (%) 5.2 ±0.35 5.3 ±0.38  5.2 ±0.32 5.2 ±0.29 15/19 0.676 0.794 0.884 
HbA1c (mmol/mol) 33 ±2.2 34 ±2.4  33 ±2.0 33 ±1.84 15/19 - - - 
Fasting glucose (mmol/L) 5.0 ±0.66 5.1 ±0.79  5.5 ±0.84 5.1 ±0.98 15/19 0.102 0.829 0.217 
Fasting insulin (pmol/L) 78.6 (58.4-85.2) 79.2 (64.5-117.6)  88.5 (38.6-114.6) 75.3 (63.2-102.6) 15/19 0.942 0.979 0.773 
Fasting C-peptide (pmol/L) 575.9 (484.9-787.8) 586.7 (448.5-916.9)  620.6 (362.4-804.3) 643.8 (458.4-852.3) 15/19 0.949 0.900 0.943 
ISRbasal (pmol/min) 74.8 (63.0-102.4) 76.3 (58.3-119.2)  80.7 (47.1-102.4) 83.7 (59.6-110.8) 13/19 0.681 0.795 0.715 
HOMA2 %IR 1.8 (1.4-2.2) 2.0 (1.1-2.9)  2.2 (1.0-2.9) 1.9 (1.4-2.6) 15/19 0.939 0.993 0.943 
HOMA2 %B 143.5 (98.9-235.6) 132.1 (117.9-208.6)  131.5 (89.9-182.7) 145.7 (97.6-199.7) 15/19 0.287 0.907 0.227 
SI x10-4(mU/l)-1 min-1 2.01 (1.29-3.24) 1.83 (1.65-32.64)  2.04 (1.20-2.77) 2.17 (1.45-3.69)* 13/19 0.094 0.711 0.037 
AIRg x103 (mU/l)-1 min-1 2.43 (2.10-4.28) 2.70 (1.91-4.21)  3.16 (1.72-4.72) 3.33 (1.68-4.33) 14/19 0.609 0.404 0.804 
DI x103 7.80 (4.53-8.78) 5.92 (5.34-8.25)  6.10 (3.61-7.12) 6.53 (5.56-9.22)* 13/19 0.151 0.294 0.035 
Sg x10-2 (min-1) 2.4 ±0.97 2.2 ±0.66  2.3 ±0.98 2.6 ±0.79 13/19 0.795 0.574 0.226 
ISRtotal (pmol/min) 4272 (3572-5798) 5560 (4536-7588)  4887 (3229-8248) 5442 (4207-9827) 13/19 0.359 0.057 0.325 
ISR/Glucosetotal 23.7 (17.0-28.0) 29.0 (20.0-39.9)  24.2 (11.8-38.6) 27.8 (18.9-51.5) 13/19 0.393 0.010 0.151 
C-peptide/Insulinbasal 8.1 (6.47-9.37) 7.5 (7.31-8.71)  7.0 (6.39-9.09) 7.7 (7.01-8.41) 15/19 0.957 0.916 0.711 
HIE (%) 56.4 ±8.3 53.6 ± 13.6  52.4 ±9.0 54.2 ±10.7 10/11 0.358 0.408 0.328 
CLp (ml/kg/min) 86.2 (74.7-131.9) 89.3 (76.7-94.6)  105.4 (97.8-158.6) 101.0 (73.1-155.4) 10/11 0.138 0.734 0.718 
Mean (±SD) for normally distributed variables and median (interquartile range) for non-normally distributed variables, Non-normally distributed variables were transformed. P-values are derived from 
Mixed Model analysis, ISR – Insulin secretion rate, HOMA – Homeostasis model of assessment, IR – insulin resistance, B - beta cell function, SI – Insulin sensitivity, AIRg – Acute insulin response to 
glucose, DI – Disposition index, Sg – Glucose effectiveness, AUC – Area-under-curve , HIE – hepatic insulin extraction, CLp – peripheral insulin clearance.  *Significant post hoc difference (pre- vs 






Figure 7.1: Average time course of glucose, insulin and C-peptide in the (A) control 
(circles) and (B) exercise group (squares), before (black symbols) and after (green 
symbols) the exercise intervention. The insert graph is an enlargement of the 0 to 60 





Figure 7.2. Changes in (A) insulin sensitivity (SI), (B) acute insulin response to glucose 
(AIRg) and (C) disposition index (DI) in the control and exercise groups. Thick black 





Figure 7.3. Comparison of changes in (A) insulin sensitivity (SI) (B) acute insulin 
response to glucose (AIRg) and (C) disposition index (DI) in the control (white bar), 
moderate exercise dose (ModExD) (vertical stripe bar) and high exercise dose (High 
ExD) (dotted bar) groups. *Post hoc test for post compared to pre vaue p≤0.05 when 
the interaction from mixed model test was significant. Between group p-value was also 
derived from mixed model analysis. 
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7.1.5 EFFECT OF EXERCISE TRAINING ON BODY COMPOSITION, BODY FAT 
DISTRIBUTION AND ECTOPIC FAT CONTENT  
 
Body composition and body fat distribution pre- and post-intervention are shown in 
Table 7.3. Exercise training resulted in a small but significant reduction in body weight 
(change: -0.8 kg, post hoc p=0.038), whereas the control group gained body weight 
(change: 0.99 kg, post hoc p=0.030) and aSAT (change: 278.3 cm3, post hoc p=0.008). 
While exercise training did not alter relative fat mass (%), fat-free soft tissue mass (kg), 
aSAT and VAT (cm3), there was a small but statistically significant decrease in gynoid 
fat mass (change: -0.27 %FM, p<0.001) in the exercise group only.  
Ectopic fat pre-and post-intervention are shown in Figure 7.3. After exercise training 
pancreatic (7.8 (6.4-10.4) % to 6.9 (6.4-10.4) %), hepatic (4.9 (4.5-6.4)% to 4.8 (3.9-
5.6)%), soleus (10.3 (9.5-11.5) % to 9.6 (8.0-10.9) %) and tibialis anterior (3.9 (3.2-
5.6) % to 3.8 (3.1-5.1) %) fat remained unaltered. Similarly, the control group showed 




Table 7.3. Body composition and body fat distribution of participants before and after the 12-week intervention period 
 
 Control group  Exercise group C/Eǂ Group Time Group 
x Time 
 Pre Post Pre Post p value 
Body weight (kg) 87.8 ±10.9 88.8 ±11*  84.1 ±8.7 83.3 ±9.7* 15/20 0.267 0.030 0.003 
Body Mass Index (kg/m2) 33.4 ±2.7 33.8 ±2.8*  34.1 ±2.8 33.8 ±3.1* 15/20 0.430 0.038 0.003 
Waist circumference (cm) 100.0 (97.0-112.0) 103.0 (98.5-116.5)*  103.2 (97.9-108.1) 99.5 (94.0-103.3) *† 15/20 0.911 0.013 <0.001 
Waist-to-hip-ratio 0.88 (0.83-0.93) 0.89 (0.86 -0.95)  0.89 (0.87-0.94) 0.87 (0.86-0.91) 15/20 0.202 0.078 0.015 
FFSTM (kg) 37.7 (35 - 41) 38.2 (35 - 41)  37.1 (34 - 39) 37.1 (34 - 40) 14/20 0.293 0.223 0.324 
Body fat mass (%) 49.8 (47-54) 50.9 (48-52)  49.9 (49-52) 49.9 (48-51) 14/20 0.981 0.480 0.471 
Trunk fat (%FM) 45.8 ±4.7 45.6 ±4.7  48.0 ±4.6 47.7 ±4.7 14/20 0.170 0.568 0.845 
Leg fat (%FM) 42.5 ±5.0 42.9 ±5.3  39.8 ±5.0 39.8 ±4.8 14/20 0.103 0.386 0.607 
Android fat (%FM) 8.0 ±1.3 7.9 ±1.5  8.3 ±1.0 8.1 ±1.0 14/20 0.572 0.163 0.860 
Gynoid fat (%FM) 19.4 ±2.3 19.6 ±2.3  18.5 ±1.7 18.2 ±1.6*† 14/20 0.129 0.323 0.002 
Visceral fat (cm3) 903.1 ±431.0 953.1 ±403.9  920.0 ±322.1 906.2 ±346.9 13/20 0.850 0.177 0.178 
Abdominal subcutaneous fat 
(cm3) 
5298.9 ±1853.8 5584.4* ±1956.9  5489.3 ±1053.4 5447.7 ±1260.7 13/20 0.850 0.008 0.018 
Mean (±SD) for normally distributed variables and median (interquartile range) for non-normally distributed variables, Non-normally distributed variables were transformed. P-values are derived from 
Mixed Model analysis. FFSTM – Fat free soft tissue mass, FM – Fat mass. *Significant post hoc difference (pre- vs post-intervention) within group p≤0.05, †Significant post-hoc difference (Exercise 





Figure 7.4: Individual changes from pre- to post-exercise training in (A) hepatic, (B) 
pancreatic, (C) soleus and (D) tibialis anterior fat in control and exercise groups. 
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The changes in body composition, regional and ectopic fat were also stratified by 
exercise dose (control vs moderate vs high exercise dose) (Figure 7.5). A significant 
reduction in body weight was observed in the high exercise dose group (p<0.001) but 
not in the moderate exercise dose group (p=0.925), with this change being significantly 
different from both the moderate exercise dose (p=0.017) and control groups 
(p<0.001). Nevertheless, no significant changes were observed in fat mass (%) after 
the intervention period. Interestingly, a significant reduction in gynoid fat mass was 
only observed in the moderate exercise dose group (p=0.001) and not in the high 
exercise dose group (p=0.102), which was significantly different compared to the 
control group (p=0.001). There was a tendency for a reduction in VAT in the high 
exercise dose group (p=0.082), but this change was not significantly different from the 
other 2 groups. No differences in other measures of body fat distribution or ectopic fat 




Figure 7.5 Comparison of changes in (A) Body weight (B) Fat mass (%) (C) Gynoid 
fat mass (%), (D) Visceral adipose tissue, (E) Abdominal subcutaneous adipose 
tissue, (F) Hepatic fat, (G) Pancreatic fat, (H) Total soleus fat, (I) Total tibialis anterior 
fat in the control (white bar), moderate exercise dose (ModExD) (vertical stripe bar) 
and high exercise dose (High ExD) (dotted bar) groups. *Post hoc test for post 
compared to pre vaue p≤0.05 when the interaction from mixed model test was 
significant. Between group p-value was also derived from mixed model analysis. 
 
7.1.6 ASSOCIATIONS BETWEEN CHANGES IN SI, AIRG, ISR, INSULIN CLEARANCE 
AND DI AND CHANGES IN BODY COMPOSITION, BODY FAT DISTRIBUTION AND 
ECTOPIC FAT AND VO2PEAK. 
 
Even though body fat distribution, except gynoid fat mass (%FM), and ectopic fat did 
not change significantly after exercise training, the variability in the participants’ 
responses allowed us to assess the associations between the changes in metabolic 
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outcomes and fat depots in response to the intervention. The exercise-induced 
increases in SI and DI were not associated with changes in body fat mass (%), gynoid 
fat mass (%FM), android fat mass (%FM) and ectopic fat (data not shown). 
Nevertheless, only the control group (significant interaction by group, p<0.05) showed 
significant associations between changes in SI and changes in trunk fat mass (%FM) 
(β -0.628, p<0.001) and leg fat mass (%FM) (β 0.745, p=0.002) (Figure 7.6). Further, 
in the combined group (no interaction by group, p>0.05), an increase in SI was 
associated with a reduction in VAT and an increase in DI was associated with a 
reduction in trunk fat mass (%FM) (Figure 7.6). No significant associations were 
observed between changes in AIRg, ISRtotal and insulin clearance and changes in 
body fat distribution and ectopic fat (data not shown). No significant associations were 
found between any of the metabolic outcomes and change in absolute or relative 
VO2peak (data not shown).  
 
In addition, the exercise dose (control vs moderate vs high exercise dose) did not 
modify the observed associations between the changes in SI, AIRg, DI and first phase 
or total ISR and changes in regional and ectopic fat deposition above those already 





Figure 7.6: Associations between changes in insulin sensitivity (SI) and changes in 
(A) trunk fat mass, (B) leg fat mass and (C) visceral adiposity (VAT); (D) changes in 
disposition index (DI) and changes in trunk fat mass in the control group (open circle) 
and exercise group (closed square). β – refers to the linear regression coefficient. A 
regression line (solid black) is indicated if an association is significant (p≤0.05) in the 
combined group or if a significant interaction by group was present, the line will 




The underlying mechanisms for lower SI and hyperinsulinemia observed in black 
African populations are incompletely understood. This is the first exercise intervention 
study conducted in Africa to evaluate whether body fat distribution and ectopic fat may 
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explain this phenomenon. While few exercise intervention studies have been 
conducted in African Americans (245,279–281), the effect of exercise training on 
insulin secretion and clearance, as well as on hepatic and pancreatic fat were not 
studied. This study demonstrated that a 12-week exercise intervention was efficacious 
to increase SI and cardiorespiratory fitness and occurred despite minimal weight loss. 
However, exercise training did not alter any of the components of hypersinulinemia 
and DI increased suggesting as dissociation between AIRg and SI. Further, exercise 
training did not result in significant changes in central, pancreatic, hepatic and skeletal 
muscle fat, but reduced gynoid fat mass (%FM). Accordingly, body fat distribution and 
ectopic fat were not important correlates of the observed increase in SI and DI. 
Nevertheless, exercise training reduced gynoid fat mass which may induce long-term 
benefits. 
 
We showed that SI improved significantly after exercise training, which occurred 
simultaneously with an increase in VO2peak, despite minimal weight loss (~1 kg). 
Contrastingly, a study conducted in a similar cohort of obese, black African American, 
premenopausal women, showed no significant improvement in SI or cardiorespiratory 
fitness after 14 weeks of high-intensity interval training (75-90% of heart rate reserve) 
(245). These discrepant findings are opposed to reports that showed that high-
intensity interval training increases SI equally or to a greater degree compared to 
moderate-intensity continuous exercise, despite being of lesser volume (227). 
Nevertheless, the improvement of SI in our study was dependent on the exercise dose. 
Exercising at a higher exercise dose produced a more consistent improvement in SI 
compared to a moderate exercise dose.The exercise dose used in this thesis is a 
composite measure of both the exercise volume and intensity and notably, the 
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exercise intensity, measured by the mean HRpeak achieved, was similar between the 
moderate (80.2 ± 3.7%) and high exercise dose groups (79.0 ±4.4%), but the volume 
differed (mean number of sessions per week 2.8 compared to 3.6 respectively). This 
is in agreement with another study in which predominately white adults (African 
Americans represented 18% of study population) undertook three exercise training 
programmes that differed based on volume and/or intensity (241). When comparing 
the two exercise training groups with a similar prescribed exercise intensity (65-80% 
VO2peak), the group with the bigger increment in SI also completed a greater number 
of sessions per week. It is plausible that more cumulative exercise sessions may 
induce greater adaptations in the expression and activity of proteins in the insulin 
signaling cascade which would augment SI (358). While, not all research supports this 
notion (359), moderate-vigorous exercise training of no less than 3 days per week may 
be required to improve SI in obese, black South African women. Further, based on the 
results of focus group discussions conducted in black South African women, the 
intervention utilized a combination of exercises, such as skipping and dancing, to 
ensure likeability and adherence to the training (360). The suitability of this intervention 
was highlighted by the fact that only three participants did not complete the exercise 
training, with one withdrawing due to pregnancy.  
An important point to highlight is the magnitude of increase in SI (6%) in this thesis. 
Greater improvements in SI has been reported in studies in obese African American 
adults (58%) after 7 days of consecutive moderate-intensity aerobic training (280), and 
in obese African American adolescents (37%) after 8 weeks of moderate-intensity 
aerobic exercise training (279). However, in these studies, the FSIGT were performed 
14-18 hours (280) and 24-48 hours (279) after the last exercise session. This contrasts 
to this thesis, in which the post-intervention FSIGTs were performed at least 72 hours 
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after the last exercise training bout. Considering that SI remains elevated for up to 72 
hours after the last exercise bout (239) due to, amongst other factors, the depletion of 
muscle glygogen post-exercise (361), the large changes observed in the 
aforementioned studies may merely reflect acute changes in the muscle. This may 
have amplified the observed change in SI, and explain the smaller observed 
improvement in SI in this thesis.  
Another reason for the small increment in SI in this thesis may be attributed to the 
concomitant marginal weight loss (~1%) in response to the exercise intervention. A 
multi-ethnic study that divided the cohort into those with less than 3% reduction in 
body weight and those with greater than 3% reduction in body weight after 8 months 
of aerobic exercise training, found that both groups showed an improvement in SI but 
a smaller increment was observed in those who attained less than 3% of weight loss 
(359). A reduction in the mobilization of free fatty acids that accompanies major weight 
loss (12%) was found to be a major correlate of the improvement in SI (60%) (254), 
which may suggest that a smaller reduction in body weight may evoke a smaller 
reduction in free fatty mobilization and an associated smaller increase in SI. However, 
further research is required to confirm this.  
The exercise training intervention, although eliciting only a small reduction in body 
weight, improved the VO2peak. However this improvement in VO2peak was not 
associated with the increase in SI. A common mechanism may improve both these 
factors, such as an enhancement in mitochondrial oxidative capacity after exercise 
training (233). Therefore, a reduced statistical power perhaps may explain the lack of 
an association. Moreover, obesity may be a common feature in both those with a low 
VO2peak (362) and in those with a low SI (73). Nevertheless, improvements in VO2peak 
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and SI may occur without alterations in adiposity. Indeed, in obese men, VO2peak and 
SI improved independent of a reduction in body weight or fat mass after 12-weeks of 
moderate-intensity endurance training (255), contemporaneous with reduced systemic 
and skeletal muscle oxidative stress markers and an increased skeletal muscle 
antioxidant capacity. Therefore in this thesis, alterations in the oxidative 
stress:antioxidant balance and/or reduced activation of inflammatory pathways such 
as nuclear factor kappa β, mitogen activated protein kinase p38 and Jun NH2-terminal 
kinases (363) may be possible reasons to explain the improvement in SI. However, 
further research is required to address this hypothesis.  
The lack of change in the ISR and hepatic insulin extraction was unexpected. Other 
exercise training studies have shown a reduction in stimulated insulin response 
(261,265) or insulin secretion (252) in those with normal glucose tolerance. However, 
in those with impaired glucose tolerance, only a reduced stimulated insulin response, 
but no change in insulin secretion, was reported (264,284). These studies were 
conducted in predominantly white older men and women known to have relatively 
lower baseline plasma insulin levels than those of black African ancestry. Notably, 
exercise-intervention studies that demonstrated reductions in AIRg either showed 
reduced body fat mass (264,265,284) or reduced VAT (261). While no change in AIRg 
was observed in those without a significant change in VAT despite an improvement in 
SI (261). These findings may suggest that either a reduction in AIRg is important for a 
reduction in VAT to occur or that a reduction in VAT is important for a change in AIRg 
to occur. In support, we showed in the combined group that a reduction in DI and 
ISRtotal was associated with a reduction in trunk fat mass (%FM). However, to 
determine whether causality exists and the direction of this causality between VAT 
and AIRg or trunk fat mass and DI and ISRtotal, further research is required. While our 
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12-week supervised moderate-to-high intensity exercise training program was unable 
to reduce hyperinsulinemia, despite increasing SI, it produced a modest decrease in 
body weight (~1 kg) with no changes in central and ectopic fat depots. Notably, even 
in lifestyle intervention studies such as the Diabetes Prevention Program that included 
both exercise training and dietary changes, black African American women 
demonstrated smaller reductions in body weight compared to black African American 
men and white and Hispanic men and women (364). It is possible that the inability to 
show greater exercise-induced changes in body weight in black women could be due 
to higher fasting and/or stimulated insulin levels. Insulin is a potent suppressor of 
lipolysis in adipose tissue and therefore limits free fatty acid mobilization (365). Even 
during exercise, excess insulin impedes the β-adrenergic stimulation of lipolysis (365). 
Lower compliance to exercise training amongst black women should also be 
considered as possible explanation for blunted weight loss. However, in our study, 
exercise was supervised and although adherence varied, a mean of 79% of sessions 
were attended. Thus, longer exercise training duration in combination with a dietary 
intervention, possibly a low carbohydrate and low glycemic diet (366), might be 
required to reduce hyperinsulinemia, fat mass and central/ectopic depots in obese 
women of black African ancestry.  
Another key finding of our study was that exercise training increased DI, a proxy of β-
cell function due to the increase in SI without a compensatory decrease in 
hyperinsulinemia. The increase in DI may delay the onset of T2D over the short term, 
but we should also consider that sustained greater insulin secretion above the level of 
SI may predispose to β-cell exhaustion over the longer term (367). Cross-sectional 
studies have shown that a greater AIRg observed in black African populations is out 
of proportion to the level of SI (47,56). Further, the current interventional study showed 
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that changes in SI and AIRg may occur independent from each which contest that 
hypersinulinemia, observed in black African populations, is merely a compensation for 
lower SI (52). In support, young black African children present with hyperinsulinemia 
prior to obesity and while SI is still equivalent to white children (58). Hyperinsulinemia 
may therefore not only precede lowered SI, but may perhaps also be the cause. 
Evidently, in vitro cell culture studies have shown that hyperinsulinemia may directly 
impact SI through its effect on the insulin receptors (153) and/or indirectly through 
obesity-related sequelae (368). Whether a higher DI, in the context of 
hyperinsulinemia out of proportion to the level of SI, may be beneficial to slow down 
progression or whether it could accelerate the progression towards T2D in black 
African populations, needs to be evaluated. 
The exercise intervention did not reduce central abdominal fat depots and thus could 
not explain the increase in SI in this thesis. Notably, significant associations were 
observed in the control group only between changes in SI and changes in trunk fat 
mass (%) and leg fat mass (%), as well as in the combined group, changes in SI was 
associated with changes in VAT. Nevertheless, exercise training ameliorated these 
associations. This indicates that the changes in SI in the exercise group possibly 
occurred via other mechanisms such as changes in systemic and skeletal muscle 
oxidative stress (255), mitochondrial biogenesis and mitochondrial function (269), as 
mentioned above. Another reason for the improvement of SI may be a reduction in 
fatty acid availability, which has been shown to occur without concurrent VAT changes 
(253). Furthermore, the significant reduction in gynoid fat mass (%) after exercise 
training is of major interest. Previous studies reported lower adipogenesis (120), and 
higher inflammation (41), fibrosis and hypoxia (369) in the gluteal fat depots of black 
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South African women, compared to white women. Accordingly, the reduction in gynoid 
fat mass may have major beneficial long-term metabolic effects. 
Notably, this is the first study to evaluate the effect of exercise training on pancreatic 
fat in obese black African women without type 2 diabetes and we found no changes in 
pancreatic fat. In addition, the increase in DI observed in our study after exercise 
training, could not be explained by changes in pancreatic fat. In accordance with our 
findings, Heiskanen et al. did not find any association between improved β-cell 
function, derived from an oral glucose tolerance test, and a decrease in pancreatic fat 
(252). Similarly, a cross-sectional study in black African men with early type 2 diabetes 
failed to show an association between pancreatic fat and β-cell function (211). 
Evidence suggests that pancreatic fat accumulation can occur from many sources. 
This includes excess dietary free fatty acids, hyperinsulinemia that promotes de novo 
lipogenesis, elevated plasma free fatty acid due to adipose tissue insulin resistance 
and VLDL secretion from the liver (370). We did not measure markers of adipose 
tissue insulin resistance or free fatty acid flux and are therefore unable to comment on 
these factors. However, hyperinsulinemia was unaltered by exercise training and 
dietary fat intake did not change, which could contribute to unaltered pancreatic fat. 
Alternatively, pancreatic fat accumulation may be a marker of obesity and may not be 
detrimental to β-cell function in our cohort.  
Similar to pancreatic fat, we found no change in hepatic fat after exercise training. 
Exercise intervention studies in black African populations that present with lower levels 
of hepatic fat compared to their white counterparts (42) or to Hispanics (204) are rare. 
A multi-ethnic study that included healthy, overweight African Americans (n=15) 
together with white (n=30) and Asian (n=1) adults reported a reduction in hepatic fat 
after 6 months of exercise training in combination with calorie restriction (251). Hepatic 
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fat has been linked to hyperinsulinemia and consuming a carbohydrate-rich diet (371). 
These factors did not change in our study and could, in part, provide a plausible 
explanation for no changes occurring in hepatic fat content. However, in response to 
training, hepatic fat content showed high inter-individual variability with 14 participants 
showing a reduction and 5 showing an increase in hepatic fat. Measurement error 
could be responsible for the observed increase in hepatic fat. However, heterogeneity 
in the hepatic fat response to exercise was also reported in Swedish adults with T2D 
(295). This study suggested that an exercise induced increase in hepatic fat might last 
longer in some individuals. Further we found no association between the change in SI 
and hepatic fat, indicating that hepatic fat might not be an important correlate of SI in 
this population, a finding also echoed by our cross-sectional analysis.  
The effect of exercise training on intramuscular fat has been extensively studied, but 
again a paucity of studies include black African populations. Our study showed no 
changes in both soleus and tibialis anterior fat content after exercise training. Arad et 
al, made similar observations in black African overweight/obese premenopausal 
women, although they measured total body skeletal muscle fat (245). The 
improvement in SI in our study could therefore not be explained by changes in skeletal 
muscle fat content. However, exercise training has been shown to improve skeletal 
muscle mitochondrial oxidative capacity and muscle GLUT4 mRNA and protein (372) 
and can attenuate the detrimental effect of lipid intermediaries on cellular insulin 
signalling pathways (292). Hence, the improvement in SI in response to exercise 
training might be due to skeletal muscle adaptions relating to lipid metabolism and 




Taken together, this thesis showed that in obese black South African women exercise 
training increased SI independent of changes in hyperinsulinemia and ectopic fat. 
These findings suggest that ectopic fat might not be the primary correlate of insulin 
resistance in this cohort, rather intrinsic factors in the muscle and adipose tissue may 
be more important correlates of the exercise-induced changes in SI. Moreover, 
hyperinsulinemia may not solely occur as compensation for reduced SI. Further, the 
exercise-induced reduction in gynoid fat mass may improve adipose tissue function 
and confer long-term benefits. Finally, exercise training attenuated weight gain and 
aSAT accumulation, observed in the control group, and are thus a valuable tool to curb 
escalating obesity in this cohort.  
193 
 
CHAPTER 8: THESIS CONCLUSIONS 
 
DI reflects the compensatory relationship between AIRg and SI (180). However, prior 
to T2D diagnosis, the DI will start deteriorating when the ability of the insulin response 
to match the level of SI is impaired (373). Nevertheless, compared to white 
populations, black African populations demonstrate an unique phenotype, 
characterized by a low SI and high insulin response, due to a combination of low 
hepatic insulin extraction and high insulin insulin secretion (39,44,48). This thesis 
therefore aimed to understand whether regional and ectopic fat distribution may 
explain this unique phenotype in an obese black South African sample. To address 
these aims we conducted a cross-sectional investigation, and for the first time in a 
South African cohort, completed a randomized controlled exercise intervention study, 
which strengthened the quality of evidence. In addition, this thesis used advanced 
methods to measure its main outcomes, SI, AIRg, insulin secretion and clearance as 
well as its main correlates, regional and ectopic fat depots. 
The outcomes of this thesis are summarized in Figure 8.1. Firstly, the associations 
between DI and its components were investigated to understand the importance of 
these components in maintaining DI (Figure 8.1 A). Secondly, the associations of DI 
and its components with regional and ectopic fat were explored (depicted by arrow 
labelled “B” in Figure 8.1). Thirdly the effect of exercise training on SI, AIRg, ISR, 
insulin clearance, DI (C1-labelled arrow in Figure 8.1) and on regional and ectopic fat 
(C2-labelled arrow in Figure 8.1). Finally, the effects of exercise training on the 
associations between metabolic outcomes and regional and ectopic fat accumulation 




Figure 8.1: Summary of findings for the cross-sectional (A, B) and exercise 
intervention studies (C, D). DI -disposition index, SI -  insulin sensitivity, AIRg -  acute 
insulin response, ISR - insulin secrection rate, HIE - hepatic insulin extraction, CLp - 
peripheral insulin clearance, SAT – abdominal subcutaneous adipose tissue, VAT – 
visceral adipose tissue. 
One of the main findings from the cross-sectional study (Figure 8.1 A) was that 
peripheral insulin clearance was positively correlated with DI. However, peripheral 
insulin clearance did not associate with AIRg, rather a lower hepatic insulin extraction 
and higher first phase ISR were independent correlates of higher AIRg, adjusted for 
SI. Considering that a hyperbolic relationship was evident between SI and AIRg at 
baseline; this thesis found that after exercise training, SI and DI increased (Figure 8.1 
C1), but without a commensurate decrease in AIRg. The increase in DI after exercise 
training could be attributed to the increase in SI (Figure 8.1 C1). DI, therefore, may not 
always reflect β-cell function due to the uncoupling of AIRg and SI. 
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The second focus of the cross-sectional study was to evaluate the associations 
between the metabolic outcomes (DI, SI, AIRg, ISR, hepatic and peripheral insulin 
clearance) and regional and ectopic fat accumulation (Figure 8.1 B). Based on findings 
from this thesis, a higher DI was present when pancreatic fat, soleus fat and VAT was 
lower, but VAT was the strongest correlate of DI. VAT is therefore an important factor 
in the pathogenesis of T2D, not only due to its association with a lower SI, but also due 
to its association with lower AIRg and first phase ISR, independent from SI. In addition, 
the association between higher hepatic insulin extraction and higher VAT-aSAT ratio 
highlights another mechanism through which VAT may associate negatively with DI. 
These findings occur despite black women having less VAT compared to their white 
counterparts (39), which may indicate a greater sensitivity to VAT accumulation.  
Nevertheless, we did not show similar relationships in the exercise intervention study. 
In fact, the exercise training-related increases in SI and DI were not associated with 
changes in regional and ectopic fat (Figure 8.1 D). Possible reasons for these finding 
are illustrated in Figure 8.2. Exercise training is known to upregulate key proteins 
involved in the insulin signaling pathway (231) and has also been shown to improve 
fatty acid oxidation (235), which may explain an increase in SI and thus DI. The reason 
why the exercise-induced increases in SI and DI was not associated with a change in 
VAT in the exercise interventional study may be due to exercise training improving 
fatty acid oxidation and thus the utilization of free fatty acids in skeletal muscle. This 
may occur through mitochondrial biogenesis and improved mitochondrial function 
(233) rather than through a reduction in VAT or an increase in muscle mass, since this 





Figure 8.2: Proposed mechanisms of exercise-induced changes in insulin sensitivity 
(SI) and disposition index (DI) and the lack of change in insulin secretion rate (ISR), 
acute insulin response to glucose (AIRg) and visceral adipose tissue (VAT)  
 
Another point to consider is that exercise training reduced gynoid fat mass. In black 
South African women, the lower adipogenic and lipogenic potential of the gynoid fat 
depot, compared to white women, has been found to associate with lower SI (120). 
Although, the reduction in the gynoid fat mass was unrelated to the increase in SI, 
molecular changes may have occurred that improve the inflammation (374), hypoxia 
and fibrosis (369), characteristically found in this depot in black South African women, 
which may have contributed to an improvement in SI after exercise training.  
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Further, exercise training was beneficial to curb an increase in the truncal fat depots. 
Notably, the control group gained weight and in particular aSAT, over the 
interventional period of 12 weeks. Exercise training therefore, also curbed an overall 
weight gain which is especially relevant in young premenopausal black South Africans, 
as previous research has shown that young black South African women significantly 
increase their weight (by ~7kg) over a relatively short period (5.5 years) (121).  
The lack of change in AIRg and its components, first phase ISR and hepatic insulin 
extraction, after exercise training may be explained by revisiting the paradigm that 
hyperinsulinemia precedes low SI and obesity, discussed in section 1.7 and depicted 
in Figure 1.1. Based upon findings from this thesis, we need to add to this paradigm 
the association of VAT accumulation with a lower ISR, the association of the VAT-
aSAT ratio with a higher hepatic insulin extraction and the associations of both VAT 
and VAT-aSAT ratio with lower AIRg and DI (red arrows in Figure 8.3). Secondly, this 
thesis posits a bi-directional association between VAT and ISR/insulin response such 
that hyperinsulinemia may promote obesity and thus VAT accumulation, which in turn 
may lead to a lower ISR and lower AIRg, which is unable to completely compensate 
for the level of SI and therefore a low DI ensues. Based on this bi-directional 
relationship we suggest that the lack of response in AIRg after exercise training may, 
in part, be due to a lack of change in VAT. The lack of change in VAT is surprising 
since this depot is more sensitive to adrenergic stimulated lipolysis induced by 
exercise training (274), such that a reduction in VAT has been observed in overweight 
and obese people after moderate-vigorous exercise training even without dietary 
changes (375). However, the lack of change in VAT may be explained by the obesity 
phenotype observed in black African populations of low VAT and high aSAT and 
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gluteal fat, together with the presence of hyperinsulinemia that may have blunted the 
β-adrenergic stimulation of lipolysis that occurs during exercise (365) (Figure 8.2).  
 
Figure 8.3: Paradigm explaining associations of hyperinsulinemia (acute insulin 
response (AIRg), insulin secetion rate (ISR), hepatic insulin extraction (HIE) with 
insulin sensitivity (SI) and visceral adipose tissue (VAT) alone or relative to abdominal 
subcutaneous adipose tissue (aSAT) and how this explains variability in disposition 
index (DI) 
A major strength of our study was the ability to not just evaluate the correlates of AIRg, 
a component of DI, but to also discriminate between ISR and insulin clearance 
components. Moreover, this thesis went further and differentiated between hepatic and 
peripheral insulin clearance. Previous studies that included African Americans, 
evaluated the correlates of insulin secretory function by using plasma insulin levels 
(51,84,128,209). This thesis therefore adds to these findings by also showing the 
associations of regional and ectopic fat depots with ISR and hepatic and peripheral 
insulin clearance. A two compartment C-peptide mathematical model was used to 
determine the ISR. The C-peptide kinetics derived from this model was validated and 
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found to be robust under various conditions (339). The two-compartmental C-peptide 
model was simplified by Van Cauter et al. by proposing the use of standard kinetic 
parameters that can be adjusted for body surface area, sex and age (337). 
Accordingly, the standard kinetic parameters were used in this thesis taking the 
obesity levels of our cohort into account. While the standard kinetic parameters for C-
peptide kinetics were derived from white populations, it has been used in previous 
studies conducted in African American women with hyperinsulinemia (49,59). Further 
the mathematical model used to determine hepatic and peripheral insulin clearance 
was developed to determine insulin clearance in African immigrants living in the USA 
(71). A limitation of this model is the assumption of a constant insulin clearance over 
the duration of the FSIGT. In black African populations, the insulin response after an 
intravenous glucose load is substantially larger than in white populations during the 
first 10 minutes of the FSIGT (39), which suggests a marked reduction in insulin 
clearance. However, over the remainder of the FSIGT, the plasma insulin levels 
decline and to return to baseline levels. This suggests that insulin clearance may be 
more dynamic across the FSIGT. A constant insulin clearance measure may therefore 
not completely represent the normal physiological response.  
Exercise training was chosen as the intervention strategy due to a large body of 
evidence showing that exercise training improves SI (227). Moreover, based on focus 
group discussions, consisting of participants recruited from the same community as 
the participants from this thesis, revealed that physical activity would be the preferred 
intervention (376). A further consideration for the use of exercise training is the low 
cardiorespiratory fitness observed in black African populations (220). Indeed, the 
women from our study had a mean baseline VO2max of 24.2 ml/kg/min, which falls 
below the 5th percentile for women aged between 20 and 29 years (median cohort age 
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23 years old) and is rated as very poor (377). Further, the VO2max of our participants 
was similar to the average VO2max of healthy women double their age, between 50-59 
years of age (378). A low hemoglobin could be an alternative explanation for a low 
VO2max in this population but all the participants in this thesis had a hemoglobin within 
normal range. This low cardiorespiratory fitness is concerning since it increases the 
risk for all-cause mortality and cardiovascular disease (379). However, this thesis 
showed that after exercise training the VO2peak increased by 10% in the exercise 
training group (Figure 8.1), while no change was observed in the control group. 
Although the post-exercise VO2peak is still rated as very poor, it now falls below the 15th 
percentile for women between 20 to 29 years of age. The VO2peak trajectory in this 
thesis was in the right direction to lower risk for all-cause mortality and 
cardiorespiratory diseases, albeit, no direct association was observed between the 
increase in VO2peak and increase in SI and DI. However, an ongoing active lifestyle 
should be advocated to ensure further improvements in cardiorespiratory fitness. since 
high sedentary time, observed in black premenopausal South African women, has 
been associated with lower cardiorespiratory fitness (219). 
Another strength of this thesis was the rigorous monitoring of the exercise intervention. 
Firstly, it was supervised and directed by a biokineticist. Secondly, the intensity of the 
exercise training was monitored at each session to allow for the adjustment of 
exercises to ensure the prescribed intensity was achieved. While the mean 
compliance was 79% it varied from 52% to 100% of sessions attended. The increase 
in SI was associated with the exercise dose but it did not account for the variance in 
the ectopic fat responses after exercise training.  
Self-reported dietary intake was monitored on a monthly basis by a registered 
dietician, which may be regarded as a strength. Dietary intake over 4 days, including 
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three weekdays and a weekend day, was recorded to account for dietary variation. No 
changes in dietary parameters were observed over the 12 week period, which 
suggested that our observed findings were not due to dietary changes. Nevertheless, 
the method of self-reported dietary intake has its limitations and is influenced by recall, 
bias, and may not be sensitive to small alterations in diet even though these alterations 
may affect substrate metabolism at rest and in response to exercise training. In 
addition, in the exercise group we reported energy intake as an average across 4 days 
but did not further stratify energy intake according to exercise compared to non-
exercise days. 
Another strength of this thesis was that the FSIGT was performed 72 hours after the 
last exercise training session to ensure that a training rather than the acute exercise 
effect was captured. This may explain the smaller improvement in SI in this thesis 
compared to previous exercise training studies undertaken in African Americans 
where the measures of SI were 14-18 (280) and 24-48 hours (279), after the last 
exercise session and could therefore rather represent the acute effect of exercise on 
SI. 
No changes were observed in central and ectopic fat depots after the exercise 
intervention. While this may be a true biological effect, the sensitivity of the MRI to 
detect small changes in these fat depots should be considered as a possible 
explanation for the lack of change in these fat depots. However, the 3-point Dixon 
method used in this thesis to quantify hepatic, pancreatic and skeletal muscle fat, as 
well as VAT and aSAT depots was previously validated and found to be a sensitive 
measure even when fat levels in abovementioned depots are low (329). Further, this 
thesis measured VAT and aSAT volumes over a 15 cm region, including 5 slices, 
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which is a more sensitive method to determine changes in these parameters, 
compared to using a single slice (328).  
Other limitations to be considered, are that this thesis did not measure glucose 
tolerance and therefore was not able to discern whether the exercise training improved 
glucose tolerance, an important clinical marker of T2D risk. Further, no distinction was 
made between hepatic and peripheral SI,  and thus cannot comment on the effect of 
hepatic insulin SI on our findings. Another limitation was that we only included those 
in whom the linear model was preferred to compare HIE and CLp between subjects 
as well as over time. This reduced the sample size which may have contributed 
towards a type II error. Also, the focus of this study was on premenopausal black 
obese South African women and our findings might not be generalizable to all black 
South African women, older women, men or to other ethnic groups.  
In conclusion, ectopic fat was not an important correlate of SI, hyperinsulinemia or DI, 
a consistent finding in both the cross-sectional and interventional studies. Instead VAT 
and the VAT-aSAT ratio were important correlates of lower DI, explained not only by 
the association with lower SI, but also with lower ISR and a higher hepatic insulin 
extraction and not peripheral insulin clearance. Moreover, exercise training was 
beneficial to increase cardiorespiratory fitness, SI, as well as DI despite minimal weight 
loss and no reduction in central and ectopic fat depots. Cellular level alterations in the 
skeletal muscle and adipose tissue may explain these findings. The unique phenotype 
of this population, characterized by low cardiorespiratory fitness coupled with 
hyperinsulinemia and relatively low VAT and ectopic fat accumulation, may have 
dampened the exercise training-related response of these fat depots. Notably, gynoid 
fat mass reduced after exercise training, which may confer a beneficial effect on 
adipose tissue health. Also, exercise training ameliorated the detrimental associations 
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between truncal fat and metabolic outcomes, and a such remains fundamental in 




CHAPTER 9: FUTURE RECOMMENDATIONS 
 
My research has shown that in obese black women without T2D, DI can vary 
considerably. (Table 6.1). The group with the lowest DI may be at the highest risk of 
developing T2D. However, longitudinal studies are needed to compare these groups 
and compare the incidence of T2D over time. Early detection of those at risk in the 
general population are required followed by appropriate interventions to delay the 
deterioration in β-cell function. Further, while screening for those at high risk of 
developing T2D are an important component in reducing T2D incidence it may require 
more expensive testing and resources to be done efficiently. Therefore, prevention of 
overweight and obesity should be another key focus, especially in black South African 
women who are disproportionately affected by obesity compared to their white 
counterparts (380). 
According to the South African Diabetes Management Guidelines, the screening of 
T2D can occur at any age in individuals classified as high risk (221). High risk is 
defined as a BMI >25kg/m2 (overweight) and having one or more additional risk factor 
such as physical inactivity, first degree relatives with diabetes, or conditions 
associated with insulin resistance, amongst others (221). Our study population 
although, young (median age 23 years of age), were all obese and physically inactive 
prior to exercise training, which make them all high-risk individuals. In addition, 
approximately half (48.8%) of the cohort and two-thirds (67%) of those in the lowest 
DI tertile were classified as insulin resistant (381). Further, our initial inclusion criteria 
for BMI 30-35 kg/m2 had to be extended to <40 kg/m2, due to a lack of volunteers that 
had Class I obesity. This emphasizes the magnitude of the obesity epidemic in young, 
black South African women. However, screening all obese and sedentary black South 
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African women may place enormous burden on the already under-resourced health 
services in South Africa. Therefore, risk stratification is important to identify those most 
at risk even amongst those deemed high risk.  
My thesis has shown that a higher VAT was the strongest correlate of lower DI, 
independent of total body fat mass percent. Identification of those with the highest VAT 
levels are therefore warranted for risk stratification. Although, waist circumference is 
cost-effective and easy to use in low-resourced settings it also encompasses aSAT. 
Thus, in this thesis waist circumference was similar across the DI tertiles while VAT 
was not, showing the discord between these measures. In addition, the waist 
circumference to VAT ratio differs by ethnicity with African American women having 
lower VAT for the same waist circumference compared to white women (382). Waist 
circumference may therefore not be the best marker of higher VAT or reduced DI in 
an obese black African population. A risk score may need to be developed that is 
specific to obese black African populations to identify those at high risk for lower β-cell 
function, which encompasses both low SI and insulin secretory function. This risk score 
should include a measure of visceral adiposity. A recent study used novel markers to 
define visceral adipose function (383). This study showed that in women, the visceral 
adiposity index, the lipid accumulation product and the product of triacylglycerol and 
glucose were independent risk factors for T2D and were stronger correlates of T2D 
compared to anthropometric and laboratory measures alone. The strength of this study 
was its size (n=9564) and longitudinal nature (median follow-up time 6.5 years). 
However, ethnicity was not mentioned in this study, but it was performed in the 
Netherlands, in a well-resourced environment and a predominately white population. 
Further, the visceral adiposity index includes measures of waist circumference, BMI, 
plasma triglycerides and high-density lipoprotein. These laboratory markers may not 
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be a feasible approach for screening in a South African setting where black African 
populations typically have lower levels of VAT, triglycerides and high-density 
lipoprotein (43), compared to their white counterparts. Although this thesis focused on 
understanding the underlying mechanism of SI, insulin secretion and clearance it also 
highlights the need to explore appropriate screening measures that takes into account 
the unique phenotype of black African women.  
After identification of those at high risk for T2D, lifestyle intervention needs to be 
implemented to delay or prevent T2D. This thesis showed that a 12-week exercise 
intervention was beneficial to increase SI and VO2peak, despite marginal weight loss (-
0.8 kg) in a cohort with low baseline cardiorespiratory fitness. In addition, the exercise 
training prevented weight gain that was observed in the control group over the 12-
week period. A longer duration of training may be needed, to ensure greater 
improvements in SI, body compostion and ectopic fat deposition. Moreover, 
persistence in exercise training should therefore be encouraged even without obvious 
short-term benefits.  
Hyperinsulinemia is already present in normal-weight African American children (58) 
which may increase propensity for obesity from an early age. Therefore, intervention 
strategies to combat rising prevalence of overweight and obesity should focus not only 
on encouraging an active lifestyle in the children but also educating parents on healthy 
dietary habits. A low glycemic diet which was more effective in reducing intra-
abdominal fat in black American women compared to a low fat diet, may be advocated 
(366), in addition to exercise training. Perceptions of body size may be a barrier to the 
success of these lifestyle interventions, as overweight is seen as acceptable and 
weight loss is undesirable due to its association with HIV/AIDS (384). Nevertheless, 
the benefits of healthy lifestyle choices should be encouraged not just as part of school 
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curricula but also by local role models. Moreover, further research is required to test 
the uptake and efficiency of various health promotion campaigns in local communities. 
While this thesis showed an improvement in SI after 12-weeks of exercise training it 
was not explained by changes in body fat mass regional and ectopic fat accumulation, 
thus the underlying mechanisms remain elusive. Intrinsic changes in the skeletal 
muscle and adipose tissue, such as mitochondrial biogenesis, oxidative capacity, 
GLUT4 expression, lipid intermediaries, as well as inflammation and reactive oxygen 
species are putative mechanisms for improved SI in obese black South African, and 
warrant further study. 
This thesis studied obese black African premenopausal women without T2D and 
without HIV. However, the effect of exercise training on SI and hyperinsulinemia has 
not been studied before in those with HIV. This would be of interest because of the 
lipodystrophic changes associated with antiretroviral medication, which may affect 
T2D risk. Further, age-related changes occur in SI and AIRg (385) and thus our study 
findings may not be extrapolated to older individuals. The effect of exercise training on 
SI and AIRg, as well as insulin secretion and clearance in older adults and those with 
HIV are therefore warranted.  
Finally, Africa has the highest proportion of undiagnosed diabetes (59.7%), which is 
higher than the global figure of 50.1% (1). Delayed diagnosis of T2D when 
complications are already present will not only increase health expenditure, but also 
increase diabetes-related morbidity and mortality. Therefore, earlier screening and 
context-appropriate screening tools to monitor VAT, as well as longer duration 
exercise interventions together with dietary modifications are advocated in black South 
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APPENDIX B: INFORMED CONSENT 
INFORMED CONSENT 
 
THE EFFECT OF EXERCISE TRAINING ON INSULIN SECRETION AND 
SENSITIVITY IN OBESE BLACK SOUTH AFRICAN WOMEN 
 
 
Why is the study being done? 
 
Within South Africa, there are many people living with diabetes (sugar disease), with 
black women being the most affected, especially those who are carrying extra body 
weight (obese). Many studies in other countries have shown that exercise training 
reduces the risk for diabetes. However, there are no studies in South Africa that 
have studied this. This study will help us understand the various factors that may 
cause diabetes in obese black women, including factors within the muscle, fat and 
blood, as well as lifestyle factors including food intake, activity levels and family 
history. Therefore, the aim of the study is to measure changes in the risk for diabetes 
in response to a 12-week exercise-training programme in obese black South African 
women, and to examine specific factors linked to the changes in diabetes risk. This 
study is important, as it will help us understand if exercise training does reduce the 
risk of diabetes in obese black South African women, and help us understand how 
this is done.  
 
Who can participate? 
If you fulfil the following criteria you will be able to take part in the study:  
I. Aged 20-35 years;  
II. Obese (weight in kg divided by height in metres squared: 30-38 kg/m2) 
III. No known diseases or not taking medication for any diseases; 
IV. Not currently pregnant or breast feeding; 
V. Self-reported Xhosa ancestry (both parents are Xhosa); 
VI. No muscle or joint pains or medical problems that prevent you from 
exercising;  
VII. Able to attend four exercise sessions per week for the 12 week study period; 
VIII. Weight stable (weight not changed more than 5 kg or no change in your 
clothes size over the past 6 months); 
IX. Using injectable contraceptives, to prevent pregnancy, for a minimum of 1 
month prior to testing; 
X. No smoking or taking of recreational drugs 
XI. Not currently taking part in organized activity (exercise training); 
XII. No previous adverse reactions to an anaesthetic (e.g. at the dentist). 
XIII. No surgical procedures in the last 6 months. 
 
 
How do we decide if you are eligible to take part in the study? 
If you meet all the criteria listed above, you will then be asked to complete some 
tests on one day at the community facility in Khayelitsha to check that you meet the 
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inclusion criteria of the study. You will be asked to complete the following 
tests/measurements: 
 Complete a questionnaire including information on your age, medication use, 
ancestry, medical history, exercise and diet history, physical activity readiness; 
 Weight and height will be measured using a scale and a height measure; 
 Blood pressure: After a 5 minute relaxation period, blood pressure will be 
measured 3 times in a row, separated by 5 minutes between readings using a 
standard blood pressure monitor;  
 Glycated haemoglobin (red blood cells that joined with blood glucose 
(sugar)) – A measure of the average blood glucose over a period of time:   A 
blood sample will be obtained; 
 HIV screening will be performed. You will receive pre- and post-test counselling 
from a trained counsellor and a referral will be made to an appropriate HIV clinic 
if you are found to be HIV positive. If you test negative, you will be able to 
participate in the trial; 
 
How many people will take part in the study? 
Forty (40) obese women, who meet all the criteria above, can take part in the study.  
 
How long will the study last? 
The study will last 14 weeks in total. The first week (week 1) and last week (week 14) 
will include testing at the Sports Science Institute in Newlands. Weeks 2-13 (12 weeks) 
will include exercise training (4 times per week) in Khayeltisha.  
 
What will happen if you decide to take part in the study? 
If you meet all the criteria listed above and decide to take part in the study, you will 
be required to complete all the testing and training procedures outlined below. You 
will be randomly assigned to either an exercise group or a control group. Neither you 
nor the investigators will be able to choose which group you will be assigned to. If 
you are assigned to the exercise group, you will be required to complete 12 weeks of 
supervised aerobic training (training that increases your heart rate and breathing 
rate) for 1 hour on 4 days/week by a trained facilitator in a central facility in 
Khayelitsha. We request that you do not participate in any new additional training 
outside of this study. If you are assigned to the control group, you can continue with 
your normal life activities, and we request that you do not start a new exercise-
training programme somewhere else for the 12 weeks.  
 
You are under no obligation to take part in the study and are not required to give a 
reason if you do not wish to participate.  If you decide to take part in the study, you are 
free to withdraw at any time and without giving a reason and without prejudice. If you 
decide to withdraw from the study, we will discuss with you what will happen to any 
information or samples that you have provided. If the incomplete samples and 
information can usefully contribute to the study, we will ask your permission to store 
them and use them in our analysis. Alternatively, on your request all your information 





If you meet all the criteria above and are in the control OR experimental group, you 
will be required to complete 2 testing sessions before and another 2 sessions at the 
end of the 12 week study, as summarised in Table 1 and explained in detail below. 
All testing will be undertaken either at the Division of Exercise Science and Sports 
Medicine, based at the Sports Science Institute of South Africa (SSISA) in Newlands, 
or at CUBIC, Department of Radiology, Groote Schuur Hospital. Appropriately 
trained medical personnel will carry out all procedures.  
 
Table 1. Summary of testing schedule the week before and after the 12 week 
exercise/control intervention 
 Testing Week  
Testing session: Testing session 1 Testing session 2 
Location: SSISA Groote Schuur Hospital 
Time of day: 8 am Morning 
Preparation: Overnight fast and no 
exercise for 3 days prior 
Overnight fast and no 
exercise for 3 days prior 
Duration: 4 hrs 1 hr 
Procedure: -Insulin test 









Testing Session 1: Early morning before breakfast - At SSISA - 4 hours 
 
You will be requested to come to the laboratory at the Sports Science Institute in the 
morning after an overnight fast.  In other words, you must not eat or drink anything, 
except water, from 10pm the night before (at least 10 hours). You cannot take part in 
any exercise training for 72 (3 days) hours before this test.  
 
Insulin test – a measure of insulin secretion and insulin sensitivity: 
A small plastic tube will be placed into a vein in each arm.  You will then be required 
to undergo a test that will measure how much insulin your body produces and how 
sensitive your body is to insulin.  We will inject a concentrated glucose solution (~ 30-
100 mL, depending on your weight) into one vein over a 1-minute period. Small 
amounts of blood (1 teaspoon) will be withdrawn from the other arm at regular intervals 
(1-2 minutes) for 20 min.  After 20 min, insulin will be infused into your arm, which will 
assist your body to take up the glucose into the cells.  Further blood samples (1 
teaspoon each) will be drawn from your other arm for a further 3.5 hrs.  During this 
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test, a maximum of 200 mL of blood will be drawn (1/3rd of the amount drawn when 
you donate blood).  During the tests, you will be required to sit or lie quietly and DVDs 
will be provided for entertainment.   
 
Questionnaires: 
You will be asked questions related to your family history, your personal health and 
reproductive history, including the number of children you have, medications that you 
use and how much physical activity you do.  You will also be interviewed by a dietician 
who will ask you questions about your diet and the foods that you normally eat. You 
will be given a form to record the foods that you eat at home for a period of three days. 
 
Body composition: 
After your insulin test, we will take measurements of your body, including weight, 
height, waist and hip circumference. In addition, you will be asked to undergo a scan, 
which will accurately measure your fat and muscle mass, as well as your bone density.  
This is called a dual x-ray absorptiometry (DXA) scan. The scan will take 
approximately 20 minutes to perform during which you will lie quietly on the scanning 
table in a medical gown provided.  
 
Physical activity: 
You will be given 2 motion sensor devices, to wear for 1 week before and 1 week after the 
12 week study period and at week 4, 8 and 12 during the intervention.  One device is an 
accelerometer that measures how fast you move and an Actipal that measures how little 
you move. Both devices are the size of a small matchbox and will be attached to your 
waist (accelerometer) and to your thigh (Actipal) with a lightweight belt.  You should wear 
the monitors at all times, except when swimming, bathing, showering and sleeping.  
 
Testing Session 2: Morning - At Groote Schuur Hospital- 1 hour 
 
Magnetic resonance spectroscopy (MRS) scan 
The MRS scans will be performed at Groote Schuur Hospital in Observatory, and will 
take approximately 1 hour.   
 
The MRS scan will be used to measure the fat content of your calf muscle, liver and 
pancreas. MRS uses magnetic and radio waves, and will be used to generate a picture 
of your calf, liver and pancreas.  You will be required to lie on a bed, which is moved 
into a wide-bore tubular structure.  This is open at both ends.  You will be required to 
lie still for 15 minutes while being in constant voice contact with the Radiographer.   
If you have any of the following conditions, you may not have an MRS scan:  
implanted medical devices such as aneurysm clips in the brain, heart pacemakers, 
and cochlear (inner ear) implants; lead-based tattoos; or pieces of metal close to or 
in an important organ (such as the eye); claustrophobia or fear of being confined in a 





12-week exercise/control intervention 
If you are assigned to the control group we will request that you do not start any 
new exercise training programs during the 12-week study period, and continue with 
your daily activities and diet as usual. When you have completed the 14-week trial, 
you will be offered the opportunity to undergo the same exercise training as the 
exercise group, as described below. This is totally voluntary.  
 
If you are assigned to the exercise group, you will be required to perform 12-weeks 
of supervised aerobic training at a moderate-vigorous intensity for one hour, four 
times per week. The exercise training will include cardiovascular exercises in the 
form of aerobic dance, boxing, running, skipping, stepping, and strengthening 
exercises using your own body weight or minimal equipment for resistance training 
(e.g. bands and weights). The frequency, duration and intensity of the exercise 
intervention are based on the recommendations from the British Association of Sport 
and Exercise Sciences (BASES), to ensure the prevention of injuries. The 60 min 
classes will include moderate exercise (70-75% of your maximum heart rate) and at 
least 30 min of vigorous activity (75-85% of your maximum heart rate), which will be 
monitored using heart rate monitors. The exercise classes will be supervised by a 
trained biokineticist, who will monitor your progress (using heart rate data) and adjust 
the classes accordingly to ensure adequate improvement in cardiorespiratory fitness 
throughout the 12-week programme. We request that you do not participate in any 
new additional training outside of this study and maintain your normal diet during the 
12-week trial.  
 
Monitoring in the control and exercise groups:  
If you are in the control or the exercise group, you will be asked to wear the accelerometer 
and Actipal for 7 days at the beginning and every 4 weeks during the 12-week trial (week -
1, 4, 8 and 12) (as described above). Accelerometers will be used to provide a more 
accurate assessment of the intensity of your activity, and Actipals provide more 
information on sedentary time. You should wear the monitors at all times, except when 
swimming, bathing, showering and sleeping. At the same time that you wear the monitors 
(week -1, 4, 8 and 12), we will request that you record your dietary intake for three days ( 
2 week days and 1 weekend day) as explained in the first session.  Attendance at each 
session, and the compliance to the exercise training will be monitored by the biokineticist.  
 
What are the risks and discomforts of this study? 
 
Insulin test – a measure of insulin secretion and insulin sensitivity: 
There are no appreciable risks for this test, other than those associated with routine 
blood sampling.  All procedures will be supervised and carried out by a medical doctor 
and appropriately trained medical personnel using sterile techniques to minimise any 
risks of infection.  These tests are used routinely in research to accurately determine 
insulin secretion and insulin sensitivity.  A maximum of 200 ml of blood will be drawn 
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The only risk associated with the DXA scan is exposure to radiation. However, the 
radiation exposure with a DXA scan is less than half that of a chest x-ray (11.3 
microSieverts).   
 
Physical activity: 
There are no risks or side-effects from wearing the physical activity monitors. 
 
Magnetic resonance spectroscopy (MRS) scan 
You will not experience any pain or discomfort when having the MRS scan, and 
there are no known harmful long-term effects of the magnetic fields used in this 
study.  When the scanner takes the pictures, the bed may shake, and you will hear 
loud banging noises.  You will be given earplugs or headphones to protect your ears.  
Also, some people feel nervous in a small closed space, such as when they are in 
the scanner.  You will be able to see out of the scanner at all times, and we will not 
start until you tell us that you are comfortable.  You will be able to stop at any time by 
squeezing a ball that you will hold in one hand and can talk to us using an intercom 
that is built into the scanner.  If you have any of the following conditions, you may not 
have an MRS scan:  implanted medical devices such as aneurysm clips in the brain, 
heart pacemakers, and cochlear (inner ear) implants; lead-based tattoos; or pieces 
of metal close to or in an important organ (such as the eye); claustrophobia or fear of 
being confined in a small space.   
 
12-week exercise/control intervention 
The training program is designed for exercise progression to ensure minimal 
physical discomfort and associated soreness. In the unlikely event that you sustain 
an injury due to the exercise intervention, you will be referred to the appropriate clinic 
for treatment at no expense to yourself. However, you might experience some 
physical discomfort and associated muscle soreness following the first session (and 
in some cases the first week) of training. All efforts will be made to ensure a suitable 
training environment, including safe setting up and provision of equipment, sufficient 
lighting, suitable temperature, suitable ventilation, and convenient access to toilets, 
etc. In the unlikely event that medical assistance is required a mobile phone and 
automated external defibrillator (AED) will be present at all exercise sessions with a 
biokineticist that has all required certificates and training for using this device.  
 
Are there any benefits to you for being in the study? 
You will receive your own results, including body composition (weight, height, waist 
circumference, muscle and fat mass and bone density), blood pressure, risk for 
diabetes, physical fitness and dietary analysis, with some recommendations made 
by a dietician on how to adapt your dietary intake to improve your health. If you are 
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in the control group, after the completion of the study, you will have the opportunity 
to participate in the same exercise training as the exercise group. This is completely 
voluntary. Following the training (if you were in the exercise or control group), you 
will receive guidelines and recommendations on how to continue your exercise 
training. If you have any abnormal results, you will be given a referral letter and 
directed to the appropriate health practitioner or local clinic.  
 
What will happen when the study is over? 
As mentioned above, when the testing of all the women has been completed, you will 
receive your individual results and the provisional findings of the study will be 
presented. Once the final analyses have been completed, the final results of the study 
will be shared with you. This information will assist in our understanding of the effect 
of exercising training on the risk for diabetes, and therefore help us to prevent and/or 
manage the problem of diabetes in South African women.   
 
Will any of your blood samples be stored and used for research in the future? 
The researchers will ask your permission to store your blood samples for future 
research. All samples will be kept in a freezer in a secure facility with access limited 
to research personnel. Future research analyses will be based on new research that 
we are at present not aware of, but may be important in our understanding of the risk 
for type 2 diabetes.  Any research done on your blood  in the future must be 
approved by the Faculty of Health Sciences Research Ethics Committee at the 
University of Cape Town that is set up to determine that the research is done 
according to accepted standards. You will not be penalized in any way for not 
allowing the use of your blood for future research.  If you decide not to donate blood 
for future research, it will be destroyed on completion of this trial. Strict confidentiality 
of results will be maintained.   
 
 
Will you receive reimbursement for transport, time and inconvenience? 
All transport required to get to the training and testing facilities will be arranged by 
the researchers and be at no cost to you. You will receive R30/day to cover their 
transport costs to the training venue in Khayelitsha (4 x training sessions per week 
for 12 weeks + 3 monthly monitoring visits). In addition, you will receive R60/day for 
transport to the testing facilities at UCT and Groote Schuur (R50 x 2 testing 
sessions).  The transport money will be paid to you at the end of each session. 
 
To compensate you for your time and inconvenience, you will be reimbursed R20/hr 
for the training session (48 hrs), and R50/hr for the testing sessions (18 hrs of testing 
and monitoring). Payment for time and inconvenience will be paid on a pro-rata basis 
at the end of the 12-week study period.  
 
Who will see the information that is collected about you during the study? 
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Strict confidentiality of results will be maintained. Your name will be removed from all 
data, and you will be assigned a number, which will be used to identify data relating 
to you.  All records will be kept in a locked room and in a secure computer database 
in the research unit.  Your name will not be used in any publication of the results. 
 
What if Something Goes Wrong? 
The University of Cape Town (UCT) has insurance cover for the event that research-
related injury or harm results from your participation in the trial. The insurer will pay 
all reasonable medical expenses in accordance with the South African Good Clinical 
Practice Guidelines (DoH 2006), based on the Association of the British 
Pharmaceutical Industry Guidelines (ABPI) in the event of an injury or side effect 
resulting directly from your participation in the trial. You will not be required to prove 
fault on the part of the University. 
 
The University will not be liable for any loss, injuries and/or harm that you may 
sustain where the loss is caused by 
 The use of unauthorised medicine or substances during the study 
 Any injury that results from you not following the protocol requirements or the 
instructions that the study doctor may give you 
 Any injury that arises from inadequate action or lack of action to deal adequately 
with a side effect or reaction to the intervention 
 An injury that results from negligence on your part 
By agreeing to participate in this study, you do not give up your right to claim 
compensation for injury where you can prove negligence, in separate litigation. In 
particular, your right to pursue such a claim in a South African court in terms of 
South African law must be ensured. Note, however, that you will usually be 
requested to accept that payment made by the University under the SA GCP 
guideline 4.11 is in full settlement of the claim relating to the medical expenses.  
 
An injury is considered trial-related if, and to the extent that, it is caused by study 
activities. You must notify the study doctor immediately of any side effects and/or 
injuries during the trial, whether they are research-related or other related 
complications. 
 
UCT reserves the right not to provide compensation if, and to the extent that, your 
injury came about because you chose not to follow the instructions that you were 
given while you were taking part in the study. Your right in law to claim compensation 
for injury where you prove negligence is not affected. Copies of these guidelines are 
available on request. 
 
Who do I contact if I have any questions about the study? 
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If you have any questions or you experience any problems during or after the tests, 
please contact Professor Julia Goedecke or Dr Amy Mendham:   
 
Associate Professor Julia Goedecke (PhD)  
Principal Investigator 
Division of Exercise Science and Sports Medicine 
Department of Human Biology 
3rd Floor, Sports Science Institute of South Africa 
Boundary Road, Newlands, 7725 
Cape Town 
Tel:  021-6504573 (w) 0828255616 (cell) 
Email : julia.goedecke@uct.ac.za  
 
 
Dr Amy Mendham (PhD 
Project coordinator 
Division of Exercise Science and Sports Medicine 
Department of Human Biology 
3rd Floor, Sports Science Institute of South Africa 
Boundary Road, Newlands, 7725 
Cape Town 
Tel:  021-6504567(w), 0723879889 (cell) 
Email : Amy.Mendham@uct.ac.za 
 
Should you have any concerns about this study, you are also free to contact the head 
of the University of Cape Town Faculty of Health Sciences Human Research Ethics 
Committee, Professor Marc Blockman. 
 
Professor Marc Blockman 
Head, Human Research Ethics Committee 
Faculty of Health Sciences 
Room E52-24 Groote Schuur Hospital Old Main Building, Observatory 7925 







Subject code:  
 
 
THE EFFECT OF EXERCISE TRAINING ON INSULIN SECRETION AND 
SENSITIVITY IN OBESE BLACK SOUTH AFRICAN WOMEN 
 
Consent to participate in the study: 
 
“I, _________________________, hereby give consent to participate in this 
research trial to be conducted by the Division of Exercise Science and Sports 
Medicine, within the Department of Human Biology at the University of Cape Town.   
 
I understand that I will undergo preliminary testing to determine if I am eligible for the 
study. I understand that I will be randomly assigned to the exercise or the control 
group. If I am assigned to the exercise group, I understand that I will be required to 
complete 12 weeks of exercise training, consisting of 1 hour of exercise training 4 
days/week by a trained facilitator in a central facility in Khayelitsha.  If I am assigned 
to the control group, I understand that I will be required to continue with my normal 
daily living and not start a new exercise-training programme during the study period, 
but can be part of the same exercise-training programme once I have completed the 
study. I understand that irrespective of the group that I am assigned to, I will be 
required to complete 2 testing sessions before and at the end of the 12-week study. 
In addition, I understand that I will be required to visit the community centre every 4 
weeks to have my weight, dietary intake and physical activity. I understand that the 
testing sessions will be performed at the Sports Science Institute and Groote Schuur 
Hospital and will include completion of a demographic and lifestyle questionnaire, the 
measurement of blood pressure, body composition including whole body scans and 
MRS scans of my calf muscle, pancreas and liver, blood glucose (sugar), 
inflammatory and hormone levels, physical fitness, as well as a test to measure 
insulin secretion and sensitivity.   
I have read and have had explained to me the procedures described. I have had an 
opportunity to ask questions and my questions have been answered in a satisfactory 
way.  I understand the nature of the trial and the risks and benefits associated with 
my participation and that I am free to withdraw from this study at any time.   
 
I understand that all the information collected during the study will be treated with the 
strictest confidentiality and will only be used for scientific research purposes. All 
samples will be kept in a freezer in a secure facility with access limited to research 
personnel. All records will be kept in a locked room and in a secure computer 
database in the research unit.  Your name will not be used in any publication of the 
results.  I understand that for data verification and quality control purposes regulatory 
authorities and/or members of the University of Cape Town Faculty of Health 
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Sciences Human Research Ethics Committee may be allowed access to my 
personal data under conditions of strict confidentiality.  
 
 
I have read the information, or it has been read to me. I have had the opportunity 
to ask questions about it and my questions have been answered to my 
satisfaction. I consent voluntarily and understand that I have the right to 
withdraw my consent without this affecting the current research study or my 
medical care.  
 
Print Name of Participant _________________________  
 
Signature of Participant ___________________________  
 









Subject code:  
 
 
CONSENT FOR HIV TESTING: 
 
Additional consent to: The effect of exercise training on insulin secretion and 




I ______________________________ agree to provide a blood sample for the 
purposes of confidential HIV testing. I understand that it is necessary for me to have 
this test to participate in the research study. If I test positive, I cannot participate in the 
study entitled “Mechanisms underlying insulin resistance in black South African 
women”, conducted by the Division of Exercise Science and Sports Medicine, within 
the Department of Human Biology at the University of Cape Town.  I aware that I will 
receive pre and post-test counselling from a qualified HIV counsellor, and will be 
referred to an appropriate health care clinic if necessary. I understand the implications 
of performing the test. 
 
I have read the information, or it has been read to me. I have had the opportunity 
to ask questions about it and my questions have been answered to my 
satisfaction. I consent voluntarily and understand that I have the right to 
withdraw my consent without this affecting the current research study or my 
medical care.  
 
Print Name of Participant _________________________  
 
Signature of Participant ___________________________  
 












Subject code:  
 
 
CONSENT FOR STORAGE AND FUTURE USE OF UNUSED SAMPLES: 
 
Additional consent to: The effect of exercise training on insulin secretion and 




We are seeking permission to store your unused blood samples for possible future in 
either our own research or collaborators’ research studies. Permission to use these 
samples is in addition to the use of your samples for the current study. This is important 
as these analyses will be based on new research that we are at present not aware of, 
but may be important in our understanding of the risk for type 2 diabetes. Before the 
samples can be used for future research, approval by the University of Cape Town 
Faculty of Health Sciences Human Research Ethics Committee will be obtained. 
Please be aware that the samples will not be sold for profit.  
 
When entering into the study, you will receive a unique code that will be used for 
sample and data analysis, which serves to maintain your confidentiality. When storing 
samples, you may choose that we keep the unique code on the sample so that we can 
link any new results to your existing data. If any clinically relevant information relating 
to this sample is found, we will inform you of the results. Alternatively, you can remove 
the identifying number, so that your information will not be linked to the sample and 
you will not be informed of any clinical results relating to the new analyses.  
 
You may also refuse to allow future analyses of samples without being penalised, and 
your results relating to the current study will not be compromised in any way. If you 
refuse to allow future analyses of samples, your samples will be destroyed on 
completion of this trial. Furthermore, you may withdraw permission to use your 
samples at any time. If you wish to do this, please contact: 
 
Associate Professor Julia Goedecke (PhD) 
Principal Investigator 
Division of Exercise Science and Sports Medicine 
Department of Human Biology 
3rd Floor, Sports Science Institute of South Africa 
Boundary Road, Newlands, 7725 
Cape Town 
Tel:  021-6504573 (w)  0828255616 (cell) 




All information collected during the study will be treated with the strictest confidentiality 
and will only be used for scientific research purposes. All samples will be kept in a 
freezer in a secure facility with access limited to research personnel; all records will 
be kept in a locked room and in a secure computer database in the research unit.  
Your name will not be used in any publication of the results. For data verification and 
quality control purposes regulatory authorities and/or members of the University of 
Cape Town Faculty of Health Sciences Human Research Ethics Committee may be 
allowed access to my personal data under conditions of strict confidentiality.  
 
Certificate of Consent: 
 
1) If any of the BLOOD that I have provided for this research project is unused or leftover 
when the project is completed (Tick one choice from each of the following boxes)  
☐ I wish my blood sample to be destroyed immediately.  
☐ I want my blood sample to be destroyed after ____ years.  
☐ I give permission for my blood sample to be stored indefinitely  
 
AND if my blood sample is to be stored: 
  I give permission for my blood sample to be stored and used in future research 
but only on the same subject as the current research project: “The effect of exercise 
training on insulin secretion and sensitivity in obese black South African women”. 
  I give my permission for my blood sample to be stored and used in future 
research of any type, which has been properly approved  
  I give permission for my blood sample to be stored and used in future research 
except for research about __________________________ 
 
AND 
  I want my identity to be removed from my blood sample.  




I have read the information, or it has been read to me. I have had the opportunity 
to ask questions about it and my questions have been answered to my 
satisfaction. I consent voluntarily and understand that I have the right to 
withdraw my consent without this affecting the current research study or my 
medical care.  
 
Print Name of Participant _________________________  
 
Signature of Participant ___________________________  
 
Date ___________________________  
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APPENDIX C: SCREENING QUESTIONNAIRE 
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